<SEC-DOCUMENT>0001104659-20-140581.txt : 20201230
<SEC-HEADER>0001104659-20-140581.hdr.sgml : 20201230
<ACCEPTANCE-DATETIME>20201230165347
ACCESSION NUMBER:		0001104659-20-140581
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20201227
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201230
DATE AS OF CHANGE:		20201230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COLLEGIUM PHARMACEUTICAL, INC
		CENTRAL INDEX KEY:			0001267565
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37372
		FILM NUMBER:		201426423

	BUSINESS ADDRESS:	
		STREET 1:		100 TECHNOLOGY CENTER DRIVE
		CITY:			STOUGHTON
		STATE:			MA
		ZIP:			02072
		BUSINESS PHONE:		781-713-3699

	MAIL ADDRESS:	
		STREET 1:		100 TECHNOLOGY CENTER DRIVE
		CITY:			STOUGHTON
		STATE:			MA
		ZIP:			02072

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COLLEGIUM PHARMACEUTICAL INC
		DATE OF NAME CHANGE:	20031020
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2039449d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:coll="http://collegiumpharma.com/20201227">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_coll_collegiumpharma.com_20201227 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20201227_20201227 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001267565 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:EntityCentralIndexKey">0001267565</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-12-27to2020-12-27" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="coll-20201227.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-12-27to2020-12-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-27</xbrli:startDate>
        <xbrli:endDate>2020-12-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES </b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_904_edei--DocumentType_c20201227__20201227_z7PiuWcrJayg"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:DocumentType">8-K</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 OR
15(d) of The Securities Exchange Act of 1934 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-style: normal; font-weight: normal">Date of Report (Date of earliest event
reported): <b> <span id="xdx_90F_edei--DocumentPeriodEndDate_c20201227__20201227_zSpuaAILRZd"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 27, 2020</ix:nonNumeric></span></b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20201227__20201227_zxa8tMvDFlnk"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:EntityRegistrantName">COLLEGIUM PHARMACEUTICAL, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified
in its Charter) </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20201227__20201227_zuWScZuIjaE1"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Virginia</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; width: 2%">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityFileNumber_c20201227__20201227_zwcvCw4fWgSa"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:EntityFileNumber">001-37372</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; width: 2%">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20201227__20201227_zI1FaJAu2WW1"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:EntityTaxIdentificationNumber">03-0416362</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="text-align: center; vertical-align: top"><span style="font-style: normal; font-weight: normal">(State or Other
    Jurisdiction <br />
    of Incorporation or Organization)</span></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt"><span style="font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-style: normal; font-weight: normal">(Commission<br />
    File Number)</span></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt"><span style="font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-style: normal; font-weight: normal">(IRS Employer
    <br />
    Identification No.)</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_906_edei--EntityAddressAddressLine1_c20201227__20201227_z6EJMImTA268"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:EntityAddressAddressLine1">100 Technology Center Drive</ix:nonNumeric></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span></span> <span id="xdx_904_edei--EntityAddressAddressLine2_c20201227__20201227_zWlfWGhg1ITb"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:EntityAddressAddressLine2">Suite 300</ix:nonNumeric></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span></span> <span id="xdx_90B_edei--EntityAddressCityOrTown_c20201227__20201227_zfN6A5R9J4Cl"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:EntityAddressCityOrTown">Stoughton</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20201227__20201227_zUek2yWYJqY"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span>  <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20201227__20201227_zQpfQjLJNice"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:EntityAddressPostalZipCode">02072</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-style: normal; font-weight: normal">Registrant&#8217;s
telephone number, including area code:</span> <b>(<span id="xdx_90C_edei--CityAreaCode_c20201227__20201227_zPybLV67BLl6"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:CityAreaCode">781</ix:nonNumeric></span></b><b>)
<span id="xdx_903_edei--LocalPhoneNumber_c20201227__20201227_zbX7cBVqvuE3"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:LocalPhoneNumber">713-3699</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="padding: 2pt 5.4pt; text-align: center; width: 37%"><b>Title of each class</b> <b></b></td>
    <td style="padding: 2pt 5.4pt; width: 19%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="padding: 2pt 5.4pt; width: 44%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding: 2pt 5.4pt; font-size: 10pt"><span style="font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20201227__20201227_zfhtSQ9kihG2"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="padding: 2pt 5.4pt; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--TradingSymbol_c20201227__20201227_ztPLfHrFR2na"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" name="dei:TradingSymbol">COLL</ix:nonNumeric></span></span></td>
    <td style="padding: 2pt 5.4pt; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--SecurityExchangeName_c20201227__20201227_z7WaNy1xxRpg"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The NASDAQ Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 0.3in; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_905_edei--WrittenCommunications_c20201227__20201227_zK8VqXvT79wb"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 0.3in; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_904_edei--SolicitingMaterial_c20201227__20201227_zkl445DNt0wk"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 0.3in; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_901_edei--PreCommencementTenderOffer_c20201227__20201227_zT1HhskmIOvl"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 0.3in; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20201227__20201227_zuX37GJgI7Pl"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20201227__20201227_zUyeTFgzbh8k"><ix:nonNumeric contextRef="From2020-12-27to2020-12-27" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>Item 5.02</b> <b>&#160;&#160;&#160;&#160;&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Collegium Pharmaceutical, Inc. (the
&#8220;<b><i>Company</i></b>&#8221;) entered into amended and restated employment agreements (the &#8220;<b><i>A&amp;R
Employment Agreements</i></b>&#8221;), to be effective January 1, 2021, with the following executive officers: Joseph
Ciaffoni, President and CEO; Paul Brannelly, Executive Vice President and Chief Financial Officer; Scott Dreyer, Executive
Vice President and Chief Commercial Officer; Alison B. Fleming, Ph.D., Executive Vice President and Chief Technical Officer;
Shirley Kuhlmann, Executive Vice President and General Counsel; and Richard Malamut, M.D., Executive Vice President and Chief
Medical Officer (each an &#8220;<b><i>Executive</i></b>&#8221; and collectively, the &#8220;<b><i>Executives</i></b>&#8221;).
The A&amp;R Employment Agreements, which have an effective date of January 1, 2021, supersede the Executives&#8217; existing
employment agreements and are substantially identical thereto except with respect to the revised severance provisions and
restrictive covenants as set forth herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the employment of an Executive is terminated by the Company
without Cause or if the Executive resigns with Good Reason (as each term is defined in the A&amp;R Employment Agreements), then
Mr. Ciaffoni would be entitled to 18 months of severance benefits and each other Executive would be entitled to 12 months of severance
benefits. During his or her applicable severance period, the applicable Executive would receive the following severance benefits,
less applicable tax withholding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">payment of any annual bonus otherwise payable (but for the cessation of Executive&#8217;s employment) with respect to a year
ended prior to the cessation of Executive&#8217;s employment;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">continuation of the Executive&#8217;s then-current base salary in accordance with normal payroll procedures for the applicable
severance period;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">payment of a cash severance benefit equal to the Executive&#8217;s annual bonus at the target percentage for the year in which
the termination occurs (except in the case of Mr. Ciaffoni, who would receive payment of a cash severance benefit equal to 150%
of his annual bonus at the target percentage for the year in which the termination occurs), paid in monthly installments over the
applicable severance period;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the Executive&#8217;s unvested equity incentives that are subject only to time-based vesting and would have vested over the
applicable severance period will become immediately and automatically fully vested and exercisable (equity incentives that are
subject to performance-based vesting will vest, if at all, in accordance with the applicable award agreements); and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">waiver of the applicable premium otherwise payable for COBRA continuation coverage for the Executive, if applicable (and, to
the extent covered immediately prior to the date of such cessation, his or her eligible dependents) during the applicable severance
period.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any Executive&#8217;s employment is terminated by the Company
without Cause or if the Executive resigns with Good Reason, in either case within 12 months following the occurrence of a Change
in Control (as defined in the A&amp;R Employment Agreements), then, subject to the Company&#8217;s receipt of a general release
of claims and the terminated Executive&#8217;s continued compliance with certain restrictive covenants, such Executive would be
entitled to receive the following severance benefits, less applicable tax withholding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">all of the Executive&#8217;s unvested equity incentives that are subject only to time-based vesting will become immediately
and automatically fully vested and exercisable (equity incentives that are subject to performance-based vesting will vest, if at
all, in accordance with the applicable award agreements);</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">a lump sum payment of 18 months (or in the case of Mr. Ciaffoni, 24 months) of the Executive&#8217;s then-current base salary;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">a lump sum payment equal to 1.5 times his or her then-current target annual bonus (or in the case of Mr. Ciaffoni, two times
his then current target annual bonus); and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">waiver of the applicable premium otherwise payable for COBRA continuation coverage for the Executive, if applicable (and, to
the extent covered immediately prior to the date of such cessation, his or her eligible dependents) for a period of 18 months (or
in the case of Mr. Ciaffoni, 24 months).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The A&amp;R Employment Agreements also provide that, while employed
and for a period of 12 months following the termination of the Executive (or in the case of Mr. Ciaffoni, 18 months), the Executive
will be subject to customary restrictive covenants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The descriptions of the A&amp;R Employment Agreements contained
herein do not purport to be complete and are qualified in their entirety by reference to the full text of the A&amp;R Employment
Agreements, copies of which are filed as exhibits hereto and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<b>Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) &#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"><a href="tm2039449d1_ex10-1.htm" style="-sec-extract: exhibit">10.1</a></td>
    <td style="text-align: justify; width: 0.25in">&#160;</td><td style="text-align: justify"><a href="tm2039449d1_ex10-1.htm" style="-sec-extract: exhibit">Amended &amp; Restated
                                                              Employment Agreement, dated December 27, 2020, by and between Collegium Pharmaceutical, Inc. and Joseph
                                                              Ciaffoni.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2039449d1_ex10-2.htm" style="-sec-extract: exhibit">10.2</a></td>
    <td style="text-align: justify">&#160;</td><td style="text-align: justify"><a href="tm2039449d1_ex10-2.htm" style="-sec-extract: exhibit">Amended &amp; Restated Employment Agreement, dated December 28, 2020, by and between Collegium Pharmaceutical, Inc. and Paul
Brannelly.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2039449d1_ex10-3.htm" style="-sec-extract: exhibit">10.3</a></td>
    <td style="text-align: justify">&#160;</td><td style="text-align: justify"><a href="tm2039449d1_ex10-3.htm" style="-sec-extract: exhibit">Amended &amp; Restated Employment Agreement, dated December 27, 2020, by and between Collegium Pharmaceutical, Inc. and Scott
Dreyer.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2039449d1_ex10-4.htm" style="-sec-extract: exhibit">10.4</a></td>
    <td style="text-align: justify">&#160;</td><td style="text-align: justify"><a href="tm2039449d1_ex10-4.htm" style="-sec-extract: exhibit">Amended &amp; Restated Employment Agreement, dated December 29, 2020, by and between Collegium Pharmaceutical, Inc. and Alison
B. Fleming, Ph.D.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2039449d1_ex10-5.htm" style="-sec-extract: exhibit">10.5</a></td>
    <td style="text-align: justify">&#160;</td><td style="text-align: justify"><a href="tm2039449d1_ex10-5.htm" style="-sec-extract: exhibit">Amended &amp; Restated Employment Agreement, dated December 27, 2020, by and between Collegium Pharmaceutical, Inc. and Shirley
Kuhlmann.</a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2039449d1_ex10-6.htm" style="-sec-extract: exhibit">10.6</a></td>
    <td style="text-align: justify">&#160;</td><td style="text-align: justify"><a href="tm2039449d1_ex10-6.htm" style="-sec-extract: exhibit">Amended &amp; Restated Employment Agreement, dated December 27, 2020, by and between Collegium Pharmaceutical, Inc. and Richard
Malamut, M.D.</a></td></tr>                       <tr style="vertical-align: top">
<td style="text-align: justify">104</td>
    <td style="text-align: justify">&#160;</td><td style="text-align: justify">Cover Page Interactive Data File (embedded within the
Inline XBRL document)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Dated: December 30, 2020</span></td>
    <td colspan="2"><span style="font-size: 10pt">Collegium Pharmaceutical,&#160;Inc.</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 51%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">/s/ Paul Brannelly</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Name: Paul Brannelly</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title: Executive Vice President and Chief Financial Officer</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2039449d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>AMENDED &amp;
RESTATED</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>EMPLOYMENT
AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS EMPLOYMENT AGREEMENT
(the &ldquo;<U>Agreement</U>&rdquo;) is made by and between COLLEGIUM PHARMACEUTICAL, INC. (the &ldquo;<U>Company</U>&rdquo;) and
JOSEPH CIAFFONI (the &ldquo;<U>Executive</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive are parties to an Employment Agreement dated as of May 31, 2017, as amended (the &ldquo;<U>Existing Agreement</U>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive desire to amend and restate the Existing Agreement and enter into this Agreement pursuant to which the Company
will continue to employ Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the foregoing and intending to be bound hereby, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Duration
of Agreement</U>. This Agreement is effective as of January 1, 2021 and has no specific expiration date. Unless terminated by
agreement of the parties, this Agreement will govern Executive&rsquo;s continued employment by the Company until that employment
ceases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Title;
Duties</U>. Executive will continue to be employed as the Company&rsquo;s President and Chief Executive Officer. Executive will
devote his best efforts and substantially all of his business time and services to the Company and its affiliates to perform such
duties as may be customarily incident to his position and as may reasonably be assigned to him from time to time. Executive shall
report to the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;). Executive will not, in any capacity, engage
in other business activities or perform services for any other individual, firm or corporation without the prior written consent
of the Board; provided, however, that without such consent, Executive may engage in charitable, non-profit and public service
activities, so long as such activities do not in any respect interfere or conflict with Executive&rsquo;s performance of his duties
and obligations to the Company; and provided further that Executive may serve on for-profit boards of directors (other than the
Board) with the consent of the Board, such consent not to be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Place
of Performance</U>. Executive will perform his services hereunder at the principal executive offices of the Company in Stoughton,
Massachusetts; <I>provided, however, </I>that Executive may be required to travel from time to time for business purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compensation
and Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Base
Salary</U>. Executive&rsquo;s annual salary will be $657,000 (the &ldquo;Base Salary&rdquo;), paid in accordance with the Company&rsquo;s
payroll practices as in effect from time to time. The Base Salary will be reviewed annually by the Compensation Committee of the
Company&rsquo;s Board of Directors (the &ldquo;<U>Committee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"> </FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Annual
Bonuses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> For each fiscal year ending during his employment, Executive will be eligible to earn an annual bonus. The target amount
of the annual bonus will be 70% of Executive&rsquo;s Base Salary for the applicable fiscal year. The actual bonus payable with
respect to a particular year will be determined by the Committee, based on the achievement of corporate and/or individual performance
objectives established by the Committee. Any bonus payable under this paragraph will be paid during the calendar year immediately
following the fiscal year in respect of which the bonus is payable and, except as otherwise provided in Section 5.1.1 and Section
5.3.1, will only be paid if Executive remains continuously employed by the Company through the actual bonus payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of determining any bonus payable to Executive, the measurement of corporate and individual performance will
be performed by the Committee in good faith. From time to time, the Committee may, in its sole discretion, make adjustments to
corporate or individual performance goals, so that required departures from the Company&rsquo;s operating budget, changes in accounting
principles, acquisitions, dispositions, mergers, consolidations and other corporate transactions, and other factors influencing
the achievement or calculation of such goals do not affect the operation of this provision in a manner inconsistent with its intended
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Employee
Benefits</U>. During Executive&rsquo;s employment, Executive will be eligible to participate in all employee benefit plans and
programs made available by the Company from time to time to employees generally, subject to applicable plan terms and policies.
The Company periodically reviews its benefits, policies, benefits providers and practices and may terminate, alter or change them
at its discretion from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Reimbursement
of Expenses</U>. Executive will be reimbursed by the Company for all reasonable business expenses incurred by Executive in accordance
with the Company&rsquo;s customary expense reimbursement policies as in effect from time to time. Notwithstanding anything herein
to the contrary, to the extent any expense, reimbursement or in-kind benefit provided to the Executive constitutes a &ldquo;deferral
of compensation&rdquo; within the meaning of Section 409A of the Internal Revenue Code (the &ldquo;<U>Code</U>&rdquo;) (i) the
amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive must be incurred during the Executive&rsquo;s
term of employment; (ii) the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive during
any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive
in any other calendar year, (iii) the reimbursements for expenses for which the Executive is entitled to be reimbursed shall be
made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred and
(iv) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination</U>.
Executive&rsquo;s employment with the Company may be terminated by the Company or Executive at any time and for any reason.
Upon any cessation of his employment with the Company, Executive will be entitled only to such compensation and benefits as
described in this <U>Section 5</U>. Upon any cessation of his employment for any reason, unless otherwise requested by the
Company, Executive agrees to resign immediately from all officer and director positions he then holds with the Company and
its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
without Cause or for Good Reason</U>. If Executive&rsquo;s employment by the Company ceases due to a termination by the Company
without Cause (as defined below) or a resignation by Executive for Good Reason (as defined below), Executive will be entitled
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>payment of any annual bonus otherwise payable (but for the cessation of Executive&rsquo;s employment) with respect to a
year ended prior to the cessation of Executive&rsquo;s employment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>continuation of Executive&rsquo;s Base Salary for a period equal to eighteen (18) months, payable in accordance with the
Company&rsquo;s standard payroll practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>payment equal to (i) Executive&rsquo;s target annual bonus described in Section 4.2.1 multiplied by (ii) 1.5, paid in eighteen
(18) substantially equal installments over an eighteen-month period and in accordance with the Company&rsquo;s standard payroll
practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>accelerated vesting of any unvested restricted stock, stock options and other equity incentives awarded to Executive by
the Company that are solely subject to time-based vesting criteria equal to what would have vested had Executive remained employed
for eighteen (18) additional months; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>waiver of the applicable premium otherwise payable for COBRA continuation coverage for Executive (and, to the extent covered
immediately prior to the date of such cessation, his eligible dependents) for a period equal to eighteen (18) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in this <U>Section
5.1</U>, and except for payment of all (i) accrued and unpaid Base Salary through the date of such cessation, (ii) any expense
reimbursements to be paid in accordance with Company policy and (iii) payments for any accrued but unused paid time off in accordance
with the Company&rsquo;s policies and applicable law, all compensation and benefits will cease at the time of such cessation and
the Company will have no further liability or obligation by reason of such cessation. The payments and benefits described in this
<U>Section 5.1</U> are in lieu of, and not in addition to, any other severance arrangement maintained by the Company. For avoidance
of doubt, any unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company that are
subject to performance-based vesting shall become vested, if at all, in accordance with the Company&rsquo;s Amended and Restated
2014 Stock Incentive Plan (or any successor provision or plan) (the &ldquo;<U>Plan</U>&rdquo;) and the applicable award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any provision of this
Agreement, the payments and benefits described in <U>Section 5.1</U> are conditioned on: (a) the Executive&rsquo;s execution
and delivery to the Company and the expiration of all applicable statutory revocation periods, by the 45th day following the
effective date of his cessation of employment, of a general release of claims against the Company and its affiliates in a
form reasonably prescribed by the Company (the &ldquo;<U>Release</U>&rdquo;); and (b) the Executive&rsquo;s continued
compliance with the Restrictive Covenants (as defined below). Subject to <U>Section 5.5</U>, below, the benefits described in <U>Section
5.1</U> will be paid or provided (or begin to be paid or provided) as soon as administratively practicable (or determinable
in the case of the benefits described in <U>Section 5.1.1</U>, if later) after the Release becomes irrevocable, provided that
if the 45 day period described above begins in one taxable year and ends in a second taxable year such payments or benefits
shall not commence until the second taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
Following a Change in Control</U>. If Executive&rsquo;s employment by the Company ceases due to a termination by the Company without
Cause or a resignation by Executive for Good Reason during the twelve (12) month period immediately following the occurrence of
a Change in Control (as defined below), (i) all unvested restricted stock, stock options and other equity incentives awarded to
Executive by the Company that are subject only to time-based vesting will become immediately and automatically fully vested and
exercisable (as applicable), (ii) in lieu of the salary continuation described in Section 5.1.2, the Executive shall receive two
(2) times his Base Salary, paid in a lump sum; (iii) in lieu of the bonus described in Section 5.1.3, the Executive shall receive
two (2) times his then-current target annual bonus payable in a lump sum, and (iv) the COBRA continuation period described in
Section 5.1.5 will be twenty-four (24) months in lieu of eighteen (18) months (provided, however, that if such COBRA continuation
period expires after eighteen (18) months under applicable law, the Company will instead pay to the Executive a taxable lump sum
payment equal to six (6) months of the monthly COBRA premium then in effect. Any unvested restricted stock, stock options and
other equity incentives awarded to Executive by the Company that are subject to performance-based vesting shall become vested,
if at all, in accordance with the Plan and the applicable award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any benefits received
under this Section 5.2 shall be governed by the terms and conditions described in Section 5.1 above, including without limitation
the requirement that Executive timely execute a Release and comply with the Restrictive Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
Due to Death or Disability</U>. If Executive&rsquo;s employment by the Company ceases due to his death or Disability (as defined
below), Executive will be entitled to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>payment of any annual bonus otherwise payable (but for the cessation of Executive&rsquo;s employment) with respect to a
year ended prior to the cessation of Executive&rsquo;s employment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>an amount equal to the annual bonus that would have been paid to Executive for the fiscal year in which his employment terminates
(had his employment not terminated), multiplied by a fraction equal to the number of days Executive worked through the date of
termination of employment over 365, which amount shall be paid in the year following employment termination at the time annual
bonuses are paid to the Company&rsquo;s senior executives;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company shall become
fully vested; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>waiver of the applicable premium otherwise payable for COBRA continuation coverage for Executive, if applicable (and, to
the extent covered immediately prior to the date of such cessation, his eligible dependents) for a period equal to twelve (12)
months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in this <U>Section
5.3</U>, and except for payment of all (i) accrued and unpaid Base Salary through the date of such cessation, (ii) any
expense reimbursements to be paid in accordance with Company policy and (iii) payments for any accrued but unused paid time
off in accordance with the Company&rsquo;s policies and applicable law, all compensation and benefits will cease at the time
of such cessation and the Company will have no further liability or obligation by reason of such cessation. Notwithstanding
any provision of this Agreement, the payments and benefits described in <U>Section 5.3</U> are conditioned on
Executive&rsquo;s (or, in the case of his death, his estate&rsquo;s) satisfaction of the Release requirements set forth in <U>Section
5.1</U>. and the Executive&rsquo;s continued compliance with the Restrictive Covenants (as defined below). Subject to <U>Section
5.5</U>, below, the benefits described in <U>Section 5.3</U> will be paid or provided (or begin to be paid or provided) as
soon as administratively practicable (or determinable in the case of the benefits described in <U>Section 5.3.1</U> and <U>Section
5.3.2</U>, if later) after the Release becomes irrevocable, provided that if the 45 day period described above begins in one
taxable year and ends in a second taxable year such payments or benefits shall not commence until the second taxable
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Other
Terminations</U>. If Executive&rsquo;s employment with the Company ceases for any reason other than as described in <U>Section
5.1</U>, <U>Section 5.2</U> or <U>Section 5.3</U> above (including but not limited to termination (i) by the Company for Cause
or (ii) by Executive without Good Reason, then the Company&rsquo;s obligation to Executive will be limited solely to (a) accrued
and unpaid Base Salary through the date of such cessation, (b) any expense reimbursements to be paid in accordance with Company
policy and (c) payments for any accrued but unused paid time off in accordance with the Company&rsquo;s policies and applicable
law. All compensation and benefits will cease at the time of such cessation and, except as otherwise provided by COBRA or this
<U>Section 5.4</U>, the Company will have no further liability or obligation by reason of such termination. The foregoing will
not be construed to limit Executive&rsquo;s right to payment or reimbursement for claims incurred prior to the date of such termination
under any insurance contract funding an employee benefit plan, policy or arrangement of the Company in accordance with the terms
of such insurance contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliance
with Section 409A</U>. If the termination giving rise to the payments described in <U>Section 5.1</U>, <U>Section 5.2 </U>or <U>Section
5.3</U> is not a &ldquo;Separation from Service&rdquo; within the meaning of Treas. Reg. &sect; 1.409A-1(h)(1) (or any successor
provision), then the amounts otherwise payable pursuant to that section will instead be deferred without interest and will not
be paid until Executive experiences a Separation from Service. To the maximum extent permitted under Section 409A of the Code
and its corresponding regulations, the cash severance benefits payable under this Agreement are intended to meet the requirements
of the short-term deferral exemption under Section 409A of the Code and the &ldquo;separation pay exception&rdquo; under Treas.
Reg. &sect;1.409A-1(b)(9)(iii). To the extent compliance with the requirements of Treas. Reg. &sect; 1.409A-3(i)(2) (or any successor
provision) is necessary to avoid the application of an additional tax under Section 409A of the Internal Revenue Code to payments
due to Executive upon or following his Separation from Service, then notwithstanding any other provision of this Agreement (or
any otherwise applicable plan, policy, agreement or arrangement), any such payments that are otherwise due within six months following
Executive&rsquo;s Separation from Service (taking into account the preceding sentence of this paragraph) will be deferred without
interest and paid to Executive in a lump sum immediately following that six month period. For purposes of the application of Treas.
Reg. &sect; 1.409A-1(b)(4) (or any successor provision), each payment in a series of payments will be deemed a separate payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>PPACA</U>.
Notwithstanding anything in this Agreement to the contrary, the waiver in respect of COBRA premiums pursuant to <U>Section
5.1</U>, <U>Section 5.2</U> or <U>Section 5.3</U> shall cease to the extent required to avoid adverse consequences to the
Company under the Patient Protection and Affordable Care Act of 2010 and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Section
280G</U>. If any payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed
or distributable pursuant to the terms of this Agreement or otherwise pursuant to or by reason of any other agreement, policy,
plan, program or arrangement or the lapse or termination of any restriction on or the vesting or exercisability of any payment
or benefit (each a &ldquo;<U>Payment</U>&rdquo;), would be subject to the excise tax imposed by Section 4999 of the Code (or any
successor provision thereto) or to any similar tax imposed by state or local law (such tax or taxes are hereafter collectively
referred to as the &ldquo;<U>Excise Tax</U>&rdquo;), then the aggregate amount of Payments payable to Executive shall be reduced
to the aggregate amount of Payments that may be made to the Executive without incurring an excise tax (the &ldquo;<U>Safe-Harbor
Amount</U>&rdquo;) in accordance with the immediately following sentence; <I>provided that </I>such reduction shall only be imposed
if the aggregate after-tax value of the Payments retained by Executive (after giving effect to such reduction) is equal to or
greater than the aggregate after-tax value (after giving effect to the Excise Tax) of the Payments to Executive without any such
reduction. Any such reduction shall be made in the following order: (i) first, any future cash payments (if any) shall be reduced
(if necessary, to zero); (ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash
payments (other than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth,
all equity or equity derivative payments shall be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Definitions</U>.
For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Cause</U>&rdquo; means (a) commission or conviction of any felony or any crime involving dishonesty; (b) commission
of any fraud against the Company; (c) intentional and material damage to any material property of the Company; (d) Executive&rsquo;s
material breach of any agreement with or duty owed to the Company or any of its affiliates (including, without limitation, Executive&rsquo;s
material breach of any of the Restrictive Covenants, as defined below); or (e) refusal to perform the lawful, reasonable and material
directives of the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">5.8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Change in Control</U>&rdquo; means the first to occur of any of the events described in Section 1(g) of the Plan
..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.8.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Disability</U>&rdquo; means a condition entitling the Executive to benefits under the Company&rsquo;s long term
disability plan, policy or arrangement; <I>provided, however</I>, that if no such plan, policy or arrangement is then maintained
by the Company and applicable to the Executive, &ldquo;<U>Disability</U>&rdquo; will mean the Executive&rsquo;s inability to perform
his duties under this Agreement due to a mental or physical condition that can be expected to result in death or that can be expected
to last (or has already lasted) for a continuous period of 90 days or more, or for 120 days in any 180 consecutive day period.
Termination as a result of a Disability will not be construed as a termination by the Company &ldquo;without Cause.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.8.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Good Reason</U>&rdquo; means any of the following, without the Executive&rsquo;s prior consent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> a material diminution of the Executive&rsquo;s duties or authority with the Company, reporting relationships or the assignment
of duties and responsibilities inconsistent with Executive&rsquo;s status at the Company; (b) a reduction in Base Salary; or (c)
the relocation of the Executive&rsquo;s primary place of employment to a location that is (i) more than 50 miles from the location
of the Executive&rsquo;s permanent primary place of employment prior to such relocation and (ii) more than 50 miles from the location
of the Executive&rsquo;s residence. However, none of the foregoing events or conditions will constitute Good Reason unless the
Executive provides the Company with written objection to the event or condition within 30 days following the occurrence thereof,
the Company does not reverse or otherwise cure the event or condition within 30 days of receiving that written objection, and the
Executive resigns Executive&rsquo;s employment within 30 days following the expiration of that cure period. Notwithstanding the
foregoing and for the avoidance of doubt, a diminution of the Executive&rsquo;s title as a result of Change in Control shall not
constitute Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Restrictive
Covenants</U>. To induce the Company to enter into this Agreement and in recognition of the compensation to be paid to the Executive
pursuant to <U>Sections 4 and 5</U> of this Agreement, the Executive agrees to be bound by the provisions of this <U>Section 6
</U>(the &ldquo;<U>Restrictive Covenants</U>&rdquo;). These Restrictive Covenants will apply without regard to whether any termination
or cessation of the Executive&rsquo;s employment is initiated by the Company or the Executive, and without regard to the reason
for that termination or cessation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Covenant
Not To Compete</U>. The Executive covenants that, during his employment by the Company and for a period of eighteen (18) months
following immediately thereafter (the &ldquo;<U>Restricted Period</U>&rdquo;), the Executive will not (except in his capacity
as an employee or director of the Company) do any of the following, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>engage or participate in any Competing Business (as defined below) wherever the Company or its affiliates do business, do
or plan to do business or sell or market their products or services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>become interested in (as owner, stockholder, lender, partner, co-venturer, director, officer, employee, agent or consultant)
any person, firm, corporation, association or other entity engaged in a Competing Business. Notwithstanding the foregoing, the
Executive may hold up to 1% of the outstanding securities of any class of any publicly-traded securities of any company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>influence or attempt to influence any employee, consultant, supplier, licensor, licensee, contractor, agent, strategic partner,
distributor, customer or other person to terminate or modify any written or oral agreement, arrangement or course of dealing with
the Company or any of its affiliates; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>solicit
for employment or retention as an independent contractor (or arrange to have any other person or entity solicit for
employment or retention) any person employed or retained by the Company or any of its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0">Executive acknowledges that
the consideration described in <U>Sections 4</U> and <U>5</U> constitutes mutually-agreed upon consideration with respect to
the covenants set forth in <U>Sections 6.1.1</U> and <U>6.1.2</U> for purposes of Section 24L(b)(vii) of Chapter 149 of the
Massachusetts General Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Confidentiality</U>.
The Executive recognizes and acknowledges that the Proprietary Information (as defined in below) is a valuable, special and unique
asset of the business of the Company and its affiliates. As a result, both during the term of the Executive&rsquo;s employment
and thereafter, the Executive will not, without the prior written consent of the Company, for any reason divulge to any third-party
or use for his own benefit, or for any purpose other than the exclusive benefit of the Company and its affiliates, any Proprietary
Information. Notwithstanding the foregoing, nothing in this Agreement prohibits Executive from initiating communications directly
with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible
violations of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory
authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department of Labor,
the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency
Inspector General (collectively, the &ldquo;<U>Regulators</U>&rdquo;), or from making other disclosures that are protected under
the whistleblower provisions of state or federal law or regulation. In connection with any such activity, the Executive must identify
any information that is confidential and ask the Regulator for confidential treatment of such information. Despite the foregoing,
Executive is not permitted to reveal to any third party, including any governmental, law enforcement, or regulatory authority,
information employee came to learn during the course of the Executive&rsquo;s employment with the Company that is protected from
disclosure by any applicable privilege, including but not limited to the attorney-client privilege, attorney work product doctrine
and/or other applicable legal privileges. The Company and its affiliates do not waive any applicable privileges or the right to
continue to protect its privileged attorney-client information, attorney work product, and other privileged information. Notwithstanding
any other provisions of this Agreement, pursuant to 18 USC Section 1833(b), Executive shall not be held criminally or civilly
liable under any federal or state trade secret law for the disclosure of the Company&rsquo;s or its affiliate&rsquo;s trade secret
that is made: (a) confidentially to a federal, state, or local government official, either directly or indirectly, or to an attorney,
and solely for the purpose of reporting or investigating a suspected violation of law; or (b) in a complaint or other document
filed in a lawsuit or other proceeding, if such filing is made under seal. If Executive files a lawsuit for retaliation by the
Company for reporting a suspected violation of law, Executive may disclose a trade secret to the Executive&rsquo;s attorney and
use the trade secret information in related court proceedings, provided that Executive files any document containing the trade
secret information under seal and does not disclose the trade secret, except pursuant to court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Property
of the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Proprietary
Information</U>. All right, title and interest in and to Proprietary Information will be and remain the sole and exclusive
property of the Company and its affiliates. The Executive will not remove from the Company&rsquo;s or its affiliates&rsquo;
offices or premises any documents, records, notebooks, files, correspondence, reports, memoranda or similar materials of or
containing Proprietary Information, or other materials or property of any kind belonging to the Company or its affiliates
unless necessary or appropriate in the performance of his duties to the Company and its affiliates. If the Executive removes
such materials or property in the performance of his duties, he will return such materials or property promptly after the
removal has served its purpose. The Executive will not make, retain, remove and/or distribute any copies of any such
materials or property, or divulge to any third person the nature of and/or contents of such materials or property, except to
the extent necessary to satisfy contractual obligations of the Company or its affiliates, to perform his duties on behalf of
the Company and its affiliates or pursuant to the exceptions set forth in <U>Section 6.2</U>. Upon termination of the
Executive&rsquo;s employment with the Company, he will leave with the Company and its affiliates or promptly return to the
Company and its affiliates all originals and copies of such materials or property then in his possession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>. The Executive agrees that all the Intellectual Property (as defined below) will be considered
 &ldquo;works made for hire&rdquo; as that term is defined in Section 101 of the Copyright Act (17 U.S.C. &sect; 101) and that all
right, title and interest in such Intellectual Property will be the sole and exclusive property of the Company and its affiliates.
To the extent that any of the Intellectual Property may not by law be considered a work made for hire, or to the extent that, notwithstanding
the foregoing, the Executive retains any interest in the Intellectual Property, the Executive hereby irrevocably assigns and transfers
to the Company and its affiliates any and all right, title, or interest that the Executive may now or in the future have in the
Intellectual Property under patent, copyright, trade secret, trademark or other law, in perpetuity or for the longest period otherwise
permitted by law, without the necessity of further consideration. The Company and its affiliates will be entitled to obtain and
hold in its own name all copyrights, patents, trade secrets, trademarks and other similar registrations with respect to such Intellectual
Property. The Executive further agrees to execute any and all documents and provide any further cooperation or assistance reasonably
required by the Company, at the Company&rsquo;s expense, to perfect, maintain or otherwise protect its rights in the Intellectual
Property. If the Company or its affiliates, as applicable, are unable after reasonable efforts to secure the Executive&rsquo;s
signature, cooperation or assistance in accordance with the preceding sentence, whether because of the Executive&rsquo;s incapacity
or any other reason whatsoever, the Executive hereby designates and appoints the Company, the appropriate affiliate, or their respective
designee as the Executive&rsquo;s agent and attorney-in-fact, to act on his behalf, to execute and file documents and to do all
other lawfully permitted acts necessary or desirable to perfect, maintain or otherwise protect the Company&rsquo;s or its affiliates&rsquo;
rights in the Intellectual Property. The Executive acknowledges and agrees that such appointment is coupled with an interest and
is therefore irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Definitions</U>.
For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Competing Business</U>&rdquo; means any person, firm, corporation, partnership, association or other entity engaged
in developing, manufacturing, marketing, distributing or selling, directly or indirectly, pharmaceutical abuse-deterrent products
or any other product for pain indications that directly competes with a product developed, manufactured, marketed, distributed
or sold by the Company. A division, subsidiary or similar business unit of an entity that does not engage in the business activities
described in this definition will not be considered a Competing Business even if another separate division, subsidiary or similar
business unit does engage in such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<U>Intellectual Property</U>&rdquo; means (a) all inventions (whether patentable or unpatentable and whether or
not reduced to practice), all improvements thereto, and all patents and patent applications claiming such inventions, (b) all trademarks,
service marks, trade dress, logos, trade names, fictitious names, brand names, brand marks and corporate names, together with all
translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications,
registrations, and renewals in connection therewith, (c) all copyrightable works, all copyrights, and all applications, registrations,
and renewals in connection therewith, (d) all mask works and all applications, registrations, and renewals in connection therewith,
(e) all trade secrets (including research and development, know-how, formulas, compositions, manufacturing and production processes
and techniques, methodologies, technical data, designs, drawings and specifications), (f) all computer software (including data,
source and object codes and related documentation), (g) all other proprietary rights, (h) all copies and tangible embodiments thereof
(in whatever form or medium), or (i) similar intangible personal property which have been or are developed or created in whole
or in part by the Executive (1) at any time and at any place while the Executive is employed by Company and which, in the case
of any or all of the foregoing, are related to and used in connection with the business of the Company or its affiliates, or (2)
as a result of tasks assigned to the Executive by the Company or its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Proprietary Information</U>&rdquo; means any and all proprietary information developed or acquired by the Company
or any of its subsidiaries or affiliates that has not been specifically authorized to be disclosed. Such Proprietary Information
shall include, but shall not be limited to, the following items and information relating to the following items: (a) all intellectual
property and proprietary rights of the Company (including, without limitation, the Intellectual Property), (b) computer codes and
instructions, processing systems and techniques, inputs and outputs (regardless of the media on which stored or located) and hardware
and software configurations, designs, architecture and interfaces, (c) business research, studies, procedures and costs, (d) financial
data, (e) distribution methods, (f) marketing data, methods, plans and efforts, (g) the identities of actual and prospective suppliers,
(h) the terms of contracts and agreements with, the needs and requirements of, and the Company&rsquo;s or its affiliates&rsquo;
course of dealing with, actual or prospective suppliers, (i) personnel information, (j) customer and vendor credit information,
and (k) information received from third parties subject to obligations of non-disclosure or non-use. Failure by the Company or
its affiliates to mark any of the Proprietary Information as confidential or proprietary shall not affect its status as Proprietary
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Acknowledgements</U>.
The Executive acknowledges that the Restrictive Covenants are reasonable and necessary to protect the legitimate interests of
the Company and its affiliates, that the duration and geographic scope of the Restrictive Covenants are reasonable given the nature
of this Agreement and the position the Executive holds within the Company, and that the Company would not enter into this Agreement
or otherwise employ the Executive unless the Executive agrees to be bound by the Restrictive Covenants set forth in this <U>Section
6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Remedies
and Enforcement Upon Breach</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Specific
Enforcement</U>. The Executive acknowledges that any breach by him, willfully or otherwise, of the Restrictive Covenants will
cause continuing and irreparable injury to the Company or its affiliates for which monetary damages would not be an adequate
remedy. The Executive shall not, in any action or proceeding to enforce any of the provisions of this Agreement, assert the
claim or defense that such an adequate remedy at law exists. In the event of any such breach or threatened breach by the
Executive of any of the Restrictive Covenants, the Company or its affiliates, as applicable, shall be entitled to injunctive
or other similar equitable relief in any court, without any requirement that a bond or other security be posted, and this
Agreement shall not in any way limit remedies of law or in equity otherwise available to the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Judicial Modification</U>. If any court determines that any of the Restrictive Covenants, or any part thereof, is unenforceable
because of the duration or geographical scope of such provision, such court shall have the power to modify such provision and,
in its modified form, such provision shall then be enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforceability</U>. If any court holds the Restrictive Covenants unenforceable by reason of their breadth or scope or
otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the right of the Company
and its affiliates to the relief provided above in the courts of any other jurisdiction within the geographic scope of such Restrictive
Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of Restrictive Covenants</U>. The Executive agrees to disclose the existence and terms of the Restrictive
Covenants to any employer that the Executive may work for during the Restricted Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Extension of Restricted Period</U>. If the Executive breaches <U>Section 6.1</U> in any respect, the restrictions contained
in that section will be extended for a period equal to the period that the Executive was in breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Right
to Consult Counsel</U>. Executive understands and acknowledges that Executive has the right to consult with counsel prior to signing
this Agreement. Executive further represents that Executive is signing this Agreement freely and voluntarily in exchange for the
benefits provided herein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Other
Agreements</U>. Executive represents and warrants to the Company that there are no restrictions, agreements or understandings
whatsoever to which he is a party that would prevent or make unlawful his execution of this Agreement, that would be inconsistent
or in conflict with this Agreement or Executive&rsquo;s obligations hereunder, or that would otherwise prevent, limit or impair
the performance by Executive of his duties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Successors
and Assigns</U>. The Company may assign this Agreement to any successor to its assets and business by means of liquidation, dissolution,
sale of assets or otherwise. The duties of Executive hereunder are personal to Executive and may not be assigned by him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing
Law and Enforcement</U>. This Agreement will be governed by and construed in accordance with the laws of the Commonwealth of
Massachusetts, without regard to the principles of conflicts of laws. Any legal proceeding arising out of or relating to this
Agreement will be instituted in a state or federal court in the Commonwealth of Massachusetts, and Executive and the Company
hereby consent to the personal and exclusive jurisdiction of such court(s) and hereby waive any objection(s) that they may
have to personal jurisdiction, the laying of venue of any such proceeding and any claim or defense of inconvenient forum.
Notwithstanding the foregoing, any action that is commenced by either party to resolve any matter arising under <U>Section
6.1</U> of this Agreement, shall be commenced only in the Massachusetts Superior Court located in Suffolk County,
Massachusetts and the parties each consent to the jurisdiction of such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Waivers</U>.
The waiver by either party of any right hereunder or of any breach by the other party will not be deemed a waiver of any other
right hereunder or of any other breach by the other party. No waiver will be deemed to have occurred unless set forth in a writing.
No waiver will constitute a continuing waiver unless specifically stated, and any waiver will operate only as to the specific
term or condition waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severability</U>.
Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable
law. However, if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability will not affect any other provision, and this Agreement will be reformed, construed and enforced
as though the invalid, illegal or unenforceable provision had never been herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Survival</U>.
This Agreement will survive the cessation of Executive&rsquo;s employment to the extent necessary to fulfill the purposes and
intent the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notices</U>.
Any notice or communication required or permitted under this Agreement will be made in writing and (a) sent by overnight courier,
(b) mailed by overnight U.S. express mail, return receipt requested or (c) sent by telecopier. Any notice or communication to
Executive will be sent to the address contained in his personnel file. Any notice or communication to the Company will be sent
to the Company&rsquo;s principal executive offices, to the attention of its Chief Financial Officer. Notwithstanding the foregoing,
either party may change the address for notices or communications hereunder by providing written notice to the other in the manner
specified in this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Entire
Agreement; Amendments</U>. This Agreement contains the entire agreement and understanding of the parties hereto relating to the
subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every
nature relating to that subject matter (including, without limitation, the Existing Agreement). This Agreement may not be changed
or modified, except by an agreement in writing signed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Withholding</U>.
All payments (or transfers of property) to Executive will be subject to tax withholding to the extent required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Section
Headings</U>. The headings of sections and paragraphs of this Agreement are inserted for convenience only and will not in any
way affect the meaning or construction of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Counterparts;
Facsimile</U>. This Agreement may be executed in multiple counterparts (including by facsimile signature), each of which will
be deemed to be an original, but all of which together will constitute but one and the same instrument. Counterparts may be delivered
via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to
have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&lt;remainder of page intentionally left
blank; signature page follows&gt;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 6pt; text-align: justify; text-indent: 0.5in">IN WITNESS
WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and Executive has executed this Agreement,
on the date(s) indicated below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">COLLEGIUM PHARMACEUTICAL, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Paul Brannelly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Paul Brannelly</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">CFO</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">12/27/2020</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">JOSEPH CIAFFONI</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Joseph Ciaffoni</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">12/24/2020</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"> </FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>tm2039449d1_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>amended &amp;
restated</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>EMPLOYMENT
AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS EMPLOYMENT AGREEMENT
(the &#8220;<U>Agreement</U>&#8221;) is made by and between COLLEGIUM PHARMACEUTICAL, INC. (the &#8220;<U>Company</U>&#8221;) and
PAUL BRANNELLY (the &#8220;<U>Executive</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive are parties to an Employment Agreement dated as of August 4, 2015 (the &#8220;<U>Existing Agreement</U>&#8221;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive desire to amend and restate the Existing Agreement and enter into this Agreement pursuant to which the Company
will continue to employ Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the foregoing and intending to be bound hereby, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Duration of Agreement</U>. This Agreement is effective as of January 1, 2021 and has no specific expiration date. Unless
terminated by agreement of the parties, this Agreement will govern Executive&#8217;s continued employment by the Company until
that employment ceases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Title; Duties</U>. Executive will continue to be employed as the Company&#8217;s Chief Financial Officer, reporting directly
to the Company&#8217;s Chief Executive Officer. Executive will devote his best efforts and substantially all of his business time
and services to the Company and its affiliates to perform such duties as may be customarily incident to his position and as may
reasonably be assigned to him from time to time. Executive will not, in any capacity, engage in other business activities or perform
services for any other individual, firm or corporation without the prior written consent of the Company; <I>provided, however</I>,
that without such consent, Executive may engage in charitable, non-profit and public service activities, so long as such activities
do not in any respect interfere or conflict with Executive&#8217;s performance of his duties and obligations to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Place of Performance</U>. Executive will perform his services hereunder at the principal executive offices of the Company
in Stoughton, Massachusetts; <I>provided, however, </I>that Executive may be required to travel from time to time for business
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation and Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Base Salary</U>. Executive&#8217;s annual salary will be $439,900 (the &#8220;<U>Base Salary</U>&#8221;), paid in accordance
with the Company&#8217;s payroll practices as in effect from time to time. The Base Salary will be reviewed annually by the Compensation
Committee of the Company&#8217;s Board of Directors (the &#8220;<U>Committee</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Annual Bonuses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>For
each fiscal year ending during his employment, Executive will be eligible to earn an annual bonus. The target amount of that
bonus will be 50% of Executive&#8217;s Base Salary for the applicable fiscal year. The actual bonus payable with respect to a
particular year will be determined by the Committee, based on the achievement of corporate and /or individual performance
objectives established by the Committee. Any bonus payable under this paragraph will be paid during the calendar year
immediately following the fiscal year in respect of which the bonus is payable and, except as otherwise provided in <U>Section
5.1.1</U>, will only be paid if Executive remains continuously employed by the Company through the actual bonus payment
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of determining any bonus payable to Executive, the measurement of corporate and individual performance will
be performed by the Committee in good faith. From time to time, the Committee may, in its sole discretion, make adjustments to
corporate or individual performance goals, so that required departures from the Company&#8217;s operating budget, changes in accounting
principles, acquisitions, dispositions, mergers, consolidations and other corporate transactions, and other factors influencing
the achievement or calculation of such goals do not affect the operation of this provision in a manner inconsistent with its intended
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Benefits</U>. During Executive&#8217;s employment, Executive will be eligible to participate in all employee
benefit plans and programs made available by the Company from time to time to employees generally, subject to applicable plan terms
and policies. The Company periodically reviews its benefits, policies, benefits providers and practices and may terminate, alter
or change them at its discretion from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reimbursement of Expenses</U>. The Executive will be reimbursed by the Company for all reasonable business expenses incurred
by Executive in accordance with the Company&#8217;s customary expense reimbursement policies as in effect from time to time. Notwithstanding
anything herein to the contrary, to the extent any expense, reimbursement or in-kind benefit provided to the Executive constitutes
a &#8220;deferral of compensation&#8221; within the meaning of Section 409A of the Internal Revenue Code (the &#8220; <U>Code</U>&#8221;)
(i) the amount of expenses eligible for reimbursement or in- kind benefits provided to the Executive must be incurred during the
Executive&#8217;s term of employment; (ii) the amount of expenses eligible for reimbursement or in-kind benefits provided to the
Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided
to the Executive in any other calendar year, (iii) the reimbursements for expenses for which the Executive is entitled to be reimbursed
shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred
and (iv) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>. Executive&#8217;s employment with the Company may be terminated by the Company or Executive at any time
and for any reason. Upon any cessation of his employment with the Company, Executive will be entitled only to such compensation
and benefits as described in this <U>Section 5</U>. Upon any cessation of his employment for any reason, unless otherwise requested
by the Company, Executive agrees to resign immediately from all officer and director positions he then holds with the Company and
its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Termination
without Cause or for Good Reason</U>. If Executive&#8217;s employment by the Company ceases due to a termination by the
Company without Cause (as defined below) or a resignation by Executive for Good Reason (as defined below), Executive will be
entitled to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>payment of any annual bonus otherwise payable (but for the cessation of Executive&#8217;s employment) with respect to a
year ended prior to the cessation of Executive&#8217;s employment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>continuation of Executive&#8217;s Base Salary for a period equal to twelve (12) months, payable in accordance with the Company&#8217;s
standard payroll practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>payment equal to Executive&#8217;s target annual bonus described in Section 4.2.1, paid in twelve (12) substantially equal
installments over a twelve-month period and in accordance with the Company&#8217;s standard payroll practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>accelerated vesting of any unvested restricted stock, stock options and other equity incentives awarded to Executive by
the Company that are solely subject to time-based vesting criteria equal to what would have vested had Executive remained employed
for twelve (12) additional months; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>waiver of the applicable premium otherwise payable for COBRA continuation coverage for Executive (and, to the extent covered
immediately prior to the date of such cessation, his eligible dependents) for a period equal to twelve (12) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in this <U>Section
5.1</U>, and except for payment of all (i) accrued and unpaid Base Salary through the date of such cessation, (ii) any expense
reimbursements to be paid in accordance with Company policy and (iii) payments for any accrued but unused paid time off in accordance
with the Company&#8217;s policies and applicable law, all compensation and benefits will cease at the time of such cessation and
the Company will have no further liability or obligation by reason of such cessation. The payments and benefits described in this
<U>Section 5.1</U> are in lieu of, and not in addition to, any other severance arrangement maintained by the Company. For avoidance
of doubt, any unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company that are
subject to performance-based vesting shall become vested, if at all, in accordance with the Company&#8217;s Amended and Restated
2014 Stock Incentive Plan (or any successor provision or plan) (the &#8220;<U>Plan</U>&#8221;) and the applicable award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any provision of this Agreement,
the payments and benefits described in <U>Section 5.1</U> are conditioned on: (a) the Executive&#8217;s execution and delivery
to the Company and the expiration of all applicable statutory revocation periods, by the 45th day following the effective date
of his cessation of employment, of a general release of claims against the Company and its affiliates in a form reasonably prescribed
by the Company (the &#8220;<U>Release</U>&#8221;); and (b) the Executive&#8217;s continued compliance with the Restrictive Covenants
(as defined below). Subject to <U>Section 5.4</U>, below, the benefits described in <U>Section 5.1</U> will be paid or provided
(or begin to be paid or provided) as soon as administratively practicable (or determinable in the case of the benefits described
in <U>Section 5.1.1</U>) after the Release becomes irrevocable, provided that if the 45 day period described above begins in one
taxable year and ends in a second taxable year such payments or benefits shall not commence until the second taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Termination Following a Change in Control</U>. If Executive&#8217;s employment by the Company ceases due to a termination
by the Company without Cause or a resignation by Executive for Good Reason during the twelve (12) month period immediately following
the occurrence of a Change in Control (as defined below), (i) all unvested restricted stock, stock options and other equity incentives
awarded to Executive by the Company that are subject only to time-based vesting will become immediately and automatically fully
vested and exercisable (as applicable), (ii) in lieu of the salary continuation described in Section 5.1.2, the Executive shall
receive eighteen (18) months of his Base Salary, paid in a lump sum; (iii) in lieu of the bonus described in Section 5.1.3, the
Executive shall receive 1.5 times his then-current target annual bonus payable in a lump sum, and (iv) the COBRA continuation period
described in Section 5.1.5 will be eighteen (18) months in lieu of twelve (12). Any unvested restricted stock, stock options and
other equity incentives awarded to Executive by the Company that are subject to performance-based vesting shall become vested,
if at all, in accordance with the Plan and the applicable award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any benefits received
under this <U>Section 5.2</U> shall be governed by the terms and conditions described in <U>Section 5.1</U> above, including without
limitation the requirement that Executive timely execute a Release and comply with the Restrictive Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Terminations</U>. If Executive&#8217;s employment with the Company ceases for any reason other than as described
in <U>Section 5.1</U> or <U>Section 5.2</U>, above (including, but not limited to, termination (i) by the Company for Cause, (ii)
as a result of Executive&#8217;s death, (iii) as a result of Executive&#8217;s Disability or (iv) by Executive without Good Reason,
then the Company&#8217;s obligation to Executive will be limited solely to (a) accrued and unpaid Base Salary through the date
of such cessation, (b) any expense reimbursements to be paid in accordance with Company policy and (c) payments for any accrued
but unused paid time off in accordance with the Company&#8217;s policies and applicable law. All compensation and benefits will
cease at the time of such cessation and, except as otherwise provided by COBRA or this <U>Section 5.3</U>, the Company will have
no further liability or obligation by reason of such termination. The foregoing will not be construed to limit Executive&#8217;s
right to payment or reimbursement for claims incurred prior to the date of such termination under any insurance contract funding
an employee benefit plan, policy or arrangement of the Company in accordance with the terms of such insurance contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Compliance
with Section 409A</U>. If the termination giving rise to the payments described in <U>Section 5.1</U> or <U>Section 5.2</U>
is not a &#8220;Separation from Service&#8221; within the meaning of Treas. Reg. &sect; 1.409A-1(h)(1) (or any successor
provision), then the amounts otherwise payable pursuant to that section will instead be deferred without interest and will
not be paid until Executive experiences a Separation from Service. To the maximum extent permitted under Section 409A of the
Code and its corresponding regulations, the cash severance benefits payable under this Agreement are intended to meet the
requirements of the short-term deferral exemption under Section 409A of the Code and the &#8220;separation pay
exception&#8221; under Treas. Reg. &sect;1.409A-1(b)(9)(iii). To the extent compliance with the requirements of Treas. Reg.
 &sect; 1.409A-3(i)(2) (or any successor provision) is necessary to avoid the application of an additional tax under Section
409A of the Internal Revenue Code to payments due to Executive upon or following his Separation from Service, then
notwithstanding any other provision of this Agreement (or any otherwise applicable plan, policy, agreement or arrangement),
any such payments that are otherwise due within six months following Executive&#8217;s Separation from Service (taking into
account the preceding sentence of this paragraph) will be deferred without interest and paid to Executive in a lump sum
immediately following that six month period. For purposes of the application of Treas. Reg. &sect; 1.409A-1(b)(4)(or any
successor provision), each payment in a series of payments will be deemed a separate payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>PPACA</U>. Notwithstanding anything in this Agreement to the contrary, the waiver in respect of COBRA premiums pursuant
to <U>Sections 5.1</U> and <U>5.2</U> shall cease to the extent required to avoid adverse consequences to the Company under the
Patient Protection and Affordable Care Act of 2010 and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 280G</U>. If any payment or distribution by the Company to or for the benefit of the Executive, whether paid
or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise pursuant to or by reason of any
other agreement, policy, plan, program or arrangement or the lapse or termination of any restriction on or the vesting or exercisability
of any payment or benefit (each a &#8220;<U>Payment</U>&#8221;), would be subject to the excise tax imposed by Section 4999 of
the Code (or any successor provision thereto) or to any similar tax imposed by state or local law (such tax or taxes are hereafter
collectively referred to as the &#8220;Excise Tax&#8221;), then the aggregate amount of Payments payable to Executive shall be
reduced to the aggregate amount of Payments that may be made to the Executive without incurring an excise tax (the &#8220; <U>Safe-Harbor
Amount</U>&#8221;) in accordance with the immediately following sentence; <I>provided that </I>such reduction shall only be imposed
if the aggregate after-tax value of the Payments retained by Executive (after giving effect to such reduction) is equal to or greater
than the aggregate after-tax value (after giving effect to the Excise Tax) of the Payments to Executive without any such reduction.
Any such reduction shall be made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary,
to zero); (ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash payments (other
than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity
derivative payments shall be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Cause</U>&#8221; means (a) commission or conviction of any felony or any crime involving dishonesty; (b) commission
of any fraud against the Company; (c) intentional and material damage to any material property of the Company; (d) Executive&#8217;s
material breach of any agreement with or duty owed to the Company or any of its affiliates (including, without limitation, Executive&#8217;s
material breach of any of the Restrictive Covenants, as defined below); or (e) refusal to perform the lawful, reasonable and material
directives of the Company&#8217;s Board of Directors (the &#8220;<U>Board</U>&#8221;) or the Company&#8217;s Chief Executive Officer.
Before &#8220;Cause&#8221; under clause (c), (d) or (e) has been deemed to have occurred, the Board must provide the Executive
with written notice detailing why the Board has determined that Cause has occurred and the actions required to cure the same, to
the extent reasonably subject to cure. The Executive shall then, where the grounds for Cause are reasonably subject to cure within
such time, have thirty (30) days after the Executive&#8217;s receipt of written notice to cure the item cited in the written notice
so that &#8220;Cause&#8221; will have not formally occurred with respect to the event in question until such period, where applicable,
shall have expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &#8220;<U>Change in Control</U>&#8221; means the first to occur of any of the events described in Section 1(g) of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Disability</U>&#8221; means a condition entitling the Executive to benefits under the Company&#8217;s long term
disability plan, policy or arrangement; <I>provided, however</I>, that if no such plan, policy or arrangement is then maintained
by the Company and applicable to the Executive, &#8220;<U>Disability</U>&#8221; will mean the Executive&#8217;s inability to perform
his duties under this Agreement due to a mental or physical condition that can be expected to result in death or that can be expected
to last (or has already lasted) for a continuous period of 90 days or more, or for 120 days in any 180 consecutive day period.
Termination as a result of a Disability will not be construed as a termination by the Company &#8220;without Cause.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Good Reason</U>&#8221; means any of the following, without the Executive&#8217;s prior consent: (a) a material
diminution of the Executive&#8217;s duties or authority with the Company, reporting relationships or the assignment of duties and
responsibilities inconsistent with Executive&#8217;s status at the Company; (b) a reduction in Base Salary; or (c) the relocation
of the Executive&#8217;s primary place of employment to a location that is (i) more than 50 miles from the location of the Executive&#8217;s
permanent primary place of employment prior to such relocation and (ii) more than 50 miles from the location of the Executive&#8217;s
residence. However, none of the foregoing events or conditions will constitute Good Reason unless the Executive provides the Company
with written objection to the event or condition within 30 days following the occurrence thereof, the Company does not reverse
or otherwise cure the event or condition within 30 days of receiving that written objection, and the Executive resigns Executive&#8217;s
employment within 30 days following the expiration of that cure period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictive Covenants</U>. To induce the Company to enter into this Agreement and in recognition of the compensation
to be paid to the Executive pursuant to <U>Sections 4 and 5</U> of this Agreement, the Executive agrees to be bound by the provisions
of this <U>Section 6</U> (the &#8220;<U>Restrictive Covenants</U>&#8221;). These Restrictive Covenants will apply without regard
to whether any termination or cessation of the Executive&#8217;s employment is initiated by the Company or the Executive, and without
regard to the reason for that termination or cessation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Covenant Not To Compete</U>. The Executive covenants that, during his employment by the Company and for a period of twelve
(12) months following immediately thereafter (the &#8220;<U>Restricted Period</U>&#8221;), the Executive will not (except in his
capacity as an employee or director of the Company) do any of the following, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>engage or participate in any Competing Business (as defined below) wherever the Company or its affiliates do business, do
or plan to do business or sell or market their products or services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>become interested in (as owner, stockholder, lender, partner, co-venturer, director, officer, employee, agent or consultant)
any person, firm, corporation, association or other entity engaged in a Competing Business. Notwithstanding the foregoing, the
Executive may hold up to 1% of the outstanding securities of any class of any publicly-traded securities of any company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> influence or attempt to influence any employee, consultant, supplier, licensor, licensee, contractor, agent, strategic
partner, distributor, customer or other person to terminate or modify any written or oral agreement, arrangement or course of dealing
with the Company or any of its affiliates; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>solicit for employment or retention as an independent contractor (or arrange to have any other person or entity solicit
for employment or retention) any person employed or retained by the Company or any of its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Executive acknowledges
that the consideration described in <U>Sections 4</U> and <U>5</U> constitutes mutually-agreed upon consideration with respect
to the covenants set forth in <U>Sections 6.1.1</U> and <U>6.1.2</U> for purposes of Section 24L(b)(vii) of Chapter 149 of the
Massachusetts General Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidentiality</U>. The Executive recognizes and acknowledges that the Proprietary Information (as defined in below)
is a valuable, special and unique asset of the business of the Company and its affiliates. As a result, both during the term of
the Executive&#8217;s employment and thereafter, the Executive will not, without the prior written consent of the Company, for
any reason divulge to any third-party or use for his own benefit, or for any purpose other than the exclusive benefit of the Company
and its affiliates, any Proprietary Information. Notwithstanding the foregoing, nothing in this Agreement prohibits Executive from
initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential information
to, reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with
a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department
of Labor, the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the Congress,
and any agency Inspector General (collectively, the &#8220;<U>Regulators</U>&#8221;), or from making other disclosures that are
protected under the whistleblower provisions of state or federal law or regulation. In connection with any such activity, the Executive
must identify any information that is confidential and ask the Regulator for confidential treatment of such information. Despite
the foregoing, Executive is not permitted to reveal to any third party, including any governmental, law enforcement, or regulatory
authority, information employee came to learn during the course of the Executive&#8217;s employment with the Company that is protected
from disclosure by any applicable privilege, including but not limited to the attorney-client privilege, attorney work product
doctrine and/or other applicable legal privileges. The Company and its affiliates do not waive any applicable privileges or the
right to continue to protect its privileged attorney-client information, attorney work product, and other privileged information.
Notwithstanding any other provisions of this Agreement, pursuant to 18 USC Section 1833(b), Executive shall not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of the Company&#8217;s or its affiliate&#8217;s
trade secret that is made: (a) confidentially to a federal, state, or local government official, either directly or indirectly,
or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (b) in a complaint
or other document filed in a lawsuit or other proceeding, if such filing is made under seal. If Executive files a lawsuit for retaliation
by the Company for reporting a suspected violation of law, Executive may disclose a trade secret to the Executive&#8217;s attorney
and use the trade secret information in related court proceedings, provided that Executive files any document containing the trade
secret information under seal and does not disclose the trade secret, except pursuant to court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Property of the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Proprietary Information</U>. All right, title and interest in and to Proprietary Information will be and remain the sole
and exclusive property of the Company and its affiliates. The Executive will not remove from the Company&#8217;s or its affiliates&#8217;
offices or premises any documents, records, notebooks, files, correspondence, reports, memoranda or similar materials of or containing
Proprietary Information, or other materials or property of any kind belonging to the Company or its affiliates unless necessary
or appropriate in the performance of his duties to the Company and its affiliates. If the Executive removes such materials or property
in the performance of his duties, he will return such materials or property promptly after the removal has served its purpose.
The Executive will not make, retain, remove and/or distribute any copies of any such materials or property, or divulge to any third
person the nature of and/or contents of such materials or property, except to the extent necessary to satisfy contractual obligations
of the Company or its affiliates or to perform his duties on behalf of the Company and its affiliates, or pursuant to the exceptions
set forth in <U>Section 6.2</U>. Upon termination of the Executive&#8217;s employment with the Company, he will leave with the
Company and its affiliates or promptly return to the Company and its affiliates all originals and copies of such materials or property
then in his possession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>. The Executive agrees that all the Intellectual Property (as defined below) will be considered
 &#8220;works made for hire&#8221; as that term is defined in Section 101 of the Copyright Act (17 U.S.C. &sect; 101) and that all
right, title and interest in such Intellectual Property will be the sole and exclusive property of the Company and its affiliates.
To the extent that any of the Intellectual Property may not by law be considered a work made for hire, or to the extent that, notwithstanding
the foregoing, the Executive retains any interest in the Intellectual Property, the Executive hereby irrevocably assigns and transfers
to the Company and its affiliates any and all right, title, or interest that the Executive may now or in the future have in the
Intellectual Property under patent, copyright, trade secret, trademark or other law, in perpetuity or for the longest period otherwise
permitted by law, without the necessity of further consideration. The Company and its affiliates will be entitled to obtain and
hold in its own name all copyrights, patents, trade secrets, trademarks and other similar registrations with respect to such Intellectual
Property. The Executive further agrees to execute any and all documents and provide any further cooperation or assistance reasonably
required by the Company, at the Company&#8217;s expense, to perfect, maintain or otherwise protect its rights in the Intellectual
Property. If the Company or its affiliates, as applicable, are unable after reasonable efforts to secure the Executive&#8217;s
signature, cooperation or assistance in accordance with the preceding sentence, whether because of the Executive&#8217;s incapacity
or any other reason whatsoever, the Executive hereby designates and appoints the Company, the appropriate affiliate, or their respective
designee as the Executive&#8217;s agent and attorney-in-fact, to act on his behalf, to execute and file documents and to do all
other lawfully permitted acts necessary or desirable to perfect, maintain or otherwise protect the Company&#8217;s or its affiliates&#8217;
rights in the Intellectual Property. The Executive acknowledges and agrees that such appointment is coupled with an interest and
is therefore irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.4<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &#8220;<U>Competing Business</U>&#8221; means any person, firm, corporation, partnership, association or other entity engaged
in developing, manufacturing, marketing, distributing or selling, directly or indirectly, pharmaceutical abuse-deterrent products
or any other product for pain indications that directly competes with a product developed, manufactured, marketed, distributed
or sold by the Company. A division, subsidiary or similar business unit of an entity that does not engage in the business activities
described in this definition will not be considered a Competing Business even if another separate division, subsidiary or similar
business unit does engage in such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Intellectual Property</U>&#8221; means (a) all inventions (whether patentable or unpatentable and whether or not
reduced to practice), all improvements thereto, and all patents and patent applications claiming such inventions, (b) all trademarks,
service marks, trade dress, logos, trade names, fictitious names, brand names, brand marks and corporate names, together with all
translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications,
registrations, and renewals in connection therewith, (c) all copyrightable works, all copyrights, and all applications, registrations,
and renewals in connection therewith, (d) all mask works and all applications, registrations, and renewals in connection therewith,
(e) all trade secrets (including research and development, know-how, formulas, compositions, manufacturing and production processes
and techniques, methodologies, technical data, designs, drawings and specifications), (f) all computer software (including data,
source and object codes and related documentation), (g) all other proprietary rights, (h) all copies and tangible embodiments thereof
(in whatever form or medium), or (i) similar intangible personal property which have been or are developed or created in whole
or in part by the Executive (1) at any time and at any place while the Executive is employed by Company and which, in the case
of any or all of the foregoing, are related to and used in connection with the business of the Company or its affiliates, or (2)
as a result of tasks assigned to the Executive by the Company or its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Proprietary Information</U>&#8221; means any and all proprietary information developed or acquired by the Company
or any of its subsidiaries or affiliates that has not been specifically authorized to be disclosed. Such Proprietary Information
shall include, but shall not be limited to, the following items and information relating to the following items: (a) all intellectual
property and proprietary rights of the Company (including, without limitation, the Intellectual Property), (b) computer codes and
instructions, processing systems and techniques, inputs and outputs (regardless of the media on which stored or located) and hardware
and software configurations, designs, architecture and interfaces, (c) business research, studies, procedures and costs, (d) financial
data, (e) distribution methods, (f) marketing data, methods, plans and efforts, (g) the identities of actual and prospective suppliers,
(h) the terms of contracts and agreements with, the needs and requirements of, and the Company&#8217;s or its affiliates&#8217;
course of dealing with, actual or prospective suppliers, (i) personnel information, (j) customer and vendor credit information,
and (k) information received from third parties subject to obligations of non-disclosure or non-use. Failure by the Company or
its affiliates to mark any of the Proprietary Information as confidential or proprietary shall not affect its status as Proprietary
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Acknowledgements</U>.
The Executive acknowledges that the Restrictive Covenants are reasonable and necessary to protect the legitimate interests of
the Company and its affiliates, that the duration and geographic scope of the Restrictive Covenants are reasonable given the
nature of this Agreement and the position the Executive holds within the Company, and that the Company would not enter into
this Agreement or otherwise employ or continue to employ the Executive unless the Executive agrees to be bound by the
Restrictive Covenants set forth in this <U>Section 6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies and Enforcement Upon Breach</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Specific Enforcement</U>. The Executive acknowledges that any breach by him, willfully or otherwise, of the Restrictive
Covenants will cause continuing and irreparable injury to the Company or its affiliates for which monetary damages would not be
an adequate remedy. The Executive shall not, in any action or proceeding to enforce any of the provisions of this Agreement, assert
the claim or defense that such an adequate remedy at law exists. In the event of any such breach or threatened breach by the Executive
of any of the Restrictive Covenants, the Company or its affiliates, as applicable, shall be entitled to injunctive or other similar
equitable relief in any court, without any requirement that a bond or other security be posted, and this Agreement shall not in
any way limit remedies of law or in equity otherwise available to the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Judicial Modification</U>. If any court determines that any of the Restrictive Covenants, or any part thereof, is unenforceable
because of the duration or geographical scope of such provision, such court shall have the power to modify such provision and,
in its modified form, such provision shall then be enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforceability</U>. If any court holds the Restrictive Covenants unenforceable by reason of their breadth or scope or
otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the right of the Company
and its affiliates to the relief provided above in the courts of any other jurisdiction within the geographic scope of such Restrictive
Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of Restrictive Covenants</U>. The Executive agrees to disclose the existence and terms of the Restrictive
Covenants to any employer that the Executive may work for during the Restricted Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Extension of Restricted Period</U>. If the Executive breaches <U>Section 6.1</U> in any respect, the restrictions contained
in that section will be extended for a period equal to the period that the Executive was in breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right to Consult Counsel</U>. Executive understands and acknowledges that Executive has the right to consult with counsel
prior to signing this Agreement. Executive further represents that Executive is signing this Agreement freely and voluntarily in
exchange for the benefits provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Other
Agreements</U>. Executive represents and warrants to the Company that there are no restrictions, agreements or understandings
whatsoever to which he is a party that would prevent or make unlawful his execution of this Agreement, that would be
inconsistent or in conflict with this Agreement or Executive&#8217;s obligations hereunder, or that would otherwise prevent,
limit or impair the performance by Executive of his duties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. The Company may assign this Agreement to any successor to its assets and business by means
of liquidation, dissolution, sale of assets or otherwise. The duties of Executive hereunder are personal to Executive and may not
be assigned by him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law and Enforcement</U>. This Agreement will be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, without regard to the principles of conflicts of laws. Any legal proceeding arising out of or relating
to this Agreement will be instituted in a state or federal court in the Commonwealth of Massachusetts, and Executive and the Company
hereby consent to the personal and exclusive jurisdiction of such court(s) and hereby waive any objection(s) that they may have
to personal jurisdiction, the laying of venue of any such proceeding and any claim or defense of inconvenient forum. Notwithstanding
the foregoing, any action that is commenced by either party to resolve any matter arising under <U>Section 6.1</U> of this Agreement,
shall be commenced only in the Massachusetts Superior Court located in Suffolk County, Massachusetts and the parties each consent
to the jurisdiction of such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waivers</U>. The waiver by either party of any right hereunder or of any breach by the other party will not be deemed
a waiver of any other right hereunder or of any other breach by the other party. No waiver will be deemed to have occurred unless
set forth in a writing. No waiver will constitute a continuing waiver unless specifically stated, and any waiver will operate only
as to the specific term or condition waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective
and valid under applicable law. However, if any provision of this Agreement is held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality or unenforceability will not affect any other provision, and this Agreement will be reformed,
construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. This Agreement will survive the cessation of Executive&#8217;s employment to the extent necessary to fulfill
the purposes and intent the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any notice or communication required or permitted under this Agreement will be made in writing and (a) sent
by overnight courier, (b) mailed by overnight U.S. express mail, return receipt requested or (c) sent by telecopier. Any notice
or communication to Executive will be sent to the address contained in his personnel file. Any notice or communication to the Company
will be sent to the Company&#8217;s principal executive offices, to the attention of its Chief Executive Officer. Notwithstanding
the foregoing, either party may change the address for notices or communications hereunder by providing written notice to the other
in the manner specified in this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Entire
Agreement; Amendments</U>. This Agreement contains the entire agreement and understanding of the parties hereto relating to
the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings
of every nature relating to that subject matter (including, without limitation, the Existing Agreement). This Agreement may
not be changed or modified, except by an agreement in writing signed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Withholding</U>. All payments (or transfers of property) to Executive will be subject to tax withholding to the extent
required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section Headings</U>. The headings of sections and paragraphs of this Agreement are inserted for convenience only and
will not in any way affect the meaning or construction of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts; Facsimile</U>. This Agreement may be executed in multiple counterparts (including by facsimile signature),
each of which will be deemed to be an original, but all of which together will constitute but one and the same instrument. Counterparts
may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall
be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&lt;<I>remainder of page intentionally
left blank; signature page follows</I>&gt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the Company has caused this Agreement to be executed by its duly authorized officer, and Executive has executed this Agreement,
on the date(s) indicated below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COLLEGIUM
    PHARMACEUTICAL, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%">/s/ Shirley Kuhlmann<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shirley Kuhlmann</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVP and General Counsel</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2020</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAUL
    BRANNELLY</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Paul Brannelly</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/27/2020</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to Employment Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>tm2039449d1_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: capitalize; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-weight: normal"><U>amended
 &amp; restATED</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>EMPLOYMENT
AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS EMPLOYMENT AGREEMENT
(the &ldquo;<U>Agreement</U>&rdquo;) is made by and between COLLEGIUM PHARMACEUTICAL, INC. (the &ldquo;<U>Company</U>&rdquo;) and
SCOTT DREYER (the &ldquo;<U>Executive</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive are parties to an Employment Agreement dated as of July 10, 2018 (the &ldquo;<U>Existing Agreement</U>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive desire to amend and restate the Existing Agreement and enter into this Agreement pursuant to which the Company
will continue to employ Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the foregoing and intending to be bound hereby, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Duration of Agreement</U>. This Agreement shall be effective as of January 1, 2021 and has no specific expiration date.
Unless terminated by agreement of the parties, this Agreement will govern Executive&rsquo;s continued employment by the Company
until that employment ceases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Title; Duties</U>. Executive will continue to be employed as the Company&rsquo;s Executive Vice President and Chief Commercial
Officer, reporting directly to the Company&rsquo;s Chief Executive Officer. Executive will devote his best efforts and substantially
all of his business time and services to the Company and its affiliates to perform such duties as may be customarily incident to
his position and as may reasonably be assigned to him from time to time. Executive will not, in any capacity, engage in other business
activities or perform services for any other individual, firm or corporation without the prior written consent of the Company;
<I>provided, however</I>, that without such consent, Executive may engage in charitable, non-profit and public service activities,
so long as such activities do not in any respect interfere or conflict with Executive&rsquo;s performance of his duties and obligations
to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Place of Performance</U>. Executive will perform his services hereunder at the principal executive offices of the Company
in Stoughton, Massachusetts; <I>provided, however, </I>that Executive may be required to travel from time to time for business
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation and Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Base Salary</U>. Executive&rsquo;s annual salary will be $395,900 (the &ldquo;<U>Base Salary</U>&rdquo;), paid in accordance
with the Company&rsquo;s payroll practices as in effect from time to time. The Base Salary will be reviewed annually by the Compensation
Committee of the Company&rsquo;s Board of Directors (the &ldquo;<U>Committee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Annual Bonuses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>For
each fiscal year ending during his employment, Executive will be eligible to earn an annual bonus. The target amount of the
annual bonus will be 50% of Executive&rsquo;s Base Salary for the applicable fiscal year. The actual bonus payable with
respect to a particular year will be determined by the Committee, based on the achievement of corporate and /or individual
performance objectives established by the Committee. Any bonus payable under this paragraph will be paid during the calendar
year immediately following the fiscal year in respect of which the bonus is payable and, except as otherwise provided in <U>Section
5.1.1</U>, will only be paid if Executive remains continuously employed by the Company through the actual bonus payment
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of determining any bonus payable to Executive, the measurement of corporate and individual performance will
be performed by the Committee in good faith. From time to time, the Committee may, in its sole discretion, make adjustments to
corporate or individual performance goals, so that required departures from the Company&rsquo;s operating budget, changes in accounting
principles, acquisitions, dispositions, mergers, consolidations and other corporate transactions, and other factors influencing
the achievement or calculation of such goals do not affect the operation of this provision in a manner inconsistent with its intended
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Benefits</U>. During Executive&rsquo;s employment, Executive will be eligible to participate in all employee
benefit plans and programs made available by the Company from time to time to employees generally, subject to applicable plan terms
and policies. The Company periodically reviews its benefits, policies, benefits providers and practices and may terminate, alter
or change them at its discretion from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reimbursement of Expenses</U>. The Executive will be reimbursed by the Company for all reasonable business expenses incurred
by Executive in accordance with the Company&rsquo;s customary expense reimbursement policies as in effect from time to time. Notwithstanding
anything herein to the contrary, to the extent any expense, reimbursement or in-kind benefit provided to the Executive constitutes
a &ldquo;deferral of compensation&rdquo; within the meaning of Section 409A of the Internal Revenue Code (the &ldquo;<U>Code</U>&rdquo;)
(i) the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive must be incurred during the
Executive&rsquo;s term of employment; (ii) the amount of expenses eligible for reimbursement or in-kind benefits provided to the
Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided
to the Executive in any other calendar year, (iii) the reimbursements for expenses for which the Executive is entitled to be reimbursed
shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred
and (iv) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>. Executive&rsquo;s employment with the Company may be terminated by the Company or Executive at any time
and for any reason. Upon any cessation of his employment with the Company, Executive will be entitled only to such compensation
and benefits as described in this <U>Section 5</U>. Upon any cessation of his employment for any reason, unless otherwise requested
by the Company, Executive agrees to resign immediately from all officer and director positions he then holds with the Company and
its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination without Cause or for Good Reason</U>. If Executive&rsquo;s employment by the Company ceases due to a termination
by the Company without Cause (as defined below) or a resignation by Executive for Good Reason (as defined below), Executive will
be entitled to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> payment of any annual bonus otherwise payable (but for the cessation of Executive&rsquo;s employment) with respect to a
year ended prior to the cessation of Executive&rsquo;s employment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>continuation of Executive&rsquo;s Base Salary for a period equal to twelve (12) months, payable in accordance with the Company&rsquo;s
standard payroll practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>payment equal to Executive&rsquo;s target annual bonus described in <U>Section 4.2.1</U>, paid in twelve (12) substantially
equal installments over a twelve-month period and in accordance with the Company&rsquo;s standard payroll practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>accelerated vesting of any unvested restricted stock, stock options and other equity incentives awarded to Executive by
the Company that are solely subject to time-based vesting criteria equal to what would have vested had Executive remained employed
for twelve (12) additional months; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>waiver of the applicable premium otherwise payable for COBRA continuation coverage for Executive (and, to the extent covered
immediately prior to the date of such cessation, his eligible dependents) for a period equal to twelve (12) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in this <U>Section
5.1</U>, and except for payment of all (i) accrued and unpaid Base Salary through the date of such cessation, (ii) any expense
reimbursements to be paid in accordance with Company policy and (iii) payments for any accrued but unused paid time off in accordance
with the Company&rsquo;s policies and applicable law, all compensation and benefits will cease at the time of such cessation and
the Company will have no further liability or obligation by reason of such cessation. The payments and benefits described in this
<U>Section 5.1</U> are in lieu of, and not in addition to, any other severance arrangement maintained by the Company. For avoidance
of doubt, any unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company that are
subject to performance-based vesting shall become vested, if at all, in accordance with the Company&rsquo;s Amended and Restated
2014 Stock Incentive Plan (or any successor provision or plan) (the &ldquo;<U>Plan</U>&rdquo;) and the applicable award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any provision of this Agreement,
the payments and benefits described in <U>Section 5.1</U> are conditioned on: (a) the Executive&rsquo;s execution and delivery
to the Company and the expiration of all applicable statutory revocation periods, by the 45th day following the effective date
of his cessation of employment, of a general release of claims against the Company and its affiliates in a form reasonably prescribed
by the Company (the &ldquo;<U>Release</U>&rdquo;); and (b) the Executive&rsquo;s continued compliance with the Restrictive Covenants
(as defined below). Subject to <U>Section 5.4</U>, below, the benefits described in <U>Section 5.1</U> will be paid or provided
(or begin to be paid or provided) as soon as administratively practicable (or determinable in the case of the benefits described
in <U>Section 5.1.1</U>) after the Release becomes irrevocable, provided that if the 45 day period described above begins in one
taxable year and ends in a second taxable year such payments or benefits shall not commence until the second taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Termination
Following a Change in Control</U>. If Executive&rsquo;s employment by the Company ceases due to a termination by the Company
without Cause or a resignation by Executive for Good Reason during the twelve (12) month period immediately following the
occurrence of a Change in Control (as defined below), (i) all unvested restricted stock, stock options and other equity
incentives awarded to Executive by the Company that are subject only to time-based vesting will become immediately and
automatically fully vested and exercisable (as applicable), (ii) in lieu of the salary continuation described in <U>Section
5.1.2</U>, the Executive shall receive eighteen (18) months of his Base Salary, paid in a lump sum; (iii) in lieu of the
bonus described in <U>Section 5.1.3</U>, the Executive shall receive 1.5 times his then-current target annual bonus payable
in a lump sum, and (iv) the COBRA continuation period described in <U>Section 5.1.5</U> will be eighteen (18) months in lieu
of twelve (12). Any unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company
that are subject to performance-based vesting shall become vested, if at all, in accordance with the Plan and the applicable
award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any benefits received
under this <U>Section 5.2</U> shall be governed by the terms and conditions described in <U>Section 5.1</U> above, including without
limitation the requirement that Executive timely execute a Release and comply with the Restrictive Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Terminations</U>. If Executive&rsquo;s employment with the Company ceases for any reason other than as described
in <U>Section 5.1</U> or <U>Section 5.2 </U>above, including, but not limited to, termination (i) by the Company for Cause, (ii)
as a result of Executive&rsquo;s death, (iii) as a result of Executive&rsquo;s Disability or (iv) by Executive without Good Reason,
then the Company&rsquo;s obligation to Executive will be limited solely to (a) accrued and unpaid Base Salary through the date
of such cessation, (b) any expense reimbursements to be paid in accordance with Company policy and (c) payments for any accrued
but unused paid time off in accordance with the Company&rsquo;s policies and applicable law. All compensation and benefits will
cease at the time of such cessation and, except as otherwise provided by COBRA or this <U>Section 5.3</U>, the Company will have
no further liability or obligation by reason of such termination. The foregoing will not be construed to limit Executive&rsquo;s
right to payment or reimbursement for claims incurred prior to the date of such termination under any insurance contract funding
an employee benefit plan, policy or arrangement of the Company in accordance with the terms of such insurance contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Compliance
with Section 409A</U>. If the termination giving rise to the payments described in <U>Section 5.1</U> or <U>Section 5.2</U>
is not a &ldquo;Separation from Service&rdquo; within the meaning of Treas. Reg. &sect; 1.409A-1(h)(1) (or any successor
provision), then the amounts otherwise payable pursuant to that section will instead be deferred without interest and will
not be paid until Executive experiences a Separation from Service. To the maximum extent permitted under Section 409A of the
Code and its corresponding regulations, the cash severance benefits payable under this Agreement are intended to meet the
requirements of the short-term deferral exemption under Section 409A of the Code and the &ldquo;separation pay
exception&rdquo; under Treas. Reg. &sect;1.409A- 1(b)(9)(iii). To the extent compliance with the requirements of Treas. Reg.
 &sect; 1.409A-3(i)(2) (or any successor provision) is necessary to avoid the application of an additional tax under Section
409A of the Internal Revenue Code to payments due to Executive upon or following his Separation from Service, then
notwithstanding any other provision of this Agreement (or any otherwise applicable plan, policy, agreement or arrangement),
any such payments that are otherwise due within six months following Executive&rsquo;s Separation from Service (taking into
account the preceding sentence of this paragraph) will be deferred without interest and paid to Executive in a lump sum
immediately following that six month period. For purposes of the application of Treas. Reg. &sect; 1.409A-1(b)(4)(or any
successor provision), each payment in a series of payments will be deemed a separate payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>PPACA</U>. Notwithstanding anything in this Agreement to the contrary, the waiver in respect of COBRA premiums pursuant
to <U>Sections 5.1</U> and <U>5.2</U> shall cease to the extent required to avoid adverse consequences to the Company under the
Patient Protection and Affordable Care Act of 2010 and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 280G</U>. If any payment or distribution by the Company to or for the benefit of the Executive, whether paid
or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise pursuant to or by reason of any
other agreement, policy, plan, program or arrangement or the lapse or termination of any restriction on or the vesting or exercisability
of any payment or benefit (each a &ldquo;<U>Payment</U>&rdquo;), would be subject to the excise tax imposed by Section 4999 of
the Code (or any successor provision thereto) or to any similar tax imposed by state or local law (such tax or taxes are hereafter
collectively referred to as the &ldquo;<U>Excise Tax</U>&rdquo;), then the aggregate amount of Payments payable to Executive shall
be reduced to the aggregate amount of Payments that may be made to the Executive without incurring an excise tax in accordance
with the immediately following sentence; <I>provided that </I>such reduction shall only be imposed if the aggregate after-tax value
of the Payments retained by Executive (after giving effect to such reduction) is equal to or greater than the aggregate after-tax
value (after giving effect to the Excise Tax) of the Payments to Executive without any such reduction. Any such reduction shall
be made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary, to zero); (ii) second,
any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash payments (other than equity or equity
derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity derivative payments
shall be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Cause</U>&rdquo; means (a) commission or conviction of any felony or any crime involving dishonesty; (b) commission
of any fraud against the Company; (c) intentional and material damage to any material property of the Company; (d) Executive&rsquo;s
material breach of any agreement with or duty owed to the Company or any of its affiliates (including, without limitation, Executive&rsquo;s
material breach of any of the Restrictive Covenants, as defined below); or (e) refusal to perform the lawful, reasonable and material
directives of the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;) or the Company&rsquo;s Chief Executive Officer.
Before &ldquo;Cause&rdquo; under clause (c), (d) or (e) has been deemed to have occurred, the Board must provide the Executive
with written notice detailing why the Board has determined that Cause has occurred and the actions required to cure the same, to
the extent reasonably subject to cure. The Executive shall then, where the grounds for Cause are reasonably subject to cure within
such time, have thirty (30) days after the Executive&rsquo;s receipt of written notice to cure the item cited in the written notice
so that &ldquo;Cause&rdquo; will have not formally occurred with respect to the event in question until such period, where applicable,
shall have expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Change in Control</U>&rdquo; means the first to occur of any of the events described in Section l(g) of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<U>Disability</U>&rdquo; means a condition entitling the Executive to benefits under the Company&rsquo;s long term
disability plan, policy or arrangement; <I>provided, however</I>, that if no such plan, policy or arrangement is then maintained
by the Company and applicable to the Executive, &ldquo;<U>Disability</U>&rdquo; will mean the Executive&rsquo;s inability to perform
his duties under this Agreement due to a mental or physical condition that can be expected to result in death or that can be expected
to last (or has already lasted) for a continuous period of 90 days or more, or for 120 days in any 180 consecutive day period.
Termination as a result of a Disability will not be construed as a termination by the Company &ldquo;without Cause.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Good Reason</U>&rdquo; means any of the following, without the Executive&rsquo;s prior consent: (a) a material
diminution of the Executive&rsquo;s duties or authority with the Company, reporting relationships or the assignment of duties and
responsibilities inconsistent with Executive&rsquo;s status at the Company; (b) a reduction in Base Salary; or (c) the relocation
of the Executive&rsquo;s primary place of employment to a location that is (i) more than 50 miles from the location of the Executive&rsquo;s
permanent primary place of employment prior to such relocation and (ii) more than 50 miles from the location of the Executive&rsquo;s
residence. However, none of the foregoing events or conditions will constitute Good Reason unless the Executive provides the Company
with written objection to the event or condition within 30 days following the occurrence thereof, the Company does not reverse
or otherwise cure the event or condition within 30 days of receiving that written objection, and the Executive resigns Executive&rsquo;s
employment within 30 days following the expiration of that cure period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictive Covenants</U>. To induce the Company to enter into this Agreement and in recognition of the compensation
to be paid to the Executive pursuant to <U>Sections 4 and 5</U> of this Agreement, the Executive agrees to be bound by the provisions
of this <U>Section 6</U> (the &ldquo;<U>Restrictive Covenants</U>&rdquo;). These Restrictive Covenants will apply without regard
to whether any termination or cessation of the Executive&rsquo;s employment is initiated by the Company or the Executive, and without
regard to the reason for that termination or cessation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Covenant Not To Compete</U>. The Executive covenants that, during his employment by the Company and for a period of twelve
(12) months following immediately thereafter (the &ldquo;<U>Restricted Period</U>&rdquo;), the Executive will not (except in his
capacity as an employee or director of the Company) do any of the following, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>engage or participate in any Competing Business (as defined below) wherever the Company or its affiliates do business, do
or plan to do business or sell or market their products or services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>become interested in (as owner, stockholder, lender, partner, co-venturer, director, officer, employee, agent or consultant)
any person, firm, corporation, association or other entity engaged in a Competing Business. Notwithstanding the foregoing, the
Executive may hold up to 1% of the outstanding securities of any class of any publicly-traded securities of any company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>influence
or attempt to influence any employee, consultant, supplier, licensor, licensee, contractor, agent, strategic partner,
distributor, customer or other person to terminate or modify any written or oral agreement, arrangement or course of dealing
with the Company or any of its affiliates; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>solicit for employment or retention as an independent contractor (or arrange to have any other person or entity solicit
for employment or retention) any person employed or retained by the Company or any of its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Executive acknowledges
that the consideration described in <U>Sections 4</U> and <U>5</U> constitutes mutually-agreed upon consideration with respect
to the covenants set forth in <U>Sections 6.1.1</U> and <U>6.1.2</U> for purposes of Section 24L(b)(vii) of Chapter 149 of the
Massachusetts General Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidentiality</U>. The Executive recognizes and acknowledges that the Proprietary Information (as defined in below)
is a valuable, special and unique asset of the business of the Company and its affiliates. As a result, both during the term of
this Agreement and thereafter, the Executive will not, without the prior written consent of the Company, for any reason divulge
to any third&#45;party or use for his own benefit, or for any purpose other than the exclusive benefit of the Company and its affiliates,
any Proprietary Information. Notwithstanding the foregoing, nothing in this Agreement prohibits the Executive from initiating communications
directly with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible
violations of law or regulation to, or from filing a claim or assisting with an investigation directly with a self- regulatory
authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department of Labor,
the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency
Inspector General (collectively, the &ldquo;<U>Regulators</U>&rdquo;), or from making other disclosures that are protected under
the whistleblower provisions of state or federal law or regulation. In connection with any such activity, the Executive must identify
any information that is confidential and ask the Regulator for confidential treatment of such information. Despite the foregoing,
Executive is not permitted to reveal to any third party, including any governmental, law enforcement, or regulatory authority,
information employee came to learn during the course of Executive&rsquo;s employment with the Company that is protected from disclosure
by any applicable privilege, including but not limited to the attorney-client privilege, attorney work product doctrine and/or
other applicable legal privileges. The Company does not waive any applicable privileges or the right to continue to protect its
privileged attorney-client information, attorney work product, and other privileged information. Notwithstanding any other provisions
of this Agreement, pursuant to 18 USC Section 1833(b), Executive shall not be held criminally or civilly liable under any federal
or state trade secret law for the disclosure of a trade secret that is made: (a) confidentially to a federal, state, or local government
official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected
violation of law; or (b) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under
seal. If Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose
a trade secret of the Company to Executive&rsquo;s attorney and use the trade secret information in related court proceedings,
provided that Executive files any document containing the trade secret information under seal and does not disclose the trade secret,
except pursuant to court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Property of the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Proprietary Information</U>. All right, title and interest in and to Proprietary Information will be and remain the
sole and exclusive property of the Company and its affiliates. The Executive will not remove from the Company&rsquo;s or its affiliates&rsquo;
offices or premises any documents, records, notebooks, files, correspondence, reports, memoranda or similar materials of or containing
Proprietary Information, or other materials or property of any kind belonging to the Company or its affiliates unless necessary
or appropriate in the performance of his duties to the Company and its affiliates. If the Executive removes such materials or property
in the performance of his duties, he will return such materials or property promptly after the removal has served its purpose.
The Executive will not make, retain, remove and/or distribute any copies of any such materials or property, or divulge to any third
person the nature of and/or contents of such materials or property, except to the extent necessary to satisfy contractual obligations
of the Company or its affiliates or to perform his duties on behalf of the Company and its affiliates or pursuant to the exceptions
set forth in <U>Section 6.2</U>. Upon termination of the Executive&rsquo;s employment with the Company, he will leave with the
Company and its affiliates or promptly return to the Company and its affiliates all originals and copies of such materials or property
then in his possession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>. The Executive agrees that all the Intellectual Property (as defined below) will be considered
 &ldquo;works made for hire&rdquo; as that term is defined in Section 101 of the Copyright Act (17 U.S.C. &sect; 101) and that all
right, title and interest in such Intellectual Property will be the sole and exclusive property of the Company and its affiliates.
To the extent that any of the Intellectual Property may not by law be considered a work made for hire, or to the extent that, notwithstanding
the foregoing, the Executive retains any interest in the Intellectual Property, the Executive hereby irrevocably assigns and transfers
to the Company and its affiliates any and all right, title, or interest that the Executive may now or in the future have in the
Intellectual Property under patent, copyright, trade secret, trademark or other law, in perpetuity or for the longest period otherwise
permitted by law, without the necessity of further consideration. The Company and its affiliates will be entitled to obtain and
hold in its own name all copyrights, patents, trade secrets, trademarks and other similar registrations with respect to such Intellectual
Property. The Executive further agrees to execute any and all documents and provide any further cooperation or assistance reasonably
required by the Company, at the Company&rsquo;s expense, to perfect, maintain or otherwise protect its rights in the Intellectual
Property. If the Company or its affiliates, as applicable, are unable after reasonable efforts to secure the Executive&rsquo;s
signature, cooperation or assistance in accordance with the preceding sentence, whether because of the Executive&rsquo;s incapacity
or any other reason whatsoever, the Executive hereby designates and appoints the Company, the appropriate affiliate, or their respective
designee as the Executive&rsquo;s agent and attorney&#45;in&#45;fact, to act on his behalf, to execute and file documents and to
do all other lawfully permitted acts necessary or desirable to perfect, maintain or otherwise protect the Company&rsquo;s or its
affiliates&rsquo; rights in the Intellectual Property. The Executive acknowledges and agrees that such appointment is coupled with
an interest and is therefore irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>&ldquo;<U>Competing
Business</U>&rdquo; means any person, firm, corporation, partnership, association or other entity engaged in developing,
manufacturing, marketing, distributing or selling, directly or indirectly, pharmaceutical abuse-deterrent products or any
other product for pain indications that directly competes with a product developed, manufactured, marketed, distributed or
sold by the Company. A division, subsidiary or similar business unit of an entity that does not engage in the business
activities described in this definition will not be considered a Competing Business even if another separate division,
subsidiary or similar business unit does engage in such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Intellectual Property</U>&rdquo; means (a) all inventions (whether patentable or unpatentable and whether or not
reduced to practice), all improvements thereto, and all patents and patent applications claiming such inventions, (b) all trademarks,
service marks, trade dress, logos, trade names, fictitious names, brand names, brand marks and corporate names, together with all
translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications,
registrations, and renewals in connection therewith, (c) all copyrightable works, all copyrights, and all applications, registrations,
and renewals in connection therewith, (d) all mask works and all applications, registrations, and renewals in connection therewith,
(e) all trade secrets (including research and development, know&#45;how, formulas, compositions, manufacturing and production processes
and techniques, methodologies, technical data, designs, drawings and specifications), (f) all computer software (including data,
source and object codes and related documentation), (g) all other proprietary rights, (h) all copies and tangible embodiments thereof
(in whatever form or medium), or (i) similar intangible personal property which have been or are developed or created in whole
or in part by the Executive (1) at any time and at any place while the Executive is employed by Company and which, in the case
of any or all of the foregoing, are related to and used in connection with the business of the Company or its affiliates, or (2)
as a result of tasks assigned to the Executive by the Company or its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Proprietary Information</U>&rdquo; means any and all proprietary information developed or acquired by the Company
or any of its subsidiaries or affiliates that has not been specifically authorized to be disclosed. Such Proprietary Information
shall include, but shall not be limited to, the following items and information relating to the following items: (a) all intellectual
property and proprietary rights of the Company (including, without limitation, the Intellectual Property), (b) computer codes and
instructions, processing systems and techniques, inputs and outputs (regardless of the media on which stored or located) and hardware
and software configurations, designs, architecture and interfaces, (c) business research, studies, procedures and costs, (d) financial
data, (e) distribution methods, (f) marketing data, methods, plans and efforts, (g) the identities of actual and prospective suppliers,
(h) the terms of contracts and agreements with, the needs and requirements of, and the Company&rsquo;s or its affiliates&rsquo;
course of dealing with, actual or prospective suppliers, (i) personnel information, (j) customer and vendor credit information,
and (k) information received from third parties subject to obligations of non-disclosure or non-use. Failure by the Company or
its affiliates to mark any of the Proprietary Information as confidential or proprietary shall not affect its status as Proprietary
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Acknowledgements</U>. The Executive acknowledges that the Restrictive Covenants are reasonable and necessary to protect
the legitimate interests of the Company and its affiliates, that the duration and geographic scope of the Restrictive Covenants
are reasonable given the nature of this Agreement and the position the Executive holds within the Company, and that the Company
would not enter into this Agreement or otherwise employ or continue to employ the Executive unless the Executive agrees to be bound
by the Restrictive Covenants set forth in this <U>Section 6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Remedies and Enforcement Upon Breach</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Specific Enforcement</U>. The Executive acknowledges that any breach by him, willfully or otherwise, of the Restrictive
Covenants will cause continuing and irreparable injury to the Company or its affiliates for which monetary damages would not be
an adequate remedy. The Executive shall not, in any action or proceeding to enforce any of the provisions of this Agreement, assert
the claim or defense that such an adequate remedy at law exists. In the event of any such breach or threatened breach by the Executive
of any of the Restrictive Covenants, the Company or its affiliates, as applicable, shall be entitled to injunctive or other similar
equitable relief in any court, without any requirement that a bond or other security be posted, and this Agreement shall not in
any way limit remedies of law or in equity otherwise available to the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Judicial Modification</U>. If any court determines that any of the Restrictive Covenants, or any part thereof, is unenforceable
because of the duration or geographical scope of such provision, such court shall have the power to modify such provision and,
in its modified form, such provision shall then be enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforceability</U>. If any court holds the Restrictive Covenants unenforceable by reason of their breadth or scope or
otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the right of the Company
and its affiliates to the relief provided above in the courts of any other jurisdiction within the geographic scope of such Restrictive
Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of Restrictive Covenants</U>. The Executive agrees to disclose the existence and terms of the Restrictive
Covenants to any employer that the Executive may work for during the Restricted Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Extension of Restricted Period</U>. If the Executive breaches <U>Section 6.1</U> in any respect, the restrictions contained
in that section will be extended for a period equal to the period that the Executive was in breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right to Consult Counsel</U>. Executive understands and acknowledges that Executive has the right to consult with counsel
prior to signing this Agreement. Executive further represents that Executive is signing this Agreement freely and voluntarily in
exchange for the benefits provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Agreements</U>. Executive represents and warrants to the Company that there are no restrictions, agreements or
understandings whatsoever to which he is a party that would prevent or make unlawful his execution of this Agreement, that would
be inconsistent or in conflict with this Agreement or Executive&rsquo;s obligations hereunder, or that would otherwise prevent,
limit or impair the performance by Executive of his duties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. The Company may assign this Agreement to any successor to its assets and business by means
of liquidation, dissolution, sale of assets or otherwise. The duties of Executive hereunder are personal to Executive and may not
be assigned by him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Governing Law and Enforcement</U>. This Agreement will be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, without regard to the principles of conflicts of laws. Any legal proceeding arising out of or relating
to this Agreement will be instituted in a state or federal court in the Commonwealth of Massachusetts, and Executive and the Company
hereby consent to the personal and exclusive jurisdiction of such court(s) and hereby waive any objection(s) that they may have
to personal jurisdiction, the laying of venue of any such proceeding and any claim or defense of inconvenient forum. Notwithstanding
the foregoing, any action that is commenced by either party to resolve any matter arising under <U>Section 6.1</U> of this Agreement,
shall be commenced only in the Massachusetts Superior Court located in Suffolk County, Massachusetts and the parties each consent
to the jurisdiction of such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waivers</U>. The waiver by either party of any right hereunder or of any breach by the other party will not be deemed
a waiver of any other right hereunder or of any other breach by the other party. No waiver will be deemed to have occurred unless
set forth in a writing. No waiver will constitute a continuing waiver unless specifically stated, and any waiver will operate only
as to the specific term or condition waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective
and valid under applicable law. However, if any provision of this Agreement is held to be invalid, illegal or enforceable in any
respect, such invalidity, illegality or unenforceability will not affect any other provision, and this Agreement will be reformed,
construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. This Agreement will survive the cessation of Executive&rsquo;s employment to the extent necessary to fulfill
the purposes and intent the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any notice or communication required or permitted under this Agreement will be made in writing and (a) sent
by overnight courier, (b) mailed by overnight U.S. express mail, return receipt requested or (c) sent by telecopier. Any notice
or communication to Executive will be sent to the address contained in his personnel file. Any notice or communication to the Company
will be sent to the Company&rsquo;s principal executive offices, to the attention of its Chief Executive Officer. Notwithstanding
the foregoing, either party may change the address for notices or communications hereunder by providing written notice to the other
in the manner specified in this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement; Amendments</U>. This Agreement contains the entire agreement and understanding of the parties hereto
relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings
of every nature relating to that subject matter (including, without limitation, the Existing Agreement). This Agreement may not
be changed or modified, except by an agreement in writing signed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Withholding</U>. All payments (or transfers of property) to Executive will be subject to tax withholding to the extent
required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Section Headings</U>. The headings of sections and paragraphs of this Agreement are inserted for convenience only and
will not in any way affect the meaning or construction of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts; Facsimile</U>. This Agreement may be executed in multiple counterparts (including by facsimile signature),
each of which will be deemed to be an original, but all of which together will constitute but one and the same instrument. Counterparts
may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall
be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&lt;<I>remainder of page intentionally left
blank; signature page follows</I>&gt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the Company has caused this Agreement to be executed by its duly authorized officer, and Executive has executed this Agreement,
on the date(s) indicated below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">COLLEGIUM PHARMACEUTICAL,
    INC.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Paul Brannelly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">Paul Brannelly</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">CFO</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">12/27/2020</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">SCOTT DREYER</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Scott Dreyer</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">12/24/2020</TD></TR>
</TABLE>




<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">[<I>Signature Page to Employment Agreement</I>]</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>tm2039449d1_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.4</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-weight: normal"><U>amended
 &amp; restATED</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>EMPLOYMENT
AGREEMENT </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS EMPLOYMENT AGREEMENT
(the &ldquo;<U>Agreement</U>&rdquo;) is made by and between COLLEGIUM PHARMACEUTICAL, INC. (the &ldquo;<U>Company</U>&rdquo;) and
Alison Fleming (the &ldquo;<U>Executive</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive are parties to an Employment Agreement dated as of August 4, 2015 (the &ldquo;<U>Existing Agreement</U>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive desire to amend and restate the Existing Agreement and enter into this Agreement pursuant to which the Company
will continue to employ Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the foregoing and intending to be bound hereby, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Duration of Agreement</U>. This Agreement is effective as of January 1, 2021 and has no specific expiration date. Unless
terminated by agreement of the parties, this Agreement will govern Executive&rsquo;s continued employment by the Company until
that employment ceases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Title; Duties</U>. Executive will continue to be employed as the Company&rsquo;s Vice President, Product Development.
Executive will devote her best efforts and substantially all of her business time and services to the Company and its affiliates
to perform such duties as may be customarily incident to her position and as may reasonably be assigned to her from time to time.
Executive shall report to such individual as designated by the Company. Executive will not, in any capacity, engage in other business
activities or perform services for any other individual, firm or corporation without the prior written consent of the Company;
<I>provided, however, </I>that without such consent, Executive may engage in charitable, non-profit and public service activities,
so long as such activities do not in any respect interfere or conflict with Executive&rsquo;s performance of her duties and obligations
to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Place of Performance</U>. Executive will perform her services hereunder at the principal executive offices of the Company
in Stoughton, Massachusetts; <I>provided, however, </I>that Executive may be required to travel from time to time for business
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation and Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Base Salary</U>. Executive&rsquo;s annual salary will be $378,500 (the &ldquo;<U>Base Salary</U>&rdquo;), paid in accordance
with the Company&rsquo;s payroll practices as in effect from time to time. The Base Salary will be reviewed annually by the Compensation
Committee of the Company&rsquo;s Board of Directors (the &ldquo;<U>Committee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Annual Bonuses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>For
each fiscal year ending during her employment, Executive will be eligible to earn an annual bonus. The target amount of that
bonus will be 50% of Executive&rsquo;s Base Salary for the applicable fiscal year. The actual bonus payable with respect to a
particular year will be determined by the Committee, based on the achievement of corporate and /or individual performance
objectives established by the Committee. Any bonus payable under this paragraph will be paid during the calendar year
immediately following the fiscal year in respect of which the bonus is payable and, except as otherwise provided in <U>Section
5.1.1</U> will only be paid if Executive remains continuously employed by the Company through the actual bonus payment
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of determining any bonus payable to Executive, the measurement of corporate and individual performance will
be performed by the Committee in good faith. From time to time, the Committee may, in its sole discretion, make adjustments to
corporate or individual performance goals, so that required departures from the Company&rsquo;s operating budget, changes in accounting
principles, acquisitions, dispositions, mergers, consolidations and other corporate transactions, and other factors influencing
the achievement or calculation of such goals do not affect the operation of this provision in a manner inconsistent with its intended
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Benefits</U>. During Executive&rsquo;s employment, Executive will be eligible to participate in all employee
benefit plans and programs made available by the Company from time to time to employees generally, subject to applicable plan terms
and policies. The Company periodically reviews its benefits, policies, benefits providers and practices and may terminate, alter
or change them at its discretion from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reimbursement of Expenses</U>. The Executive will be reimbursed by the Company for all reasonable business expenses incurred
by Executive in accordance with the Company&rsquo;s customary expense reimbursement policies as in effect from time to time. Notwithstanding
anything herein to the contrary, to the extent any expense, reimbursement or in-kind benefit provided to the Executive constitutes
a &ldquo;deferral of compensation&rdquo; within the meaning of Section 409A of the Internal Revenue Code (the &ldquo;<U>Code</U>&rdquo;)
(i) the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive must be incurred during the
Executive&rsquo;s term of employment; (ii) the amount of expenses eligible for reimbursement or in-kind benefits provided to the
Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided
to the Executive in any other calendar year, (iii) the reimbursements for expenses for which the Executive is entitled to be reimbursed
shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred
and (iv) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>. Executive&rsquo;s employment with the Company may be terminated by the Company or Executive at any time
and for any reason. Upon any cessation of her employment with the Company, Executive will be entitled only to such compensation
and benefits as described in this <U>Section 5</U>. Upon any cessation of her employment for any reason, unless otherwise requested
by the Company, Executive agrees to resign immediately from all officer and director positions she then holds with the Company
and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination without Cause or for Good Reason</U>. If Executive&rsquo;s employment by the Company ceases due to a termination
by the Company without Cause (as defined below) or a resignation by Executive for Good Reason (as defined below), Executive will
be entitled to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> payment of any annual bonus otherwise payable (but for the cessation of Executive&rsquo;s employment) with respect to a
year ended prior to the cessation of Executive&rsquo;s employment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>continuation of Executive&rsquo;s Base Salary for a period equal to twelve (12) months, payable in accordance with the Company&rsquo;s
standard payroll practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>payment equal to Executive&rsquo;s target annual bonus described in <U>Section 4.2.1</U>, paid in twelve (12) substantially
equal installments over a twelve-month period and in accordance with the Company&rsquo;s standard payroll practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>accelerated vesting of any unvested restricted stock, stock options and other equity incentives awarded to Executive by
the Company that are solely subject to time-based vesting criteria equal to what would have vested had Executive remained employed
for twelve (12) additional months; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>waiver of the applicable premium otherwise payable for COBRA continuation coverage for Executive (and, to the extent covered
immediately prior to the date of such cessation, her eligible dependents) for a period equal to twelve (12) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in this <U>Section
5.1</U>. and except for payment of all (i) accrued and unpaid Base Salary through the date of such cessation, (ii) any expense
reimbursements to be paid in accordance with Company policy and (iii) payments for any accrued but unused paid time off in accordance
with the Company&rsquo;s policies and applicable law, all compensation and benefits will cease at the time of such cessation and
the Company will have no further liability or obligation by reason of such cessation. The payments and benefits described in this
<U>Section 5.1</U> are in lieu of, and not in addition to, any other severance arrangement maintained by the Company. For avoidance
of doubt, any unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company that are
subject to performance-based vesting shall become vested, if at all, in accordance with the Company&rsquo;s Amended and Restated
2014 Stock Incentive Plan (or any successor provision or plan) (the &ldquo;<U>Plan</U>&rdquo;) and the applicable award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any provision of this Agreement,
the payments and benefits described in <U>Section 5.1</U> are conditioned on: (a) the Executive&rsquo;s execution and delivery
to the Company and the expiration of all applicable statutory revocation periods, by the 45th day following the effective date
of her cessation of employment, of a general release of claims against the Company and its affiliates in a form reasonably prescribed
by the Company (the <U>&ldquo;Release</U>&rdquo;); and (b) the Executive&rsquo;s continued compliance with the Restrictive Covenants
(as defined below). Subject to <U>Section 5.4</U>. below, the benefits described in <U>Section 5.1</U> will be paid or provided
(or begin to be paid or provided) as soon as administratively practicable (or determinable in the case of the benefits described
in <U>Section 5.1.1</U>) after the Release becomes irrevocable, provided that if the 45 day period described above begins in one
taxable year and ends in a second taxable year such payments or benefits shall not commence until the second taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Termination
Following a Change in Control</U>. If Executive&rsquo;s employment by the Company ceases due to a termination by the Company
without Cause or a resignation by Executive for Good Reason during the twelve (12) month period immediately following the
occurrence of a Change in Control (as defined below), (i) all unvested restricted stock, stock options and other equity
incentives awarded to Executive by the Company that are subject only to time-based vesting will become immediately and
automatically fully vested and exercisable (as applicable), (ii) in lieu of the salary continuation described in <U>Section
5.1.2</U>, the Executive shall receive eighteen (18) months of her Base Salary, paid in a lump sum; (iii) in lieu of the
bonus described in <U>Section 5.1.3</U>, the Executive shall receive 1.5 times her then-current target annual bonus payable
in a lump sum, and (iv) the COBRA continuation period described in <U>Section 5.1.5</U> will be eighteen (18) months in lieu
of twelve (12). Any unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company
that are subject to performance-based vesting shall become vested, if at all, in accordance with the Plan and the applicable
award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any benefits received
under this <U>Section 5.2</U> shall be governed by the terms and conditions described in <U>Section 5.1</U> above, including without
limitation the requirement that Executive timely execute a Release and comply with the Restrictive Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Terminations</U>. If Executive&rsquo;s employment with the Company ceases for any reason other than as described
in <U>Section 5.1</U> or <U>Section 5.2</U> above (including, but not limited to, termination (i) by the Company for Cause, (ii)
as a result of Executive&rsquo;s death, (iii) as a result of Executive&rsquo;s Disability or (iv) by Executive without Good Reason,
then the Company&rsquo;s obligation to Executive will be limited solely to (a) accrued and unpaid Base Salary through the date
of such cessation, (b) any expense reimbursements to be paid in accordance with Company policy and (c) payments for any accrued
but unused paid time off in accordance with the Company&rsquo;s policies and applicable law. All compensation and benefits will
cease at the time of such cessation and, except as otherwise provided by COBRA or this <U>Section 5.3</U>. the Company will have
no further liability or obligation by reason of such termination. The foregoing will not be construed to limit Executive&rsquo;s
right to payment or reimbursement for claims incurred prior to the date of such termination under any insurance contract funding
an employee benefit plan, policy or arrangement of the Company in accordance with the terms of such insurance contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Compliance
with Section 409A</U>. If the termination giving rise to the payments described in <U>Section 5.1</U> or <U>Section 5.2</U>
is not a &ldquo;Separation from Service&rdquo; within the meaning of Treas. Reg. &sect; 1.409A-l(h)(l) (or any successor
provision), then the amounts otherwise payable pursuant to that section will instead be deferred without interest and will
not be paid until Executive experiences a Separation from Service. To the maximum extent permitted under Section 409A of the
Code and its corresponding regulations, the cash severance benefits payable under this Agreement are intended to meet the
requirements of the short-term deferral exemption under Section 409A of the Code and the &ldquo;separation pay
exception&rdquo; under Treas. Reg. &sect; 1.409A-1(b)(9) (iii). To the extent compliance with the requirements of Treas. Reg.
 &sect; 1.409A-3(i)(2) (or any successor provision) is necessary to avoid the application of an additional tax under Section
409A of the Internal Revenue Code to payments due to Executive upon or following her Separation from Service, then
notwithstanding any other provision of this Agreement (or any otherwise applicable plan, policy, agreement or arrangement),
any such payments that are otherwise due within six months following Executive&rsquo;s Separation from Service (taking into
account the preceding sentence of this paragraph) will be deferred without interest and paid to Executive in a lump sum
immediately following that six month period. For purposes of the application of Treas. Reg. &sect; 1.409A-l(b)(4)(or any
successor provision), each payment in a series of payments will be deemed a separate payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>PPACA</U>. Notwithstanding anything in this Agreement to the contrary, the waiver in respect of COBRA premiums pursuant
to <U>Sections 5.1</U> and <U>5.2</U> shall cease to the extent required to avoid adverse consequences to the Company under the
Patient Protection and Affordable Care Act of 2010 and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 280G</U>. If any payment or distribution by the Company to or for the benefit of the Executive, whether paid
or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise pursuant to or by reason of any
other agreement, policy, plan, program or arrangement or the lapse or termination of any restriction on or the vesting or exercisability
of any payment or benefit (each a &ldquo;<U>Payment</U>&rdquo;), would be subject to the excise tax imposed by Section 4999 of
the Code (or any successor provision thereto) or to any similar tax imposed by state or local law (such tax or taxes are hereafter
collectively referred to as the &ldquo;<U>Excise Tax</U>&rdquo;), then the aggregate amount of Payments payable to Executive shall
be reduced to the aggregate amount of Payments that may be made to the Executive without incurring an excise tax (the &ldquo;<U>Safe-Harbor
Amount</U>&rdquo;) in accordance with the immediately following sentence; <I>provided that </I>such reduction shall only be imposed
if the aggregate after-tax value of the Payments retained by Executive (after giving effect to such reduction) is equal to or greater
than the aggregate after-tax value (after giving effect to the Excise Tax) of the Payments to Executive without any such reduction.
Any such reduction shall be made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary,
to zero); (ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash payments (other
than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity
derivative payments shall be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Cause</U>&rdquo; means (a) commission or conviction of any felony or any crime involving dishonesty; (b) commission
of any fraud against the Company; (c) intentional and material damage to any material property of the Company; (d) Executive&rsquo;s
material breach of any agreement with or duty owed to the Company or any of its affiliates (including, without limitation, Executive&rsquo;s
material breach of any of the Restrictive Covenants, as defined below); or (e) refusal to perform the lawful, reasonable and material
directives of the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;) or the Company&rsquo;s Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Change in Control</U>&rdquo; means the first to occur of any of the events described in Section l(g) of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>&ldquo;<U>Disability</U>&rdquo;
means a condition entitling the Executive to benefits under the Company&rsquo;s long term disability plan, policy or
arrangement; <I>provided, however, </I>that if no such plan, policy or arrangement is then maintained by the Company and
applicable to the Executive, &ldquo;<U>Disability</U>&rdquo; will mean the Executive&rsquo;s inability to perform her duties
under this Agreement due to a mental or physical condition that can be expected to result in death or that can be expected to
last (or has already lasted) for a continuous period of 90 days or more, or for 120 days in any 180 consecutive day period.
Termination as a result of a Disability will not be construed as a termination by the Company &ldquo;without
Cause.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Good Reason</U>&rdquo; means any of the following, without the Executive&rsquo;s prior consent: (a) a diminution
of the Executive&rsquo;s title below the rank of Vice President; (b) a reduction in Base Salary; or (c) the relocation of the Executive&rsquo;s
primary place of employment to a location that is (i) more than 50 miles from the location of the Executive&rsquo;s permanent primary
place of employment prior to such relocation and (ii) more than 50 miles from the location of the Executive&rsquo;s residence.
However, none of the foregoing events or conditions will constitute Good Reason unless the Executive provides the Company with
written objection to the event or condition within 30 days following the occurrence thereof, the Company does not reverse or otherwise
cure the event or condition within 30 days of receiving that written objection, and the Executive resigns Executive&rsquo;s employment
within 30 days following the expiration of that cure period. Notwithstanding the foregoing and for the avoidance of doubt, a diminution
of the Executive&rsquo;s title as a result of Change in Control shall not constitute Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictive Covenants</U>. To induce the Company to enter into this Agreement and in recognition of the compensation
to be paid to the Executive pursuant to <U>Section 4</U> and <U>Section 5</U> of this Agreement, the Executive agrees to be bound
by the provisions of this <U>Section 6</U> (the <U>&ldquo;Restrictive Covenants</U>&rdquo;). These Restrictive Covenants will apply
without regard to whether any termination or cessation of the Executive&rsquo;s employment is initiated by the Company or the Executive,
and without regard to the reason for that termination or cessation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Covenant Not To Compete</U>. The Executive covenants that, during her employment by the Company and for a period of twelve
(12) months following immediately thereafter (the &ldquo;<U>Restricted Period</U>&rdquo;), the Executive will not (except in her
capacity as an employee or director of the Company) do any of the following, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>engage or participate in any Competing Business (as defined below) wherever the Company or its affiliates do business, do
or plan to do business or sell or market their products or services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>become interested in (as owner, stockholder, lender, partner, co-venturer, director, officer, employee, agent or consultant)
any person, firm, corporation, association or other entity engaged in a Competing Business. Notwithstanding the foregoing, the
Executive may hold up to 1% of the outstanding securities of any class of any publicly-traded securities of any company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>influence or attempt to influence any employee, consultant, supplier, licensor, licensee, contractor, agent, strategic partner,
distributor, customer or other person to terminate or modify any written or oral agreement, arrangement or course of dealing with
the Company or any of its affiliates; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>solicit
for employment or retention as an independent contractor (or arrange to have any other person or entity solicit for
employment or retention) any person employed or retained by the Company or any of its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Executive acknowledges that
the consideration described in <U>Sections 4</U> and <U>5</U> constitutes mutually-agreed upon consideration with respect to
the covenants set forth in <U>Sections 6.1.1</U> and <U>6.1.2</U> for purposes of Section 24L(b)(vii) of Chapter 149 of the
Massachusetts General Laws</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidentiality</U>. The Executive recognizes and acknowledges that the Proprietary Information (as defined in below)
is a valuable, special and unique asset of the business of the Company and its affiliates. As a result, both during the term of
the Executive&rsquo;s employment and thereafter, the Executive will not, without the prior written consent of the Company, for
any reason divulge to any third-party or use for her own benefit, or for any purpose other than the exclusive benefit of the Company
and its affiliates, any Proprietary Information. Notwithstanding the foregoing, nothing in this Agreement prohibits Executive from
initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential information
to, reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with
a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department
of Labor, the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the Congress,
and any agency Inspector General (collectively, the &ldquo;<U>Regulators</U>&rdquo;), or from making other disclosures that are
protected under the whistleblower provisions of state or federal law or regulation. In connection with any such activity, the Executive
must identify any information that is confidential and ask the Regulator for confidential treatment of such information. Despite
the foregoing, Executive is not permitted to reveal to any third party, including any governmental, law enforcement, or regulatory
authority, information employee came to learn during the course of the Executive&rsquo;s employment with the Company that is protected
from disclosure by any applicable privilege, including but not limited to the attorney-client privilege, attorney work product
doctrine and/or other applicable legal privileges. The Company and its affiliates do not waive any applicable privileges or the
right to continue to protect its privileged attorney-client information, attorney work product, and other privileged information.
Notwithstanding any other provisions of this Agreement, pursuant to 18 USC Section 1833(b), Executive shall not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of the Company&rsquo;s or its affiliate&rsquo;s
trade secret that is made: (a) confidentially to a federal, state, or local government official, either directly or indirectly,
or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (b) in a complaint
or other document filed in a lawsuit or other proceeding, if such filing is made under seal. If Executive files a lawsuit for retaliation
by the Company for reporting a suspected violation of law, Executive may disclose a trade secret to the Executive&rsquo;s attorney
and use the trade secret information in related court proceedings, provided that Executive files any document containing the trade
secret information under seal and does not disclose the trade secret, except pursuant to court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Property of the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Proprietary
Information</U>. All right, title and interest in and to Proprietary Information will be and remain the sole and exclusive
property of the Company and its affiliates. The Executive will not remove from the Company&rsquo;s or its affiliates&rsquo;
offices or premises any documents, records, notebooks, files, correspondence, reports, memoranda or similar materials of or
containing Proprietary Information, or other materials or property of any kind belonging to the Company or its affiliates
unless necessary or appropriate in the performance of her duties to the Company and its affiliates. If the Executive removes
such materials or property in the performance of her duties, she will return such materials or property promptly after the
removal has served its purpose. The Executive will not make, retain, remove and/or distribute any copies of any such
materials or property, or divulge to any third person the nature of and/or contents of such materials or property, except to
the extent necessary to satisfy contractual obligations of the Company or its affiliates or to perform her duties on behalf
of the Company and its affiliates or pursuant to the exceptions set forth in <U>Section 6.2</U>. Upon termination of the
Executive&rsquo;s employment with the Company, she will leave with the Company and its affiliates or promptly return to the
Company and its affiliates all originals and copies of such materials or property then in her possession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>. The Executive agrees that all the Intellectual Property (as defined below) will be considered
 &ldquo;works made for hire&rdquo; as that term is defined in Section 101 of the Copyright Act (17 U.S.C. &sect; 101) and that all
right, title and interest in such Intellectual Property will be the sole and exclusive property of the Company and its affiliates.
To the extent that any of the Intellectual Property may not by law be considered a work made for hire, or to the extent that, notwithstanding
the foregoing, the Executive retains any interest in the Intellectual Property, the Executive hereby irrevocably assigns and transfers
to the Company and its affiliates any and all right, title, or interest that the Executive may now or in the future have in the
Intellectual Property under patent, copyright, trade secret, trademark or other law, in perpetuity or for the longest period otherwise
permitted by law, without the necessity of further consideration. The Company and its affiliates will be entitled to obtain and
hold in its own name all copyrights, patents, trade secrets, trademarks and other similar registrations with respect to such Intellectual
Property. The Executive further agrees to execute any and all documents and provide any further cooperation or assistance reasonably
required by the Company, at the Company&rsquo;s expense, to perfect, maintain or otherwise protect its rights in the Intellectual
Property. If the Company or its affiliates, as applicable, are unable after reasonable efforts to secure the Executive&rsquo;s
signature, cooperation or assistance in accordance with the preceding sentence, whether because of the Executive&rsquo;s incapacity
or any other reason whatsoever, the Executive hereby designates and appoints the Company, the appropriate affiliate, or their respective
designee as the Executive&rsquo;s agent and attorney-in-fact, to act on her behalf, to execute and file documents and to do all
other lawfully permitted acts necessary or desirable to perfect, maintain or otherwise protect the Company&rsquo;s or its affiliates&rsquo;
rights in the Intellectual Property. The Executive acknowledges and agrees that such appointment is coupled with an interest and
is therefore irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Competing Business</U>&rdquo; means any person, firm, corporation, partnership, association or other entity engaged
in developing, manufacturing, marketing, distributing or selling, directly or indirectly, pharmaceutical abuse-deterrent products
or any other product for pain indications that directly competes with a product developed, manufactured, marketed, distributed
or sold by the Company. A division, subsidiary or similar business unit of an entity that does not engage in the business activities
described in this definition will not be considered a Competing Business even if another separate division, subsidiary or similar
business unit does engage in such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<U>Intellectual Property</U>&rdquo; means (a) all inventions (whether patentable or unpatentable and whether or
not reduced to practice), all improvements thereto, and all patents and patent applications claiming such inventions, (b) all trademarks,
service marks, trade dress, logos, trade names, fictitious names, brand names, brand marks and corporate names, together with all
translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications,
registrations, and renewals in connection therewith, (c) all copyrightable works, all copyrights, and all applications, registrations,
and renewals in connection therewith, (d) all mask works and all applications, registrations, and renewals in connection therewith,
(e) all trade secrets (including research and development, know-how, formulas, compositions, manufacturing and production processes
and techniques, methodologies, technical data, designs, drawings and specifications), (f) all computer software (including data,
source and object codes and related documentation), (g) all other proprietary rights, (h) all copies and tangible embodiments thereof
(in whatever form or medium), or (i) similar intangible personal property which have been or are developed or created in whole
or in part by the Executive (1) at any time and at any place while the Executive is employed by Company and which, in the case
of any or all of the foregoing, are related to and used in connection with the business of the Company or its affiliates, or (2)
as a result of tasks assigned to the Executive by the Company or its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Proprietary Information</U>&rdquo; means any and all proprietary information developed or acquired by the Company
or any of its subsidiaries or affiliates that has not been specifically authorized to be disclosed. Such Proprietary Information
shall include, but shall not be limited to, the following items and information relating to the following items: (a) all intellectual
property and proprietary rights of the Company (including, without limitation, the Intellectual Property), (b) computer codes and
instructions, processing systems and techniques, inputs and outputs (regardless of the media on which stored or located) and hardware
and software configurations, designs, architecture and interfaces, (c) business research, studies, procedures and costs, (d) financial
data, (e) distribution methods, (f) marketing data, methods, plans and efforts, (g) the identities of actual and prospective suppliers,
(h) the terms of contracts and agreements with, the needs and requirements of, and the Company&rsquo;s or its affiliates&rsquo;
course of dealing with, actual or prospective suppliers, (i) personnel information, (j) customer and vendor credit information,
and (k) information received from third parties subject to obligations of non-disclosure or non- use.&#9;Failure by the Company
or its affiliates to mark any of the Proprietary Information as confidential or proprietary shall not affect its status as Proprietary
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Acknowledgements</U>. The Executive acknowledges that the Restrictive Covenants are reasonable and necessary to protect
the legitimate interests of the Company and its affiliates, that the duration and geographic scope of the Restrictive Covenants
are reasonable given the nature of this Agreement and the position the Executive holds within the Company, and that the Company
would not enter into this Agreement or otherwise employ or continue to employ the Executive unless the Executive agrees to be bound
by the Restrictive Covenants set forth in this <U>Section 6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies and Enforcement Upon Breach</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Specific
Enforcement</U>. The Executive acknowledges that any breach by him, willfully or otherwise, of the Restrictive Covenants will
cause continuing and irreparable injury to the Company or its affiliates for which monetary damages would not be an adequate
remedy. The Executive shall not, in any action or proceeding to enforce any of the provisions of this Agreement, assert the
claim or defense that such an adequate remedy at law exists. In the event of any such breach or threatened breach by the
Executive of any of the Restrictive Covenants, the Company or its affiliates, as applicable, shall be entitled to injunctive
or other similar equitable relief in any court, without any requirement that a bond or other security be posted, and this
Agreement shall not in any way limit remedies of law or in equity otherwise available to the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Judicial Modification</U>. If any court determines that any of the Restrictive Covenants, or any part thereof, is unenforceable
because of the duration or geographical scope of such provision, such court shall have the power to modify such provision and,
in its modified form, such provision shall then be enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforceability</U>. If any court holds the Restrictive Covenants unenforceable by reason of their breadth or scope or
otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the right of the Company
and its affiliates to the relief provided above in the courts of any other jurisdiction within the geographic scope of such Restrictive
Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of Restrictive Covenants</U>. The Executive agrees to disclose the existence and terms of the Restrictive
Covenants to any employer that the Executive may work for during the Restricted Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Extension of Restricted Period</U>. If the Executive breaches <U>Section 6.1</U> in any respect, the restrictions contained
in that section will be extended for a period equal to the period that the Executive was in breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right to Consult Counsel</U>. Executive understands and acknowledges that Executive has the right to consult with counsel
prior to signing this Agreement. Executive further represents that Executive is signing this Agreement freely and voluntarily in
exchange for the benefits provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Agreements</U>. Executive represents and warrants to the Company that there are no restrictions, agreements or
understandings whatsoever to which she is a party that would prevent or make unlawful her execution of this Agreement, that would
be inconsistent or in conflict with this Agreement or Executive&rsquo;s obligations hereunder, or that would otherwise prevent,
limit or impair the performance by Executive of her duties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. The Company may assign this Agreement to any successor to its assets and business by means
of liquidation, dissolution, sale of assets or otherwise. The duties of Executive hereunder are personal to Executive and may not
be assigned by him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Governing
Law and Enforcement</U>. This Agreement will be governed by and construed in accordance with the laws of the Commonwealth of
Massachusetts, without regard to the principles of conflicts of laws. Any legal proceeding arising out of or relating to this
Agreement will be instituted in a state or federal court in the Commonwealth of Massachusetts, and Executive and the Company
hereby consent to the personal and exclusive jurisdiction of such court(s) and hereby waive any objection(s) that they may
have to personal jurisdiction, the laying of venue of any such proceeding and any claim or defense of inconvenient forum.
Notwithstanding the foregoing, any action that is commenced by either party to resolve any matter arising under <U>Section
6.1</U> of this Agreement, shall be commenced only in the Massachusetts Superior Court located in Suffolk County,
Massachusetts and the parties each consent to the jurisdiction of such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waivers</U>. The waiver by either party of any right hereunder or of any breach by the other party will not be deemed
a waiver of any other right hereunder or of any other breach by the other party. No waiver will be deemed to have occurred unless
set forth in a writing. No waiver will constitute a continuing waiver unless specifically stated, and any waiver will operate only
as to the specific term or condition waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective
and valid under applicable law. However, if any provision of this Agreement is held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality or unenforceability will not affect any other provision, and this Agreement will be reformed,
construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. This Agreement will survive the cessation of Executive&rsquo;s employment to the extent necessary to fulfill
the purposes and intent the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any notice or communication required or permitted under this Agreement will be made in writing and (a) sent
by overnight courier, (b) mailed by overnight U.S. express mail, return receipt requested or (c) sent by telecopier. Any notice
or communication to Executive will be sent to the address contained in her personnel file. Any notice or communication to the Company
will be sent to the Company&rsquo;s principal executive offices, to the attention of its Chief Executive Officer. Notwithstanding
the foregoing, either party may change the address for notices or communications hereunder by providing written notice to the other
in the manner specified in this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement; Amendments</U>. This Agreement contains the entire agreement and understanding of the parties hereto
relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings
of every nature relating to that subject matter (including, without limitation, the Existing Agreement). This Agreement may not
be changed or modified, except by an agreement in writing signed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Withholding</U>. All payments (or transfers of property) to Executive will be subject to tax withholding to the extent
required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section Headings</U>. The headings of sections and paragraphs of this Agreement are inserted for convenience only and
will not in any way affect the meaning or construction of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Counterparts; Facsimile</U>. This Agreement may be executed in multiple counterparts (including by facsimile signature),
each of which will be deemed to be an original, but all of which together will constitute but one and the same instrument. Counterparts
may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall
be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&lt;<I>remainder of page intentionally left
blank; signature page follows</I>&gt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the Company has caused this Agreement to be executed by its duly authorized officer, and Executive has executed this Agreement,
on the date(s) indicated below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>COLLEGIUM PHARMACEUTICAL, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Paul Brannelly</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">Paul Brannelly</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">12/29/2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ALISON FLEMING</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Alison Fleming&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">CTO</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">12/29/2020</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">[<I>signature page to Employment Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>tm2039449d1_ex10-5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: capitalize; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-weight: normal"><U>amended
 &amp; restATED</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>EMPLOYMENT
AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS EMPLOYMENT AGREEMENT
(the &ldquo;<U>Agreement</U>&rdquo;) is made by and between COLLEGIUM PHARMACEUTICAL, INC. (the &ldquo;<U>Company</U>&rdquo;) and
SHIRLEY R. KUHLMANN (the &ldquo;<U>Executive</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive are parties to an Employment Agreement dated as of March 16, 2018 (the &ldquo;<U>Existing Agreement</U>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive desire to amend and restate the Existing Agreement and enter into this Agreement pursuant to which the Company
will continue to employ Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the foregoing and intending to be bound hereby, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Duration of Agreement</U>. This Agreement effective as of January 1, 2021 and has no specific expiration date. Unless
terminated by agreement of the parties, this Agreement will govern Executive&rsquo;s continued employment by the Company until
that employment ceases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Title; Duties</U>. Executive will continue to be employed as the Company&rsquo;s Executive Vice President and General
Counsel, reporting directly to the Company&rsquo;s Chief Executive Officer. Executive will devote her best efforts and substantially
all of her business time and services to the Company and its affiliates to perform such duties as may be customarily incident to
her position and as may reasonably be assigned to her from time to time. Executive will not, in any capacity, engage in other business
activities or perform services for any other individual, firm or corporation without the prior written consent of the Company;
<I>provided, however</I>, that without such consent, Executive may engage in charitable, non-profit and public service activities,
so long as such activities do not in any respect interfere or conflict with Executive&rsquo;s performance of her duties and obligations
to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Place of Performance</U>. Executive will perform her services hereunder at the principal executive offices of the Company
in Stoughton, Massachusetts; <I>provided, however, </I>that Executive may be required to travel from time to time for business
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Base Salary</U>. Executive&rsquo;s annual salary will be $411,500 (the &ldquo;<U>Base Salary</U>&rdquo;), paid in accordance
with the Company&rsquo;s payroll practices as in effect from time to time. The Base Salary will be reviewed annually by the Compensation
Committee of the Company&rsquo;s Board of Directors (the &ldquo;<U>Committee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Annual Bonuses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>For
each fiscal year ending during her employment, Executive will be eligible to earn an annual bonus. The target amount of that
bonus will be 50% of Executive&rsquo;s Base Salary for the applicable fiscal year. The actual bonus payable with respect to a
particular year will be determined by the Committee, based on the achievement of corporate and/or individual performance
objectives established by the Committee. Any bonus payable under this paragraph will be paid during the calendar year
immediately following the fiscal year in respect of which the bonus is payable and, except as otherwise provided in <U>Section
5.1.1</U>, will only be paid if Executive remains continuously employed by the Company through the actual bonus payment
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of determining any bonus payable to Executive, the measurement of corporate and individual performance will
be performed by the Committee in good faith. From time to time, the Committee may, in its sole discretion, make adjustments to
corporate or individual performance goals, so that required departures from the Company&rsquo;s operating budget, changes in accounting
principles, acquisitions, dispositions, mergers, consolidations and other corporate transactions, and other factors influencing
the achievement or calculation of such goals do not affect the operation of this provision in a manner inconsistent with its intended
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Benefits</U>. During Executive&rsquo;s employment, Executive will be eligible to participate in all employee
benefit plans and programs made available by the Company from time to time to employees generally, subject to applicable plan terms
and policies. The Company periodically reviews its benefits, policies, benefits providers and practices and may terminate, alter
or change them at its discretion from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reimbursement of Expenses</U>. The Executive will be reimbursed by the Company for all reasonable business expenses incurred
by Executive in accordance with the Company&rsquo;s customary expense reimbursement policies as in effect from time to time. Notwithstanding
anything herein to the contrary, to the extent any expense, reimbursement or in-kind benefit provided to the Executive constitutes
a &ldquo;deferral of compensation&rdquo; within the meaning of Section 409A of the Internal Revenue Code (the &ldquo;<U>Code</U>&rdquo;)
(i) the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive must be incurred during the
Executive&rsquo;s term of employment; (ii) the amount of expenses eligible for reimbursement or in-kind benefits provided to the
Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided
to the Executive in any other calendar year, (iii) the reimbursements for expenses for which the Executive is entitled to be reimbursed
shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred
and (iv) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>. Executive&rsquo;s employment with the Company may be terminated by the Company or Executive at any time
and for any reason. Upon any cessation of her employment with the Company, Executive will be entitled only to such compensation
and benefits as described in this <U>Section 5</U>. Upon any cessation of her employment for any reason, unless otherwise requested
by the Company, Executive agrees to resign immediately from all officer and director positions she then holds with the Company
and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination without Cause or for Good Reason</U>. If Executive&rsquo;s employment by the Company ceases due to a termination
by the Company without Cause (as defined below) or a resignation by Executive for Good Reason (as defined below), Executive will
be entitled to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> payment of any annual bonus otherwise payable (but for the cessation of Executive&rsquo;s employment) with respect to a
year ended prior to the cessation of Executive&rsquo;s employment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>continuation of Executive&rsquo;s Base Salary for a period equal to twelve (12) months, payable in accordance with the Company&rsquo;s
standard payroll practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>payment equal to Executive&rsquo;s target annual bonus described in <U>Section 4.2.1</U>, paid in twelve (12) substantially
equal installments over a twelve-month period and in accordance with the Company&rsquo;s standard payroll practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>accelerated vesting of any unvested restricted stock, stock options and other equity incentives awarded to Executive by
the Company that are solely subject to time-based vesting criteria equal to what would have vested had Executive remained employed
for twelve (12) additional months; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>waiver of the applicable premium otherwise payable for COBRA continuation coverage for Executive (and, to the extent covered
immediately prior to the date of such cessation, his eligible dependents) for a period equal to twelve (12) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in this <U>Section
5.1</U>, and except for payment of all (i) accrued and unpaid Base Salary through the date of such cessation, (ii) any expense
reimbursements to be paid in accordance with Company policy and (iii) payments for any accrued but unused paid time off in accordance
with the Company&rsquo;s policies and applicable law, all compensation and benefits will cease at the time of such cessation and
the Company will have no further liability or obligation by reason of such cessation. The payments and benefits described in this
<U>Section 5.1</U> are in lieu of, and not in addition to, any other severance arrangement maintained by the Company. For avoidance
of doubt, any unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company that are
subject to performance-based vesting shall become vested, if at all, in accordance with the Company&rsquo;s Amended and Restated
2014 Stock Incentive Plan (or any successor provision or plan) (the &ldquo;<U>Plan</U>&rdquo;) and the applicable award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any provision of this Agreement,
the payments and benefits described in <U>Section 5.1</U> are conditioned on: (a) the Executive&rsquo;s execution and delivery
to the Company and the expiration of all applicable statutory revocation periods, by the 45th day following the effective date
of her cessation of employment, of a general release of claims against the Company and its affiliates in a form reasonably prescribed
by the Company (the &ldquo;<U>Release</U>&rdquo;); and (b) the Executive&rsquo;s continued compliance with the Restrictive Covenants
(as defined below). Subject to <U>Section 5.4</U>, below, the benefits described in <U>Section 5.1</U> will be paid or provided
(or begin to be paid or provided) as soon as administratively practicable (or determinable in the case of the benefits described
in <U>Section 5.1.1</U>) after the Release becomes irrevocable, provided that if the 45 day period described above begins in one
taxable year and ends in a second taxable year such payments or benefits shall not commence until the second taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Termination
Following a Change in Control</U>. If Executive&rsquo;s employment by the Company ceases due to a termination by the Company
without Cause or a resignation by Executive for Good Reason during the twelve (12) month period immediately following the
occurrence of a Change in Control (as defined below), (i) all unvested restricted stock, stock options and other equity
incentives awarded to Executive by the Company that are subject onlt to time-based vesting will become immediately and
automatically fully vested and exercisable (as applicable), (ii) in lieu of the salary continuation described in <U>Section
5.1.2</U>, the Executive shall receive eighteen (18) months of his Base Salary, paid in a lump sum; (iii) in lieu of the
bonus described in <U>Section 5.1.3</U>, the Executive shall receive 1.5 times his then-current target annual bonus payable
in a lump sum, and (iv) the COBRA continuation period described in <U>Section 5.1.5</U> will be eighteen (18) months in lieu
of twelve (12). Any unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company
that are subject to performance-based vesting shall become vested, if at all, in accordance with the Plan and the applicable
award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any benefits received
under this <U>Section 5.2</U> shall be governed by the terms and conditions described in <U>Section 5.1</U> above, including without
limitation the requirement that Executive timely execute a Release and comply with the Restrictive Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Terminations</U>. If Executive&rsquo;s employment with the Company ceases for any reason other than as described
in <U>Section 5.1</U> or <U>Section 5.2</U> above (including but not limited to termination (i) by the Company for Cause, (ii)
as a result of Executive&rsquo;s death, (iii) as a result of Executive&rsquo;s Disability or (iv) by Executive without Good Reason,
then the Company&rsquo;s obligation to Executive will be limited solely to (a) accrued and unpaid Base Salary through the date
of such cessation, (b) any expense reimbursements to be paid in accordance with Company policy and (c) payments for any accrued
but unused paid time off in accordance with the Company&rsquo;s policies and applicable law. All compensation and benefits will
cease at the time of such cessation and, except as otherwise provided by COBRA or this <U>Section 5.3</U>, the Company will have
no further liability or obligation by reason of such termination. The foregoing will not be construed to limit Executive&rsquo;s
right to payment or reimbursement for claims incurred prior to the date of such termination under any insurance contract funding
an employee benefit plan, policy or arrangement of the Company in accordance with the terms of such insurance contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Compliance
with Section 409A</U>. If the termination giving rise to the payments described in <U>Section 5.1</U> or <U>Section 5.2 </U>is
not a &ldquo;Separation from Service&rdquo; within the meaning of Treas. Reg. &sect; 1.409A-1(h)(1) (or any successor
provision), then the amounts otherwise payable pursuant to that section will instead be deferred without interest and will
not be paid until Executive experiences a Separation from Service. To the maximum extent permitted under Section 409A of the
Code and its corresponding regulations, the cash severance benefits payable under this Agreement are intended to meet the
requirements of the short-term deferral exemption under Section 409A of the Code and the &ldquo;separation pay
exception&rdquo; under Treas. Reg. &sect;1.409A-1(b)(9) (iii). To the extent compliance with the requirements of Treas. Reg.
 &sect; 1.409A-3(i)(2) (or any successor provision) is necessary to avoid the application of an additional tax under Section
409A of the Internal Revenue Code to payments due to Executive upon or following her Separation from Service, then
notwithstanding any other provision of this Agreement (or any otherwise applicable plan, policy, agreement or arrangement),
any such payments that are otherwise due within six months following Executive&rsquo;s Separation from Service (taking into
account the preceding sentence of this paragraph) will be deferred without interest and paid to Executive in a lump sum
immediately following that six month period. For purposes of the application of Treas. Reg. &sect; 1.409A-1(b)(4)(or any
successor provision), each payment in a series of payments will be deemed a separate payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>PPACA</U>. Notwithstanding anything in this Agreement to the contrary, the waiver in respect of COBRA premiums pursuant
to <U>Sections 5.1</U> and <U>5.2</U> shall cease to the extent required to avoid adverse consequences to the Company under the
Patient Protection and Affordable Care Act of 2010 and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 280G</U>. If any payment or distribution by the Company to or for the benefit of the Executive, whether paid
or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise pursuant to or by reason of any
other agreement, policy, plan, program or arrangement or the lapse or termination of any restriction on or the vesting or exercisability
of any payment or benefit (each, a &ldquo;<U>Payment</U>&rdquo;), would be subject to the excise tax imposed by Section 4999 of
the Code (or any successor provision thereto) or to any similar tax imposed by state or local law (such tax or taxes are hereafter
collectively referred to as the &ldquo;<U>Excise Tax</U>&rdquo;), then the aggregate amount of Payments payable to Executive shall
be reduced to the aggregate amount of Payments that may be made to the Executive without incurring an excise tax (the &ldquo;<U>Safe-Harbor
Amount</U>&rdquo;) in accordance with the immediately following sentence; <I>provided that </I>such reduction shall only be imposed
if the aggregate after-tax value of the Payments retained by Executive (after giving effect to such reduction) is equal to or greater
than the aggregate after-tax value (after giving effect to the Excise Tax) of the Payments to Executive without any such reduction.
Any such reduction shall be made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary,
to zero); (ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash payments (other
than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity
derivative payments shall be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Cause</U>&rdquo; means (a) commission or conviction of any felony or any crime involving dishonesty; (b) commission
of any fraud against the Company; (c) intentional and material damage to any material property of the Company; (d) Executive&rsquo;s
material breach of any agreement with or duty owed to the Company or any of its affiliates (including, without limitation, Executive&rsquo;s
material breach of any of the Restrictive Covenants, as defined below); or (e) refusal to perform the lawful, reasonable and material
directives of the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;) or the Company&rsquo;s Chief Executive Officer.
Before &ldquo;Cause&rdquo; under clause (c), (d) or (e) has been deemed to have occurred, the Board must provide the Executive
with written notice detailing why the Board has determined that Cause has occurred and the actions required to cure the same, to
the extent reasonably subject to cure. The Executive shall then, where the grounds for Cause are reasonably subject to cure within
such time, have thirty (30) days after the Executive&rsquo;s receipt of written notice to cure the item cited in the written notice
so that &ldquo;Cause&rdquo; will have not formally occurred with respect to the event in question until such period, where applicable,
shall have expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Change in Control</U>&rdquo; means the first to occur of any of the events described in Section l(g) of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<U>Disability</U>&rdquo; means a condition entitling the Executive to benefits under the Company&rsquo;s long term
disability plan, policy or arrangement; <I>provided, however</I>, that if no such plan, policy or arrangement is then maintained
by the Company and applicable to the Executive, &ldquo;<U>Disability</U>&rdquo; will mean the Executive&rsquo;s inability to perform
her duties under this Agreement due to a mental or physical condition that can be expected to result in death or that can be expected
to last (or has already lasted) for a continuous period of 90 days or more, or for 120 days in any 180 consecutive day period.
Termination as a result of a Disability will not be construed as a termination by the Company &ldquo;without Cause.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Good Reason</U>&rdquo; means any of the following, without the Executive&rsquo;s prior consent: (a) a material
diminution of the Executive&rsquo;s duties or authority with the Company, reporting relationships or the assignment of duties and
responsibilities inconsistent with Executive&rsquo;s status at the Company; (b) a reduction in Base Salary; or (c) the relocation
of the Executive&rsquo;s primary place of employment to a location that is (i) more than 50 miles from the location of the Executive&rsquo;s
permanent primary place of employment prior to such relocation and (ii) more than 50 miles from the location of the Executive&rsquo;s
residence. However, none of the foregoing events or conditions will constitute Good Reason unless the Executive provides the Company
with written objection to the event or condition within 30 days following the occurrence thereof, the Company does not reverse
or otherwise cure the event or condition within 30 days of receiving that written objection, and the Executive resigns Executive&rsquo;s
employment within 30 days following the expiration of that cure period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictive Covenants</U>. To induce the Company to enter into this Agreement and in recognition of the compensation
to be paid to the Executive pursuant to <U>Sections 4 and 5</U> of this Agreement, the Executive agrees to be bound by the provisions
of this <U>Section 6</U> (the &ldquo;<U>Restrictive Covenants</U>&rdquo;). These Restrictive Covenants will apply without regard
to whether any termination or cessation of the Executive&rsquo;s employment is initiated by the Company or the Executive, and without
regard to the reason for that termination or cessation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Covenant Not To Compete</U>. The Executive covenants that, during her employment by the Company and for a period of twelve
(12) months following immediately thereafter (the &ldquo;<U>Restricted Period</U>&rdquo;), the Executive will not (except in her
capacity as an employee or director of the Company) do any of the following, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>engage or participate in any Competing Business (as defined below) wherever the Company or its affiliates do business, do
or plan to do business or sell or market their products or services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>become interested in (as owner, stockholder, lender, partner, co- venturer, director, officer, employee, agent or consultant)
any person, firm, corporation, association or other entity engaged in a Competing Business. Notwithstanding the foregoing, the
Executive may hold up to 1% of the outstanding securities of any class of any publicly-traded securities of any company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>influence
or attempt to influence any employee, consultant, supplier, licensor, licensee, contractor, agent, strategic partner,
distributor, customer or other person to terminate or modify any written or oral agreement, arrangement or course of dealing
with the Company or any of its affiliates; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>solicit for employment or retention as an independent contractor (or arrange to have any other person or entity solicit
for employment or retention) any person employed or retained by the Company or any of its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Executive acknowledges
that the consideration described in <U>Sections 4</U> and <U>5</U> constitutes mutually-agreed upon consideration with respect
to the covenants set forth in <U>Sections 6.1.1</U> and <U>6.1.2</U> for purposes of Section 24L(b)(vii) of Chapter 149 of the
Massachusetts General Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidentiality</U>. The Executive recognizes and acknowledges that the Proprietary Information (as defined in below)
is a valuable, special and unique asset of the business of the Company and its affiliates. As a result, both during the Term and
thereafter, the Executive will not, without the prior written consent of the Company, for any reason divulge to any third&#45;party
or use for her own benefit, or for any purpose other than the exclusive benefit of the Company and its affiliates, any Proprietary
Information. Notwithstanding the foregoing, nothing in this Agreement prohibits the Executive from initiating communications directly
with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations
of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or
a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department of Labor, the National
Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector
General (collectively, the &ldquo;<U>Regulators</U>&rdquo;), or from making other disclosures that are protected under the whistleblower
provisions of state or federal law or regulation. In connection with any such activity, the Executive must identify any information
that is confidential and ask the Regulator for confidential treatment of such information. Despite the foregoing, Executive is
not permitted to reveal to any third party, including any governmental, law enforcement, or regulatory authority, information employee
came to learn during the course of Executive&rsquo;s employment with the Company that is protected from disclosure by any applicable
privilege, including but not limited to the attorney-client privilege, attorney work product doctrine and/or other applicable legal
privileges. The Company does not waive any applicable privileges or the right to continue to protect its privileged attorney-client
information, attorney work product, and other privileged information. Notwithstanding any other provisions of this Agreement, pursuant
to 18 USC Section 1833(b), Executive shall not be held criminally or civilly liable under any federal or state trade secret law
for the disclosure of a trade secret that is made: (a) confidentially to a federal, state, or local government official, either
directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law;
or (b) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. If Executive
files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose a trade secret
of the Company to Executive&rsquo;s attorney and use the trade secret information in related court proceedings, provided that Executive
files any document containing the trade secret information under seal and does not disclose the trade secret, except pursuant to
court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.3<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Property of the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Proprietary Information</U>. All right, title and interest in and to Proprietary Information will be and remain the
sole and exclusive property of the Company and its affiliates. The Executive will not remove from the Company&rsquo;s or its affiliates&rsquo;
offices or premises any documents, records, notebooks, files, correspondence, reports, memoranda or similar materials of or containing
Proprietary Information, or other materials or property of any kind belonging to the Company or its affiliates unless necessary
or appropriate in the performance of her duties to the Company and its affiliates. If the Executive removes such materials or property
in the performance of her duties, she will return such materials or property promptly after the removal has served its purpose.
The Executive will not make, retain, remove and/or distribute any copies of any such materials or property, or divulge to any third
person the nature of and/or contents of such materials or property, except to the extent necessary to satisfy contractual obligations
of the Company or its affiliates or to perform her duties on behalf of the Company and its affiliates or pursuant to the exceptions
set forth in <U>Section 6.2</U>. Upon termination of the Executive&rsquo;s employment with the Company, she will leave with the
Company and its affiliates or promptly return to the Company and its affiliates all originals and copies of such materials or property
then in her possession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>. The Executive agrees that all the Intellectual Property (as defined below) will be considered
 &ldquo;works made for hire&rdquo; as that term is defined in Section 101 of the Copyright Act (17 U.S.C. &sect; 101) and that all
right, title and interest in such Intellectual Property will be the sole and exclusive property of the Company and its affiliates.
To the extent that any of the Intellectual Property may not by law be considered a work made for hire, or to the extent that, notwithstanding
the foregoing, the Executive retains any interest in the Intellectual Property, the Executive hereby irrevocably assigns and transfers
to the Company and its affiliates any and all right, title, or interest that the Executive may now or in the future have in the
Intellectual Property under patent, copyright, trade secret, trademark or other law, in perpetuity or for the longest period otherwise
permitted by law, without the necessity of further consideration. The Company and its affiliates will be entitled to obtain and
hold in its own name all copyrights, patents, trade secrets, trademarks and other similar registrations with respect to such Intellectual
Property. The Executive further agrees to execute any and all documents and provide any further cooperation or assistance reasonably
required by the Company, at the Company&rsquo;s expense, to perfect, maintain or otherwise protect its rights in the Intellectual
Property. If the Company or its affiliates, as applicable, are unable after reasonable efforts to secure the Executive&rsquo;s
signature, cooperation or assistance in accordance with the preceding sentence, whether because of the Executive&rsquo;s incapacity
or any other reason whatsoever, the Executive hereby designates and appoints the Company, the appropriate affiliate, or their respective
designee as the Executive&rsquo;s agent and attorney&#45;in&#45;fact, to act on her behalf, to execute and file documents and to
do all other lawfully permitted acts necessary or desirable to perfect, maintain or otherwise protect the Company&rsquo;s or its
affiliates&rsquo; rights in the Intellectual Property. The Executive acknowledges and agrees that such appointment is coupled with
an interest and is therefore irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>&ldquo;<U>Competing
Business</U>&rdquo; means any person, firm, corporation, partnership, association or other entity engaged in developing,
manufacturing, marketing, distributing or selling, directly or indirectly, pharmaceutical abuse-deterrent products or any
other product for pain indications that directly competes with a product developed, manufactured, marketed, distributed or
sold by the Company. A division, subsidiary or similar business unit of an entity that does not engage in the business
activities described in this definition will not be considered a Competing Business even if another separate division,
subsidiary or similar business unit does engage in such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Intellectual Property</U>&rdquo; means (a) all inventions (whether patentable or unpatentable and whether or not
reduced to practice), all improvements thereto, and all patents and patent applications claiming such inventions, (b) all trademarks,
service marks, trade dress, logos, trade names, fictitious names, brand names, brand marks and corporate names, together with all
translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications,
registrations, and renewals in connection therewith, (c) all copyrightable works, all copyrights, and all applications, registrations,
and renewals in connection therewith, (d) all mask works and all applications, registrations, and renewals in connection therewith,
(e) all trade secrets (including research and development, know&#45;how, formulas, compositions, manufacturing and production processes
and techniques, methodologies, technical data, designs, drawings and specifications), (f) all computer software (including data,
source and object codes and related documentation), (g) all other proprietary rights, (h) all copies and tangible embodiments thereof
(in whatever form or medium), or (i) similar intangible personal property which have been or are developed or created in whole
or in part by the Executive (1) at any time and at any place while the Executive is employed by Company and which, in the case
of any or all of the foregoing, are related to and used in connection with the business of the Company or its affiliates, or (2)
as a result of tasks assigned to the Executive by the Company or its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Proprietary Information</U>&rdquo; means any and all proprietary information developed or acquired by the Company
or any of its subsidiaries or affiliates that has not been specifically authorized to be disclosed. Such Proprietary Information
shall include, but shall not be limited to, the following items and information relating to the following items: (a) all intellectual
property and proprietary rights of the Company (including, without limitation, the Intellectual Property), (b) computer codes and
instructions, processing systems and techniques, inputs and outputs (regardless of the media on which stored or located) and hardware
and software configurations, designs, architecture and interfaces, (c) business research, studies, procedures and costs, (d) financial
data, (e) distribution methods, (f) marketing data, methods, plans and efforts, (g) the identities of actual and prospective suppliers,
(h) the terms of contracts and agreements with, the needs and requirements of, and the Company&rsquo;s or its affiliates&rsquo;
course of dealing with, actual or prospective suppliers, (i) personnel information, (j) customer and vendor credit information,
and (k) information received from third parties subject to obligations of non- disclosure or non-use. Failure by the Company or
its affiliates to mark any of the Proprietary Information as confidential or proprietary shall not affect its status as Proprietary
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Acknowledgements</U>. The Executive acknowledges that the Restrictive Covenants are reasonable and necessary to protect
the legitimate interests of the Company and its affiliates, that the duration and geographic scope of the Restrictive Covenants
are reasonable given the nature of this Agreement and the position the Executive holds within the Company, and that the Company
would not enter into this Agreement or otherwise employ or continue to employ the Executive unless the Executive agrees to be bound
by the Restrictive Covenants set forth in this <U>Section 6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Remedies and Enforcement Upon Breach</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Specific Enforcement</U>. The Executive acknowledges that any breach by her, willfully or otherwise, of the Restrictive
Covenants will cause continuing and irreparable injury to the Company or its affiliates for which monetary damages would not be
an adequate remedy. The Executive shall not, in any action or proceeding to enforce any of the provisions of this Agreement, assert
the claim or defense that such an adequate remedy at law exists. In the event of any such breach or threatened breach by the Executive
of any of the Restrictive Covenants, the Company or its affiliates, as applicable, shall be entitled to injunctive or other similar
equitable relief in any court, without any requirement that a bond or other security be posted, and this Agreement shall not in
any way limit remedies of law or in equity otherwise available to the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Judicial Modification</U>. If any court determines that any of the Restrictive Covenants, or any part thereof, is unenforceable
because of the duration or geographical scope of such provision, such court shall have the power to modify such provision and,
in its modified form, such provision shall then be enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforceability</U>. If any court holds the Restrictive Covenants unenforceable by reason of their breadth or scope or
otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the right of the Company
and its affiliates to the relief provided above in the courts of any other jurisdiction within the geographic scope of such Restrictive
Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of Restrictive Covenants</U>. The Executive agrees to disclose the existence and terms of the Restrictive
Covenants to any employer that the Executive may work for during the Restricted Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Extension of Restricted Period</U>. If the Executive breaches <U>Section 6.1</U> in any respect, the restrictions contained
in that section will be extended for a period equal to the period that the Executive was in breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right to Consult Counsel</U>. Executive understands and acknowledges that Executive has the right to consult with counsel
prior to signing this Agreement. Executive further represents that Executive is signing this Agreement freely and voluntarily in
exchange for the benefits provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Agreements</U>. Executive represents and warrants to the Company that there are no restrictions, agreements or
understandings whatsoever to which she is a party that would prevent or make unlawful her execution of this Agreement, that would
be inconsistent or in conflict with this Agreement or Executive&rsquo;s obligations hereunder, or that would otherwise prevent,
limit or impair the performance by Executive of her duties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. The Company may assign this Agreement to any successor to its assets and business by means
of liquidation, dissolution, sale of assets or otherwise. The duties of Executive hereunder are personal to Executive and may not
be assigned by her.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Governing Law and Enforcement</U>. This Agreement will be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, without regard to the principles of conflicts of laws. Any legal proceeding arising out of or relating
to this Agreement will be instituted in a state or federal court in the Commonwealth of Massachusetts, and Executive and the Company
hereby consent to the personal and exclusive jurisdiction of such court(s) and hereby waive any objection(s) that they may have
to personal jurisdiction, the laying of venue of any such proceeding and any claim or defense of inconvenient forum. Notwithstanding
the foregoing, any action that is commenced by either party to resolve any matter arising under <U>Section 6.1</U> of this Agreement,
shall be commenced only in the Massachusetts Superior Court located in Suffolk County, Massachusetts and the parties each consent
to the jurisdiction of such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waivers</U>. The waiver by either party of any right hereunder or of any breach by the other party will not be deemed
a waiver of any other right hereunder or of any other breach by the other party. No waiver will be deemed to have occurred unless
set forth in a writing. No waiver will constitute a continuing waiver unless specifically stated, and any waiver will operate only
as to the specific term or condition waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective
and valid under applicable law. However, if any provision of this Agreement is held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality or unenforceability will not affect any other provision, and this Agreement will be reformed,
construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. This Agreement will survive the cessation of Executive&rsquo;s employment to the extent necessary to fulfill
the purposes and intent the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any notice or communication required or permitted under this Agreement will be made in writing and (a) sent
by overnight courier, (b) mailed by overnight U.S. express mail, return receipt requested or (c) sent by telecopier. Any notice
or communication to Executive will be sent to the address contained in her personnel file. Any notice or communication to the Company
will be sent to the Company&rsquo;s principal executive offices, to the attention of its Chief Executive Officer. Notwithstanding
the foregoing, either party may change the address for notices or communications hereunder by providing written notice to the other
in the manner specified in this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement; Amendments</U>. This Agreement contains the entire agreement and understanding of the parties hereto
relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings
of every nature relating to that subject matter (including, without limitation, the Existing Agreement). This Agreement may not
be changed or modified, except by an agreement in writing signed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Withholding</U>. All payments (or transfers of property) to Executive will be subject to tax withholding to the extent
required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Section Headings</U>. The headings of sections and paragraphs of this Agreement are inserted for convenience only and
will not in any way affect the meaning or construction of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts; Facsimile</U>. This Agreement may be executed in multiple counterparts (including by facsimile signature),
each of which will be deemed to be an original, but all of which together will constitute but one and the same instrument. Counterparts
may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall
be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&lt;remainder of page intentionally left
blank; signature page follows&gt;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Company has caused
this Agreement to be executed by its duly authorized officer, and Executive has executed this Agreement, on the date(s) indicated
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">COLLEGIUM PHARMACEUTICAL, INC.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Paul Brannelly</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Paul Brannelly</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">CFO</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Date: </TD>
    <TD STYLE="border-bottom: Black 1pt solid">12/27/2020</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">SHIRLEY R. KUHLMANN</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Shirley Kuhlmann</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Date: </TD>
    <TD STYLE="border-bottom: Black 1pt solid">12/24/2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>signature page
to Employment Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>tm2039449d1_ex10-6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.6</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-weight: normal"><U>amended
 &amp; restATED</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>EMPLOYMENT
AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS EMPLOYMENT AGREEMENT
(the &ldquo;Agreement&rdquo;) is made by and between COLLEGIUM PHARMACEUTICAL, INC. (the &ldquo;<U>Company</U>&rdquo;) and RICHARD
MALAMUT, M.D. (the &ldquo;<U>Executive</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive are parties to an Employment Agreement dated as of April 1, 2019 (the &ldquo;<U>Existing Agreement</U>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
and the Executive desire to amend and restate the Existing Agreement and enter into this Agreement pursuant to which the Company
will continue to employ Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the foregoing and intending to be bound hereby, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Duration of Agreement</U>. This Agreement is effective as of January 1, 2021 and has no specific expiration date. Unless
terminated by agreement of the parties, this Agreement will govern Executive&rsquo;s employment by the Company until that employment
ceases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Title; Duties</U>. Executive will continue to be employed as the Company&rsquo;s Executive Vice President and Chief Medical
Officer and will report to the Company&rsquo;s Chief Executive Officer. Executive will devote his best efforts and substantially
all of his business time and services to the Company and its affiliates to perform such duties as may be customarily incident to
his position and as may reasonably be assigned to him from time to time consistent with his position. Executive will not, in any
capacity, engage in other business activities or perform services for any other individual, firm or corporation without the prior
written consent of the Company; <I>provided, however</I>, that without such consent, Executive may engage in charitable, non-profit
and public service activities, so long as such activities do not materially interfere or conflict with Executive&rsquo;s performance
of his duties and obligations to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Place of Performance</U>. Executive will perform his services hereunder at the principal executive offices of the Company
in Stoughton, Massachusetts, or such other locations approved by the Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Base Salary</U>. Executive&rsquo;s annual salary will be $423,300 (the &ldquo;<U>Base Salary</U>&rdquo;), paid in accordance
with the Company&rsquo;s payroll practices as in effect from time to time. The Base Salary will be reviewed annually for increase
by the Compensation Committee of the Company&rsquo;s Board of Directors (the &ldquo;<U>Committee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Annual Bonuses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>For
each fiscal year ending during his employment, Executive will be eligible to earn an annual bonus. The target amount of that
bonus will be 50% of Executive&rsquo;s Base Salary for the applicable fiscal year. The actual bonus payable with respect to a
particular year will be determined by the Committee, based on the achievement of corporate and/or individual performance
objectives established by the Committee. Any bonus payable under this paragraph will be paid during the calendar year
immediately following the fiscal year in respect of which the bonus is payable and, except as otherwise provided in <U>Section
5.1.1</U>, will only be paid if Executive remains continuously employed by the Company through the actual bonus payment
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of determining any bonus payable to Executive, the measurement of corporate and individual performance will
be performed by the Committee in good faith. From time to time, the Committee may, in its sole discretion, make adjustments to
corporate or individual performance goals, so that required departures from the Company&rsquo;s operating budget, changes in accounting
principles, acquisitions, dispositions, mergers, consolidations and other corporate transactions, and other factors influencing
the achievement or calculation of such goals do not affect the operation of this provision in a manner inconsistent with its intended
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Benefits</U>. During Executive&rsquo;s employment, Executive will be eligible to participate in all employee
benefit plans and programs made available by the Company from time to time to employees generally, subject to applicable plan terms
and policies. The Company periodically reviews its benefits, policies, benefits providers and practices and may terminate, alter
or change them at its discretion from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reimbursement of Expenses</U>. The Executive will be reimbursed by the Company for all reasonable business expenses incurred
by Executive in accordance with the Company&rsquo;s customary expense reimbursement policies as in effect from time to time. Notwithstanding
anything herein to the contrary, to the extent any expense, reimbursement or in-kind benefit provided to the Executive constitutes
a &ldquo;deferral of compensation&rdquo; within the meaning of Section 409A of the Internal Revenue Code (the &ldquo;<U>Code</U>&rdquo;)
(i) the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive must be incurred during the
Executive&rsquo;s term of employment; (ii) the amount of expenses eligible for reimbursement or in- kind benefits provided to the
Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided
to the Executive in any other calendar year, (iii) the reimbursements for expenses for which the Executive is entitled to be reimbursed
shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred
and (iv) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Commuting Costs</U>. The Company shall pay or shall reimburse the Executive for his reasonable costs incurred for commuting
to and from the Company&rsquo;s principal executive office and for costs for lodging in the area of such office, subject to the
Company&rsquo;s travel and entertainment policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Termination</U>.
Executive&rsquo;s employment with the Company may be terminated by the Company or Executive at any time and for any reason.
Upon any cessation of his employment with the Company, Executive will be entitled only to such compensation and benefits as
described in this <U>Section 5</U>. Upon any cessation of his employment for any reason, unless otherwise requested by the
Company, Executive agrees to resign immediately from all officer and director positions he then holds with the Company and
its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination without Cause or for Good Reason</U>. If Executive&rsquo;s employment by the Company ceases due to a termination
by the Company without Cause (as defined below) or a resignation by Executive for Good Reason (as defined below), Executive will
be entitled to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>payment of any annual bonus otherwise payable (but for the cessation of Executive&rsquo;s employment) with respect to a
year ended prior to the cessation of Executive&rsquo;s employment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>continuation of Executive&rsquo;s Base Salary for a period equal to twelve (12) months, payable in accordance with the Company&rsquo;s
standard payroll practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>payment equal to Executive&rsquo;s target annual bonus described in <U>Section 4.2.1</U>, paid in twelve (12) substantially
equal installments over a twelve-month period and in accordance with the Company&rsquo;s standard payroll practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>accelerated vesting of any unvested restricted stock, stock options and other equity incentives awarded to Executive by
the Company that are solely subject to time-based vesting criteria equal to what would have vested had Executive remained employed
for twelve (12) additional months; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>waiver of the applicable premium otherwise payable for COBRA continuation coverage for Executive (and, to the extent covered
immediately prior to the date of such cessation, his eligible dependents) for a period equal to twelve (12) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in this <U>Section
5.1</U>, and except for payment of all (i) accrued and unpaid Base Salary through the date of such cessation, (ii) any expense
reimbursements to be paid in accordance with Company policy, (iii) payments for any accrued but unused paid time off in accordance
with the Company&rsquo;s policies and applicable law and (iv) payments and benefits accrued under the Plan or any other employee
benefit plan maintained by the Company or any of its affiliates, all compensation and benefits will cease at the time of such cessation
and the Company will have no further liability or obligation by reason of such cessation. The payments and benefits described in
this <U>Section 5.1</U> are in lieu of, and not in addition to, any other severance arrangement maintained by the Company. For
avoidance of doubt, any unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company
that are subject to performance-based vesting shall become vested, if at all, in accordance with the Company&rsquo;s Amended and
Restated 2014 Stock Incentive Plan (or any successor provision or plan) (the &ldquo;<U>Plan</U>&rdquo;) and the applicable award
agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any provision of this
Agreement, the payments and benefits described in <U>Section 5.1</U> are conditioned on: (a) the Executive&rsquo;s execution and
delivery to the Company and the expiration of all applicable statutory revocation periods, by the 45th day following the effective
date of his cessation of employment, of a release of employment claims against the Company and its affiliates in a form reasonably
prescribed by the Company, which release shall include Executive&rsquo;s affirmation of his obligation not to compete with the
Company as described in <U>Section 6.1.1(a)-(b)</U> herein (the &ldquo;<U>Release</U>&rdquo;); and (b) the Executive&rsquo;s continued
compliance with the Restrictive Covenants (as defined below). Subject to <U>Section 5.4</U>, below, the benefits described in
<U>Section 5.1</U> will be paid or provided (or begin to be paid or provided) as soon as administratively practicable (or determinable
in the case of the benefits described in <U>Section 5.1.1</U>) after the Release becomes irrevocable, provided that if the 45
day period described above begins in one taxable year and ends in a second taxable year such payments or benefits shall not commence
until the second taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination Following a Change in Control</U>. If Executive&rsquo;s employment by the Company ceases due to a termination
by the Company without Cause or a resignation by Executive for Good Reason during the twelve (12) month period immediately following
the occurrence of a Change in Control (as defined below), (i) all unvested restricted stock, stock options and other equity incentives
awarded to Executive by the Company that are subject only to time-based vesting will become immediately and automatically fully
vested and exercisable (as applicable), (ii) in lieu of the salary continuation described in <U>Section 5.1.2</U>, the Executive
shall receive eighteen (18) months of his Base Salary, paid in a lump sum; (iii) in lieu of the bonus described in <U>Section 5.1.3</U>,
the Executive shall receive 1.5 times his then-current target annual bonus payable in a lump sum, and (iv) the COBRA continuation
period described in <U>Section 5.1.5 </U>will be eighteen (18) months in lieu of twelve (12). Any unvested restricted stock, stock
options and other equity incentives awarded to Executive by the Company that are subject to performance-based vesting shall become
vested, if at all, in accordance with the Plan and the applicable award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">For the avoidance of
doubt, any benefits received under this <U>Section 5.2</U> shall be governed by the otherwise applicable terms and conditions described
in <U>Section 5.1</U> above, including without limitation the requirement that Executive timely execute a Release and comply with
the Restrictive Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Terminations</U>. If Executive&rsquo;s employment with the Company ceases for any reason other than as described
in <U>Section 5.1</U> or <U>Section 5.2</U> above (including but not limited to termination (i) by the Company for Cause, (ii)
as a result of Executive&rsquo;s death, (iii) as a result of Executive&rsquo;s Disability or (d) by Executive without Good Reason,
then the Company&rsquo;s obligation to Executive will be limited solely to (a) accrued and unpaid Base Salary through the date
of such cessation, (b) any expense reimbursements to be paid in accordance with Company policy and (c) payments for any accrued
but unused paid time off in accordance with the Company&rsquo;s policies and applicable law. All compensation and benefits will
cease at the time of such cessation and, except as otherwise provided by COBRA or this <U>Section 5.3</U>, the Company will have
no further liability or obligation by reason of such termination. The foregoing will not be construed to limit Executive&rsquo;s
right to payment or reimbursement for claims incurred prior to the date of such termination under any insurance contract funding
an employee benefit plan, policy or arrangement of the Company in accordance with the terms of such insurance contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Compliance
with Section 409A</U>. If the termination giving rise to the payments described in <U>Section 5.1</U> or <U>Section 5.2</U>
is not a &ldquo;Separation from Service&rdquo; within the meaning of Treas. Reg. &sect; 1.409A-1(h)(1) (or any successor
provision), then the amounts otherwise payable pursuant to that section will instead be deferred without interest and will
not be paid until Executive experiences a Separation from Service. To the maximum extent permitted under Section 409A of the
Code and its corresponding regulations, the cash severance benefits payable under this Agreement are intended to meet the
requirements of the short-term deferral exemption under Section 409A of the Code and the &ldquo;separation pay
exception&rdquo; under Treas. Reg. &sect;1.409A-1(b)(9) (iii). To the extent compliance with the requirements of Treas. Reg.
 &sect; 1.409A-3(i)(2) (or any successor provision) is necessary to avoid the application of an additional tax under Section
409A of the Internal Revenue Code to payments due to Executive upon or following his Separation from Service, then
notwithstanding any other provision of this Agreement (or any otherwise applicable plan, policy, agreement or arrangement),
any such payments that are otherwise due within six months following Executive&rsquo;s Separation from Service (taking into
account the preceding sentence of this paragraph) will be deferred without interest and paid to Executive in a lump sum
immediately following that six month period. For purposes of the application of Treas. Reg. &sect; 1.409A-1(b)(4)(or any
successor provision), each payment in a series of payments will be deemed a separate payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>PPACA</U>. Notwithstanding anything in this Agreement to the contrary, the waiver in respect of COBRA premiums pursuant
to <U>Sections 5.1</U> and <U>5.2</U> shall cease to the extent required to avoid adverse consequences to the Company under the
Patient Protection and Affordable Care Act of 2010 and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 280G</U>. If any payment or distribution by the Company to or for the benefit of the Executive, whether paid
or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise pursuant to or by reason of any
other agreement, policy, plan, program or arrangement or the lapse or termination of any restriction on or the vesting or exercisability
of any payment or benefit (each a &ldquo;<U>Payment</U>&rdquo;), would be subject to the excise tax imposed by Section 4999 of
the Code (or any successor provision thereto) or to any similar tax imposed by state or local law (such tax or taxes are hereafter
collectively referred to as the &ldquo;<U>Excise Tax</U>&rdquo;), then the aggregate amount of Payments payable to Executive shall
be reduced to the aggregate amount of Payments that may be made to the Executive without incurring an excise tax (the &ldquo;<U>Safe-Harbor
Amount</U>&rdquo;) in accordance with the immediately following sentence; <I>provided that </I>such reduction shall only be imposed
if the aggregate after-tax value of the Payments retained by Executive (after giving effect to such reduction) is equal to or greater
than the aggregate after-tax value (after giving effect to the Excise Tax) of the Payments to Executive without any such reduction.
Any such reduction shall be made in the following order: (i) first, any future cash payments (if any) shall be reduced (if necessary,
to zero); (ii) second, any current cash payments shall be reduced (if necessary, to zero); (iii) third, all non-cash payments (other
than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv) fourth, all equity or equity
derivative payments shall be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Cause</U>&rdquo; means (a) conviction of any felony or any crime involving dishonesty; (b) commission of any fraud
against the Company; (c) intentional and material damage to any material property of the Company; (d) Executive&rsquo;s material
breach of any agreement with or duty owed to the Company or any of its affiliates (including, without limitation, Executive&rsquo;s
material breach of any of the Restrictive Covenants, as defined below); or (e) refusal to perform the lawful, reasonable and material
directives of the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;) or the Company&rsquo;s Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<U>Change in Control</U>&rdquo; means the first to occur of any of the events described in Section l(g) of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Disability</U>&rdquo; means a condition entitling the Executive to benefits under the Company&rsquo;s long term
disability plan, policy or arrangement; <I>provided, however</I>, that if no such plan, policy or arrangement is then maintained
by the Company and applicable to the Executive, &ldquo;<U>Disability</U>&rdquo; will mean the Executive&rsquo;s inability to perform
his duties under this Agreement due to a mental or physical condition that can be expected to result in death or that can be expected
to last (or has already lasted) for a continuous period of 90 days or more, or for 120 days in any 180 consecutive day period.
Termination as a result of a Disability will not be construed as a termination by the Company &ldquo;without Cause.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Good Reason</U>&rdquo; means any of the following, without the Executive&rsquo;s prior consent: (a) a material
diminution of the Executive&rsquo;s duties or authority with the Company, reporting relationships or the assignment of duties and
responsibilities inconsistent with Executive&rsquo;s status at the Company; or (b) a reduction in Base Salary. However, none of
the foregoing events or conditions will constitute Good Reason unless the Executive provides the Company with written objection
to the event or condition within 30 days following the occurrence thereof, the Company does not reverse or otherwise cure the event
or condition within 30 days of receiving that written objection, and the Executive resigns Executive&rsquo;s employment within
30 days following the expiration of that cure period. Notwithstanding the foregoing and for the avoidance of doubt, a diminution
of the Executive&rsquo;s title as a result of Change in Control shall not, in itself, constitute Good Reason; provided that (i)
any new title resulting from such diminution shall be reasonably equivalent in seniority and eligibility for executive compensation
(including equity compensation) as the prior title; and (ii) <U>Sections 5.7.4(a)</U> and <U>(b)</U> shall otherwise fully continue
to apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictive Covenants</U>. To induce the Company to enter into this Agreement and in recognition of the consideration
set forth in <U>Sections 4</U> and <U>5</U> of this Agreement, the Executive agrees to be bound by the provisions of this <U>Section
6</U> (the &ldquo;<U>Restrictive Covenants</U>&rdquo;). These Restrictive Covenants will apply without regard to whether any termination
or cessation of the Executive&rsquo;s employment is initiated by the Company or the Executive, and without regard to the reason
for that termination or cessation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Competition and Non-Solicitation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Executive covenants that, during his employment by the Company and for a period of twelve (12) months following immediately
thereafter (the &ldquo;<U>Restricted Period</U>&rdquo;), the Executive will not (except in his capacity as an employee or director
of the Company) do any of the following, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>engage or participate in any Competing Business (as defined below) wherever the Company or its affiliates do business, do
or plan to do business or sell or market their products or services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>become
interested in (as owner, stockholder, lender, partner, co-venturer, director, officer, employee, agent or consultant) any
person, firm, corporation, association or other entity engaged in a Competing Business. Notwithstanding the foregoing, the
Executive may hold up to 1% of the outstanding securities of any class of any publicly-traded securities of any company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>influence or attempt to influence any employee, consultant, supplier, licensor, licensee, contractor, agent, strategic partner,
distributor, customer or other person to terminate or modify any written or oral agreement, arrangement or course of dealing with
the Company or any of its affiliates; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>solicit for employment or retention as an independent contractor (or arrange to have any other person or entity solicit
for employment or retention) any person employed or retained by the Company or any of its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Consideration for Covenant Not to Compete After Cessation of Employment</U>. Executive acknowledges that the consideration
described in <U>Sections 4</U> and <U>5</U>, constitutes mutually-agreed upon consideration with respect to the covenants set forth
in <U>Section 6.1.1(a)-(b)</U> for purposes of Section 24L(b)(vii) of Chapter 149 of the Massachusetts General Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidentiality</U>. The Executive recognizes and acknowledges that the Proprietary Information (as defined in below)
is a valuable, special and unique asset of the business of the Company and its affiliates. As a result, both during the term of
employment and thereafter, the Executive will not, without the prior written consent of the Company, for any reason divulge to
any third&#45;party or use for his own benefit, or for any purpose other than the exclusive benefit of the Company and its affiliates,
any Proprietary Information. Notwithstanding the foregoing, if the Executive is compelled to disclose Proprietary Information by
court order or other legal or regulatory process, to the extent permitted by applicable law, he shall promptly so notify the Company
so that it may seek a protective order or other assurance that confidential treatment of such Proprietary Information shall be
afforded, and the Executive shall reasonably cooperate with the Company and its affiliates in connection therewith. If the Executive
is so obligated by court order or other legal process to disclose Proprietary Information it will disclose only the minimum amount
of such Proprietary Information as is necessary for the Executive to comply with such court order or other legal process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, nothing in this Agreement shall (x) prohibit Executive from making reports of possible
violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules
promulgated under Section 21F of the Securities Exchange Act of 1934, as amended, or Section 806 of the Sarbanes- Oxley Act
of 2002, or of any other whistleblower protection provisions of federal law or regulation, or (y) require notification or
prior approval by the Company of any such report; provided that, Executive is not authorized to disclose communications with
counsel that were made for the purpose of receiving legal advice or that contain legal advice or that are protected by the
attorney work product or similar privilege. Furthermore, Executive shall not be held criminally or civilly liable under any
federal or state trade secret law for the disclosure of a trade secret that is made (1) in confidence to a federal, state or
local government official, either directly or indirectly, or to an attorney, in each case, solely for the purpose of
reporting or investigating a suspected violation of law or (2) in a complaint or other document filed in a lawsuit or
proceeding, if such filings are made under seal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Property of the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Proprietary Information</U>. All right, title and interest in and to Proprietary Information will be and remain the sole
and exclusive property of the Company and its affiliates. The Executive will not remove from the Company&rsquo;s or its affiliates&rsquo;
offices or premises any documents, records, notebooks, files, correspondence, reports, memoranda or similar materials of or containing
Proprietary Information, or other materials or property of any kind belonging to the Company or its affiliates unless necessary
or appropriate in the performance of his duties to the Company and its affiliates. If the Executive removes such materials or property
in the performance of his duties, he will return such materials or property promptly after the removal has served its purpose.
The Executive will not make, retain, remove and/or distribute any copies of any such materials or property, or divulge to any third
person the nature of and/or contents of such materials or property, except to the extent necessary to satisfy contractual obligations
of the Company or its affiliates or to perform his duties on behalf of the Company and its affiliates or pursuant to the exceptions
set forth in <U>Section 6.2</U>. Upon termination of the Executive&rsquo;s employment with the Company, he will leave with the
Company and its affiliates or promptly return to the Company and its affiliates all originals and copies of such materials or property
then in his possession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>. The Executive agrees that all the Intellectual Property (as defined below) will be considered
 &ldquo;works made for hire&rdquo; as that term is defined in Section 101 of the Copyright Act (17 U.S.C. &sect; 101) and that all
right, title and interest in such Intellectual Property will be the sole and exclusive property of the Company and its affiliates.
To the extent that any of the Intellectual Property may not by law be considered a work made for hire, or to the extent that, notwithstanding
the foregoing, the Executive retains any interest in the Intellectual Property, the Executive hereby irrevocably assigns and transfers
to the Company and its affiliates any and all right, title, or interest that the Executive may now or in the future have in the
Intellectual Property under patent, copyright, trade secret, trademark or other law, in perpetuity or for the longest period otherwise
permitted by law, without the necessity of further consideration. The Company and its affiliates will be entitled to obtain and
hold in its own name all copyrights, patents, trade secrets, trademarks and other similar registrations with respect to such Intellectual
Property. The Executive further agrees to execute any and all documents and provide any further cooperation or assistance reasonably
required by the Company, at the Company&rsquo;s expense, to perfect, maintain or otherwise protect its rights in the Intellectual
Property. If the Company or its affiliates, as applicable, are unable after reasonable efforts to secure the Executive&rsquo;s
signature, cooperation or assistance in accordance with the preceding sentence, whether because of the Executive&rsquo;s incapacity
or any other reason whatsoever, the Executive hereby designates and appoints the Company, the appropriate affiliate, or their respective
designee as the Executive&rsquo;s agent and attorney&#45;in&#45;fact, to act on his behalf, to execute and file documents and to
do all other lawfully permitted acts necessary or desirable to perfect, maintain or otherwise protect the Company&rsquo;s or its
affiliates&rsquo; rights in the Intellectual Property. The Executive acknowledges and agrees that such appointment is coupled with
an interest and is therefore irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<U>Competing Business</U>&rdquo; means any person, firm, corporation, partnership, association or other entity engaged
in developing, manufacturing, marketing, distributing or selling, directly or indirectly, pharmaceutical abuse-deterrent products
or any other product for pain indications that directly competes with a product developed, manufactured, marketed, distributed
or sold by the Company. A division, subsidiary or similar business unit of an entity that does not engage in the business activities
described in this definition will not be considered a Competing Business even if another separate division, subsidiary or similar
business unit does engage in such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Intellectual Property</U>&rdquo; means (a) all inventions (whether patentable or unpatentable and whether or not
reduced to practice), all improvements thereto, and all patents and patent applications claiming such inventions, (b) all trademarks,
service marks, trade dress, logos, trade names, fictitious names, brand names, brand marks and corporate names, together with all
translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications,
registrations, and renewals in connection therewith, (c) all copyrightable works, all copyrights, and all applications, registrations,
and renewals in connection therewith, (d) all mask works and all applications, registrations, and renewals in connection therewith,
(e) all trade secrets (including research and development, know&#45;how, formulas, compositions, manufacturing and production processes
and techniques, methodologies, technical data, designs, drawings and specifications), (f) all computer software (including data,
source and object codes and related documentation), (g) all other proprietary rights, (h) all copies and tangible embodiments thereof
(in whatever form or medium), or (i) similar intangible personal property which have been or are developed or created in whole
or in part by the Executive (1) at any time and at any place while the Executive is employed by Company and which, in the case
of any or all of the foregoing, are related to and used in connection with the business of the Company or its affiliates, or (2)
as a result of tasks assigned to the Executive by the Company or its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Proprietary Information</U>&rdquo; means any and all proprietary information developed or acquired by the Company
or any of its subsidiaries or affiliates that has not been specifically authorized to be disclosed. Such Proprietary Information
shall include, but shall not be limited to, the following items and information relating to the following items: (a) all intellectual
property and proprietary rights of the Company (including, without limitation, the Intellectual Property), (b) computer codes and
instructions, processing systems and techniques, inputs and outputs (regardless of the media on which stored or located) and hardware
and software configurations, designs, architecture and interfaces, (c) business research, studies, procedures and costs, (d) financial
data, (e) distribution methods, (f) marketing data, methods, plans and efforts,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the identities of actual and prospective suppliers, (h) the terms of contracts and agreements with, the needs and requirements
of, and the Company&rsquo;s or its affiliates&rsquo; course of dealing with, actual or prospective suppliers, (i) personnel information,
(j) customer and vendor credit information, and (k) information received from third parties subject to obligations of non- disclosure
or non-use. Failure by the Company or its affiliates to mark any of the Proprietary Information as confidential or proprietary
shall not affect its status as Proprietary Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Acknowledgements</U>.
The Executive acknowledges that the Restrictive Covenants are reasonable and necessary to protect the legitimate interests of
the Company and its affiliates, that the duration and geographic scope of the Restrictive Covenants are reasonable given the
nature of this Agreement and the position the Executive holds within the Company, and that the Company would not enter into
this Agreement or otherwise employ or continue to employ the Executive unless the Executive agrees to be bound by the
Restrictive Covenants set forth in this <U>Section 6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies and Enforcement Upon Breach</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Specific Enforcement</U>. The Executive acknowledges that any breach by him, willfully or otherwise, of the Restrictive
Covenants will cause continuing and irreparable injury to the Company or its affiliates for which monetary damages would not be
an adequate remedy. The Executive shall not, in any action or proceeding to enforce any of the provisions of this Agreement, assert
the claim or defense that such an adequate remedy at law exists. In the event of any such breach or threatened breach by the Executive
of any of the Restrictive Covenants, the Company or its affiliates, as applicable, shall be entitled to injunctive or other similar
equitable relief in any court, without any requirement that a bond or other security be posted, and this Agreement shall not in
any way limit remedies of law or in equity otherwise available to the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Judicial Modification</U>. If any court determines that any of the Restrictive Covenants, or any part thereof, is unenforceable
because of the duration or geographical scope of such provision, such court shall have the power to modify such provision and,
in its modified form, such provision shall then be enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforceability</U>. If any court holds the Restrictive Covenants unenforceable by reason of their breadth or scope or
otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the right of the Company
and its affiliates to the relief provided above in the courts of any other jurisdiction within the geographic scope of such Restrictive
Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of Restrictive Covenants</U>. The Executive agrees to disclose the existence and terms of the Restrictive
Covenants to any employer that the Executive may work for during the Restricted Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Extension of Restricted Period</U>. If the Executive breaches <U>Section 6.1</U> in any respect, the restrictions contained
in that section will be extended for a period equal to the period that the Executive was in breach, provided that, to the extent
applicable, such extension is permitted under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right to Consult Counsel</U>. Executive understands and acknowledges that Executive has the right to consult with counsel
prior to signing this Agreement. Executive further represents that Executive is signing this Agreement freely and voluntarily in
exchange for the benefits provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Other
Agreements</U>. Executive represents and warrants to the Company that there are no restrictions, agreements or understandings
whatsoever to which he is a party that would prevent or make unlawful his execution of this Agreement, that would be
inconsistent or in conflict with this Agreement or Executive&rsquo;s obligations hereunder, or that would otherwise prevent,
limit or impair the performance by Executive of his duties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. The Company may assign this Agreement to any successor to its assets and business by means
of liquidation, dissolution, sale of assets or otherwise; provided, however, that any such successor must expressly assume this
Agreement. The duties of Executive hereunder are personal to Executive and may not be assigned by him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law and Enforcement</U>. This Agreement will be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, without regard to the principles of conflicts of laws. Any legal proceeding arising out of or relating
to this Agreement will be instituted in a state or federal court in the Commonwealth of Massachusetts, and Executive and the Company
hereby consent to the personal and exclusive jurisdiction of such court(s) and hereby waive any objection(s) that they may have
to personal jurisdiction, the laying of venue of any such proceeding and any claim or defense of inconvenient forum. Notwithstanding
the foregoing, any action that is commenced by either party to resolve any matter arising under <U>Section 6.1</U> of this Agreement,
shall be commenced only in the Massachusetts Superior Court located in Suffolk County, Massachusetts and the parties each consent
to the jurisdiction of such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waivers</U>. The waiver by either party of any right hereunder or of any breach by the other party will not be deemed
a waiver of any other right hereunder or of any other breach by the other party. No waiver will be deemed to have occurred unless
set forth in a writing. No waiver will constitute a continuing waiver unless specifically stated, and any waiver will operate only
as to the specific term or condition waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective
and valid under applicable law. However, if any provision of this Agreement is held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality or unenforceability will not affect any other provision, and this Agreement will be reformed,
construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. This Agreement will survive the cessation of Executive&rsquo;s employment to the extent necessary to fulfill
the purposes and intent the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any notice or communication required or permitted under this Agreement will be made in writing and (a) sent
by overnight courier, (b) mailed by overnight U.S. express mail, return receipt requested or (c) sent by telecopier. Any notice
or communication to Executive will be sent to the address contained in his personnel file. Any notice or communication to the Company
will be sent to the Company&rsquo;s principal executive offices, to the attention of its Chief Executive Officer. Notwithstanding
the foregoing, either party may change the address for notices or communications hereunder by providing written notice to the other
in the manner specified in this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Entire
Agreement; Amendments</U>. This Agreement contains the entire agreement and understanding of the parties hereto relating to
the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings
of every nature relating to that subject matter (including, without limitation, the Existing Agreement). This Agreement may
not be changed or modified, except by an agreement in writing signed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Withholding</U>. All payments (or transfers of property) to Executive will be subject to tax withholding to the extent
required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section Headings</U>. The headings of sections and paragraphs of this Agreement are inserted for convenience only and
will not in any way affect the meaning or construction of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts; Facsimile</U>. This Agreement may be executed in multiple counterparts (including by facsimile signature),
each of which will be deemed to be an original, but all of which together will constitute but one and the same instrument. Counterparts
may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall
be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&lt;remainder of page intentionally left
blank; signature page follows&gt;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.6pt 0pt 33.9pt; text-align: justify; text-indent: 0.5in">IN WITNESS
WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and Executive has executed this Agreement,
on the date(s) indicated below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.6pt 0pt 33.9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COLLEGIUM
    PHARMACEUTICAL, INC.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul Brannelly</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Brannelly</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/27/2020</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RICHARD
    MALAMUT, M.D.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Richard Malamut</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/24/2020</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page
to Employment Agreement</I>]</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>coll-20201227.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K85w7xRiXgen8uNbXAsWaOLGbPtzp5xKekhuWh2bdlKLykjLSSywiCmidZGYU4F -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:coll="http://collegiumpharma.com/20201227" elementFormDefault="qualified" targetNamespace="http://collegiumpharma.com/20201227">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://collegiumpharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="coll-20201227_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="coll-20201227_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>coll-20201227_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>coll-20201227_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://collegiumpharma.com/role/Cover" xlink:href="coll-20201227.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://collegiumpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>tm2039449d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="coll-20201227.xsd" xlink:type="simple"/>
    <context id="From2020-12-27to2020-12-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267565</identifier>
        </entity>
        <period>
            <startDate>2020-12-27</startDate>
            <endDate>2020-12-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-12-27to2020-12-27">0001267565</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-12-27to2020-12-27">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2020-12-27to2020-12-27">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-12-27to2020-12-27">2020-12-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2020-12-27to2020-12-27">COLLEGIUM PHARMACEUTICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-12-27to2020-12-27">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-12-27to2020-12-27">001-37372</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-12-27to2020-12-27">03-0416362</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-12-27to2020-12-27">100 Technology Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-12-27to2020-12-27">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-12-27to2020-12-27">Stoughton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-12-27to2020-12-27">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-12-27to2020-12-27">02072</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-12-27to2020-12-27">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-12-27to2020-12-27">713-3699</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2020-12-27to2020-12-27">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-12-27to2020-12-27">COLL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-12-27to2020-12-27">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="From2020-12-27to2020-12-27">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-12-27to2020-12-27">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2020-12-27to2020-12-27">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-12-27to2020-12-27">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-12-27to2020-12-27">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139693745076600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 27,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COLLEGIUM PHARMACEUTICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001267565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">03-0416362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Technology Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Stoughton<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">713-3699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">COLL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( +>&GE$'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ MX:>4=F37C_O    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ MX:>49E<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "W
MAIY1&QV..5<$  #D$   &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ MX:>48.II0/4 0  ,@8   T
M         ( !FPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "WAIY1EXJ[
M',     3 @  "P              @ &:#@  7W)E;',O+G)E;'-02P$"% ,4
M    " "WAIY1JL0B%C,!   B @  #P              @ &##P  >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ MX:>420>FZ*M    ^ $  !H
M     ( !XQ   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ MX:>4660>9(9 0  SP,  !,              ( !R!$  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  $A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2039449d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://collegiumpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2039449d1_8k.htm">tm2039449d1_8k.htm</File>
    <File>coll-20201227.xsd</File>
    <File>coll-20201227_lab.xml</File>
    <File>coll-20201227_pre.xml</File>
    <File>tm2039449d1_ex10-1.htm</File>
    <File>tm2039449d1_ex10-2.htm</File>
    <File>tm2039449d1_ex10-3.htm</File>
    <File>tm2039449d1_ex10-4.htm</File>
    <File>tm2039449d1_ex10-5.htm</File>
    <File>tm2039449d1_ex10-6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2039449d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2039449d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "coll-20201227_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "coll-20201227_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "coll-20201227.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "coll",
   "nsuri": "http://collegiumpharma.com/20201227",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2039449d1_8k.htm",
      "contextRef": "From2020-12-27to2020-12-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://collegiumpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2039449d1_8k.htm",
      "contextRef": "From2020-12-27to2020-12-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-20-140581-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-140581-xbrl.zip
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M([[0G*M&9SKT.\)/I%90[!/.>=B&L%<S,Z8R5L$LTTV2F-W 9DGDO"V26#G
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MY6*+FYZ=G4WR5"UM*7<K0?4Q3B?:3I6S3$TZ]#4G:7*>YO:N>82SO-)[#X-
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M=$Z'HG,:-#JG[T)'5G\ [<Y,;MZ*)7^UO1H.*KV T[9JQ>8@"P^:EK<^9%2
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M<X%*N[AID813KHY[[9>-[FGC=_+%L'K@BG?!R]-<<D'% W/7H/72%-%[J80
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M9+Z$R L2N,R$^*<PD0UR,&."HX\XC(TZ;P+V\$:P1^Y /]!^:FKH9U--WAN
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M:N2<.N[[<8A>[Z*(8L_2)Y*;$)P8]?\#4$L#!!0    ( +>&GE%<B+1(\SH
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M.W,0!![-6_B7'7.Y-BXXND[/.$<<UND9MYKN)&+QYX)C?L1$/.-;HZ:V0:Y
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MZ*JZNJ ;'C0VQ22Y[!SW:Z9US9_VM%Z+ZE=-B[+>H7HX6RH(NN]L[K&UOFI
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MC$+<%_$CN2,@#?HYQ30F:5E)@O.D01Q"=H18 V8KI=N_[88TI(A_L19\3'K
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MD5F*%B@9UL@#6UH$L;X%R=S[6Y?.;,Y4OF',#<]ZO<@T[JA=JF+WC)7+*A:
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M1.J'_,FPII3%3LXN8Q4"R167[.^W[0\"H':O+*430/6C]W[RRV,:_0GG@7=
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M$"36ML- B/,BO]8J0\?F) K:8[CH4=A4%73S?)S.,VUR'4F],"$?;', ]\0
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M3NCAJ_>O?Z?K\.;B[=G+_P]02P,$%     @ MX:>4>6(.;Y0.0  NSX! !8
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M) &^OQV][:JK<>=Z,);)RX;N0*!S$ + $"N#;"N&'[_!A%+<"IQH3?X^-]6
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MJ;ZQRL;X9]V4XV\Q_Q.5\V[$$0.B#152H&*-Z3#)!>PS.[:<^CVZY"BC2_A
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MP+)^X]J2C!*BT":0"RA)?]5 <I\N'9A; 3>DAH']^4@3Y46!U@7A*F O%/R
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M#>1-3[:U*> <) TL*C^JJS/HGO25D%R)&6-SLYG)#9P7/#ME @HVZMK0 PC
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MBEN5G54^*M@1])-HEGCS:ZWSV8XTCX"_J@4*JR1!70E@%M,HV":<A,1J8(B
MA3OS<??#;G)$50]'GK+?+G&&L,[-!5]13PFR3.'/Z>IX#MS!7%^I22FT_T9)
M5BQ]A^!8LB24>-E]&Q?J'\@<I4@=-0MK-B/1'<G5FKT! #\"FJEK<<US;BS-
M\K@@S0>A-T79V H+>]).*<][NX!U[$.U&[7@,G(^,GA9=5[6;:5]]3J!532<
MM^13S<Z!K)M<3X"-A>7UC,-BBY-F.J,!]DAE%V:!]%<X& NB""G^0"3?,]K&
MB-F,1W0_+I.L6(X!V;IH?D37M'CU)\GCE:5@H)OPL0;+8.R&"8Y,<-R?PY$S
MB*34.>?1;;'H@O80&)0-=J8Y"]CQ,[*:(_K$GSPIJSREU=+8^U1L8+]T)286
MN'.01M-W[NVIXFN=<ZVJ")/5&\]7<OT>\)==7$<+8-,A^7B*0:N)R#2\40/V
M,=>G$21=']6+X]:@7%6%OMB9YD92)>R[]J?DO*P^6<_J>)25TP;F1DG4MYVW
M(42'TJ>4F2X-=:Z%'X#JSDH:&94.KYQ++>&S %#) FY3IB$O4,+W%LL[66]Z
MP<ZMF& :X'T&#85T.1X-@;YW$"\&"C[2*,BZ_UOR\<.ALWGV?[M[%XR>D+A]
MQ'^"!85Y1@4'IN![G/ LX?" =2.RE<-EX3(%Y@#H!2>N0-Y#=!Z"L4V4;O,6
M D):D?O>==+[C)^H44NI6"_V2&HI_$EG%#5E!Y;RL%)?2AF(%?+T&GQ(&V&/
M0S&@E): 3KG;2=X\@6VS4W3JR2R0KM24DX,D,NNVECQ1)W%%X'(RU(3+%!D1
M!C-L:0#"P<MIRUA>)K<.9'BQ;DT3>.2J<JHU5T@8X7<BL&7A9 MKX%\Q2B"U
M6P>-SL1QDAM1'@80^?QL+YM<2''HL1:*0 C*>(/+%?S++CZ+3%082=4-WPT9
M)B4J< 4=<L8F6):Z"^;>FS_E'<E2X_&';7"Z-78X'@WTZ!>5;T*PB4MNIMWQ
M.CRZ\+SR8,DBWJ#2NP<W VGSW7 =%-F3F[%9UO5\=SVQXB3>"['>QJ/ ?&/C
M'F$C28*G-O&-DI<$_,@(AG6YTJ*W($(,PX&5#K3AR/,%O5VL3E*@AXABT&R/
M?0XNMP%Z*,54O)9PK.47-%\P7EGS51H:C(P.^ZI3\FQ4>'\*]*0G9?FI3IG/
MI0%"&[KQK%D(/RQ@0!7>LTBR75 *;"D;Z1PE00XXUKAB'5,OEH*WJZB@$(<+
M5@K'\(M3L7PO#>!C>0?EJWHXLY*40QJ%9 V04/;XYQ;6G@M$NET,;=9Q1Y66
M;:H)G6J^8D)7=9S2/>ZT\R "6M#A+VD,_E@L425Q=Y0@SAT,0N546(*Y!YH'
M+NK'2A(#2Y V&#<LM00GNK7'#I%0[S((_.+P? UE-+Z4DVWZCAT7%82Q%*H1
MM4]Z0ZJQD':KY^Z$HXT!"!9/!&"'N6GU[,*%E- 'X"%7>XZT?B((JW;]^B&$
M'9EH4(QG+J/V$LN"XPL1PHI#!UP9LD@><'AB-_F(49 .#$H<X[^.$1<0%MB&
M9WV\W54CMS0FY,@30"C'E6\1T@5P5[01+(JY)9E+J+G!HC%.WR*WDR:/R :A
ML?WZ,TJR$25#J!ZM-S<*V S"<I+C$)FB55R'(A\V?WK.5W\0RQA\>3#A3O0D
M&\1%UY&K$"RK3V)PDF\?+&I;L:1L4 4C%28*GCA/Q=Z^Y]_+"W;'($+:UOZO
MY/,]]!B2>_OV*D">@WAO5NE^Q*.&IVCG,ZSLK0)"&%(?QJ,8X97'YK-/A_M'
MTYA<,1?D/XE6%DQE<B%%*YJ*#.OT1-I>Z#SJ>3>[J@TJ!K6X7?U2K1QIMP$,
M(L&@_95I%Q03.)6;;4 \%_4,M(+!BP&[\D6^5ATE/F5_BHS.1>5BQT)1GO-C
M'+9AK"#*+.&OT%@86GDVWS'E%%UH4TMR:<=DIT^8#.HU6_)N&+I-: DR5&(8
MUB^$.BT.U^90^]HE[T[FW8[#;*SH&*8U"RX?Y4I<Z?%TMQ91G3E[8\L);C17
M:%/6('S US#J5J!OF2^"E=FCJX16I([7H0X6(KRZR)H*0&5R?Q\7GD4Y'?WS
M-Q[9;>@R)SMQ7^3AKBX)B,19.PQKR\X=P8JR"X?MNWQ,#E>1=N[O;708TMT<
MH=3>+="UR^1^A=0JD1H=N[8LOH.F%WB.>6F'CE>X$,=7**^$4>)]V"D!PK6"
M/$+V0@!%HA%JDM&Z*+=3#WO9P+2AR^#:BA($5ZW9"ARU/C:QQRR<Z"G?.;<J
M/F$*F]%/#D_OZY8 ,M[37I=<]#C(>C*YR,Y?) &,KJGCC:1@1& GNN5,Q?%O
M*DNI9-QSHUI;%+T!O^2I#:2[*  H2C.%I( V$=T@E_ 2H$&1QD2<D2W>H6!.
M0R=!YE@,7R#G>8;"_//(_L6Q5A9OX9KD^&7>AM6$FZPZP%$B!:U2H&YP0) W
MRM8U3<MVF0MB-<>1/6(UI510O@(*LO!^SDW)UA-OZ7=[$<1/H++KF@CWOA^@
MLEX)PC"XP"7E#I(N7L_-\EJU#W1Y5 ;,/"^7I(W")%ODF13/3J7:1DJS+' N
MQ].P(.>2FBT8RUQ5"S75+5V]F:@)B)T=NC&XDAP=JMWI2!GYFI-%D5UBDS9'
MAYB5ZV_*=7:BURCWJLP'L77\=/@3S@;_"E!ZJ?\:-;#N+?('Z%,SG"U2MQ-0
M^(QP>*M>N4PQS&^1"QMD@7FH-O8D)57"L-UKDH-!0#E1+B^=R,R=VQY"C#-$
M!LJQL *?;I L1!>TL/M7S 8OD JG0X/W P^31LQWD99]N9/GMY].GG6EPGX'
M)1GWUNSX"7+#5CJ ^GB4BNX9.N,*"OC* XVC[6<AQO$V.O>92LKE,8P%<1C+
M83_+C>UXES$UOD"CS%X_QT#8J3/?Q,24.TG(AQ%<'%)SEB&9%9R[90<J%]VA
MS\H9HRG&YOD2%?XL=FM&^79@C9^6[CNT=RD8!D.%!MO:?C/!V%?\P5NZ5O"Y
M]YORE->!Y0%J[>3N<+<=J4PM&_O!@N[R+WSKYL1>W,AKP[&2,(TLQ]25,F-T
M 1&O6E)W.6_4KF6X<"E:M($AGDHXL]#GZ)LW499>T!8"\D1N -IQ<N>E/?_
M8,>Q T#2'*_1<<8=+S"IC]V'UVG^>M,:CQ"]TU&+]60$B*)H^6E5H;S!! X6
MYYQ2A4;,SKP\I\3F19LKBIXBRK>1,40:C/5#6-0C2C[!B >O!)A><TH IU!K
M,R^S$@B3HH/\TY2P6!N5BE6+=%,IK%7G%:%4\IE=#[PP?&:W;+%LT?:ORUES
MCAZ!8'K4(IR/LJVF?((9^0;>RL0ZLSDSUAZE#K#]4V[?*4LNVFOI8&ONB,;F
MOS:J.*7<8KV8E)D)3C\FI\/ R*BG>FV*OV'=H,Y,N^ ,5@1NLAH/VK#2&*NA
M(2KM^=S GI&/;Z*YTA!G[O0QJBTD*'12<L[G)=Y8S4Y"U%RM!A;@K:-#F=VU
M#8+OLGG/6C A/T&7><>'0N#KMN!L<A$YYFB$J=7#IJK6#JH7!XL+VX%P8G>.
MW0X*KE+64]:A;^=\654],. WPK6]T[\^M8%35XO75@]@M_0+YS:S8BX0]NNM
M#0XNM1A.OQBVXYS8#5X*$]FB<Z.F@RY1;SUQW:33[ U'E0,O-%DDF*W =@2<
M3\>]T*,E"<__88J;N%Q1G>TF'U#>KY@;\+$YZRW(WC1?*!SELD8W"X=X'S!B
M+==OA_.FPQ:DGW2>?Q2H2J''UK$AX?D=SM@]CU<!6*_TK&VG%NV;.;QCVFA,
M(W;G5"21"!M2F"YJ-]50Z)@"VA#'?=O0WUL,#)0'+(3 7!+RO2*#K9NR8J(@
MK#I$,L4&P-S.SJF4@+-B1>Y07NYI6WF]1P09"EB#SD?T0KO0'(A.'!BJ'HZ3
M67&,>;RP8MK.+:,2!M:=:I(]"*H*.E0Q9:1MDIPH[:-;=UC2UBPLG8=!Y*S[
M$7% N''QF;/PP_7@-&.'BL#;([MN7<:NZ!ZU'I2)S3RX;\<FJ@2N4'MI'>H_
M'/?1F97%T?V/'ISN^@[;X8KZU(Z=LS,&ADZREP5MH:/Z(?CI7]L>!P"'!.IX
MQA(V,W'N.Y/$UJ?MSCE#%#Z@),EWLY43N*[!_3N=1!Z\2B-,(Z_HFX2P9__W
MP\<OE,FE3J'+ICI1,;PU%.-W02QV51:@ZM2;E+'JX[F-XNM2B!/"06Y1C(:M
M1AF*&R,G64K>B+OI#GR8@L[;8*+$8$WH, X<*V_130!1YIK$7S@JGX,U VHF
MYRURM.,:1:"I'T,F;):>.M4EW0)JIDD-RK@+N0T.% '"HY&>FC/=3=P;P &D
M<)\8/]UP7)EG=7B=LH^BVA2-Z(3RW5OLK5P%/1C%KEC)%D0>5YHCW\9C&80U
MO00P<'@SHPR^013!#<G^Y@-](^[D>X^7O[I"3%]PQ]F6S^@FD W:.6NRK G:
M,,C;_R#*_W@4[,KUV"WR0;G#!<[KW"Q2"E!P9#QD$>FE/$]N2N=\!&$AUF>#
M(64,6R K-,6_6N;6ER<18\B(->1%6;!FP/?HU(GG;51+D*@,KV=K.(U;9[UH
MN=,H4HM[IZ8VCN8+F!BFE18OU&(N+PI$J(%*[DIW9=MX/W1!I4DN&N\'F? 8
MT?%!5:N?09FNJ;B7DLW.I*#65?;:ZW4PCX*\+90GZ/8K3FF^WBT\7Y8 X^XN
M"Q.><!<+R>9PT4CK5J*;T&BSP?C#&W-DU:D*R]MGC&/@M'&A1I =1>8CG(*9
M1O?_@6BD>!]+/ -BULLRKS5*9^?J@BU 7G Q+Z2LVOA;XIP 5&>@[(87:UR2
MAK@YV=4/?P;>-B2[>DVH,Z%Z\8\VH^KAY#4"W8DC/KK[EPLY*>]@@>Z,7@+P
M"I9GT4X4,VM&Q#<8&Q>6CP<?KUJ-\NF<!0"O>P, QN=, +[6QXJ(E#_S()DC
MD?^<]7I$?4 SF4'\XC>1R:24OX&<AAXQFH""%VGW46Z8ZCZ(*[OQ;XP)[$EV
MO:YBO/;7+K_Q&$@1K;+AMEIMBB@PO@^:$R>1UV5\,9*0724)C*R4&7MWE+^
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M']?,5_.3#*S0[6=OG_^3J/?ER>M73_\_4$L#!!0    ( +>&GE'?6NWC03D
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MX90>#\P(I_FUCPP6YCZN#"_&C[WORV7(2H2\$^"OT(,DQB!R"\LZ.2;2Y5W
M=MT1YXC(3*NZK889Z!+N2:P#9(>V7PXP3F0\9V69)1,%;'\[>=554-/.]6 *
MDP\-G7U YR #@"%6&ME6"C]^A@EEN!4XT9J\>7ZJ2_D\3$'EL-YUR9XM9VAG
M&D4/O'<MJO. @EO.*=@$ZSAJ,Q">*;JZBC-=6Z4=_?+%&4@Q]AODN+-J#$]@
M#R-\@G>P_D;X--,@@ROX WUJ>)39!<4N*?+U^5>B[ 0UECO]%1/%JK8I)CGR
M&II 3Q!6*'=0KMHP";G8:#&L=TVQX8"WRHO:J!K*%Q0?-7Z#KPK+7Q3DB:08
M7-UP6 .D.6X6!]TPHV0U/HG=59NU#VZ\DH^Y "RYP234A9[ OK%Q^Y(UE;[&
M=WV=DW4X,T>J16J!*T1-T,@CZ&G)/%="Z$!:H#'-)#%%G2N3$V?J:!1]_Y>+
MBFM8TC,.;>3 ,^J65#G2*+U*B@],D!/6'-^?PWD;&RW:L'T*$+XI,[@%S6 V
MC&LB:IDW;)6],77?6>6JLB_D+'+XA!X]%RB$@YO#!] V*^$=^(XS]#?B.)[#
M#=COM\,2XQ/T\$<X01^TF8W:JG:B\N@+NDML'.\T2B#QSA:YJ:<R4Y '+G*Q
M)^VC8EI&1H[;5A7RUE&0#!([C9*E/B,;!UO8 ?UT."E%2/M*5]+;LL&'8# O
M(X$#3P$YP>:IAELEAH*V0@7/2^T7L-<<C'132#MS(-&]]=E0=IKP"FN[R"#^
MO5'\-*9I&XVGVGJ:,CW1%3 #5E^\#TL\3K0^IK#*#BE&<*681,G#G2<'UL5U
MC"&F D;Z )(4@["')?"HGE<KBQQ:ZVL;9I,M'V=<NPUTC!*W^ZHWKR]Y]1GL
M)1*4I8C QEQ?Z[-O9$$T$<?&]Y,-\ZWF&<S SHM#H8'MZR*EH>;QWYN)B^/%
MI\1%4:.YI+@6LAC1(SCVZN:"'[SU'8Q<8ZH7QO(SB=/[<[Z^5D\5'WZ2<*A5
M86P<;2X:)E<U)O$M+-'%JQ0[!>+?X(7\; )99T^W"1D&"J,-<RXOB6G +*P7
M=BFO7EL?($.IAEL'+Y4;4' Y!Y&6BN5:U@E:RQBW0XI)8.71#QV;.A6EQ8:F
M+M4)>S+'1C+C'*GP B"/(-6590)*%Z942STL#;>33_-2TBE 'CK;)':&]B8Q
MJ*G:<TJ>+C@!DM00ACI42/0@"S,->ID9L?>,["'O0DL>\>I<:X+Q6Z5)2YED
M@9L.[5$-]A0+^"6O0IEFE/:"V3UG8).%3D24UIQ90PDZI(1F$I%QR2Y@4D^)
M^Q3)M,RSNK=TO AQHLVMBDX^^C&BD\$I=6DZAZJMR0>"Y/8K^EP^$+TQH1X/
M^?.7YQIR4B%(<<Y^=@>:#DKGVG@"&W1R)NRTUR#$-G%.2HB6IQQIL9WI#@S0
M/=#D<PHD[_?-VEVID70=I_/>?O)N3L?]*3Y>.-9^\@^5M_CS]_%)]RMH>B<D
M]CKO##R3CE'_0(:';"M<"KL(^\GI8@Z7'%1J9,;[R5LUT[Q0;TM\_;W(-VWO
MPE^V@N*GV^4_ORED;K6HW=6P8L=FO9(\23@%U0=3PQ";N-0W1FWC@J*1-G 9
MW]T<"H?:^*_.))/3VM77'74E.[9:6EEM]$6BHY=L3C=TKL3IF #O :K"';[0
M.0BXC=V]S60&XTW1ZRC$=3U/#]B<Z)K!?)Q>GM M)(F5..0=25CNX?9WP#LC
MR1@A8XF,CL#>X"P5BMC;A+&08#HY]OQ04\!W><X>#:P\046.;MHB K,DR"&^
M:_D2[P@L(+"5^*L=@<%VZ1PC=D KYYKK$$54M<4YF9-4K%B9,?Y9-^7X<\K_
M).6\&W+$B&A#=1*H6&,^C+J ?6;/EE>_1PL.,_J,#[3A*TVQ6K!#@R@,6O5;
MG*1CIP>4#7J@4?Y07%"A0=GF6( %X\N\IRKKY:"XVB@TDTG0!O2OLHPL7!B5
M>>=^\KVK6F\$23Y:*4E>*(-<1CR:81@.MM"TLP&U"3?R\-V+#P=))$/'R*Y0
MY9U$#J,-RG2*HPIT*=)$Z ^)]*:,D@,D^NV4J#1!EX[S,V=ZKFD]Z\UK"^@_
M;83[WO.C*[+).OXP2BEC\405T'PWKF.H18.\P" )<*ZJU2QWVH+$6:@>A5ED
MR[:.@AA!/&E]K>/ 9W]\/[>:19L+_&+HBZO+.!0@L_7%5W:NJ-VWF!R;\: 4
M&2LGD^MG;KLH&Q:<^:.1JXN45B9T1B:1+Y(K M$C8TM4Y.F=96$XAM@U W<2
M8RW*9-)6Q.IS T9QCMP>WM'70*%7ACV4_9$YKND6)YI=STT*1!GX29DL2$;
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MH$ ,6\812E]ACQR;#A^%6T./19A+A$^WV3OPN)R8&P;N<V5FB,N 2<?-527
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M$<&!GSS:28"(PEXT[H9ESUQ?PRP[55"^W26/=VF[XIAV POTR7\\#>DXCMF
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MSW<^TL!'^O.=C_3F>KK$F=&/-%WG>=\4K&BXXI4\&+?$"^E\V@]6W7!<]F/
M \0>)40V)D43[![32.&M ^@STAJB7.I&LD!W#+J$E1SL:D0U1KJB6%_(DDKH
M05_1Z:#C!Y]06M_%4"E++VU#?D'YCS'ZFCM4:;!Z.T*X3LF=5F%;,GB2'I7E
MYSHEC:A. Q!19(#640$_S&!"%;8O)A54(&EL<CNIQFSTB7Q?7UNRCJE7M(*[
MJVC-<+I@-G/B2G$FKIC+LU8DS]DA77!$>#ZG64BJ#*F9OJU((GW6)$-^H.M;
M=[...]F'LDTU*XF#[T.H[9<^&+3LJ>P\:#(M&)7+1\,_9G/4L7WI+\U!Y50W
M@_DVFN<M^C06MPR3V$Q]I@W&'4LMP8G%YY&B)+UA'B0[+)]>R@EF?8\C9=K7
MTBVA4(TU3OAI2#9:8%<O&UQTO!AX+<)8Q7S,>K)PL2KT27E0\+JG'??IB(T5
M6[,?D <J[QK,M\G5ISKAP$4$I^7P:['1_' P)'G,@8_MY!/&5SJ@5U>FO?;K
M1!Q=Y5J=>R@CQ V^=.J6QH0<KSP8A!Q3 G-%0]9VV; 4<]G1H*(XSEDD1Z@F
M%]TME)VK318#$D188?)RXHFQ>LU0*,8FE$^YVQ)1QN#-@QF((D-MZ!!+_UQU
M7%E]%O.:@A&F<C #RD9Y,'1BHFB.\[7L[/IS.5^P1PFQ$C=V?R8']:''P-W9
MM=U7^1T$S7^97D $//R*]GWPL?^9'@!<.N)J/#>?CCO\?'0$D#-I06[-:&43
MQ4ZP:$6M,Z;S)-($0O\7XU_$6761V$.A48N3V"_5TIEV!\#(%TS:=ZE<2-4:
M<P_@W44] 8DQV(NURWQL]6Q'P4O9>R2S<V'"V(U2E!=\&3N?&32,\AFL?C>\
M\NRAP!Q<] *.+<FE':\$?<+L6*_UD"_'4 .W.?!70=NR7C#4=W"Z-JG<UD-Q
MJ1K[OGFWX]@@2T'#M&9[8T01^MA%.[".KE$<U5BS^[@<X49SN)*R*.$#WH9A
MP@(=X=Q[6]X>O4&T(G6\#G6P$&&W.*M& I5)RU2N9HM!0WKGCW5+W(8N<[(O
M[JM>7-^E@$B<)LRPW() PZ!Q=N%P?)>?RK$UTMP\:HN#P.]FIJ2=4LF@W3"U
MATFM@J'1-6U+PCNXFH'SFY=VZ'B%"W%\A6)#8$4!H K%GEJ!(")=,L DT@@Z
MR[!]E.NJA[4/T&2H_V9;4<+DLC5; JC8QU;WZ*4C/>8VG\OT'E/8$@=6])V[
M7L+>%W#<ZY(K*0=93R:]0WT?'&!T31UO)$5/ AO"+6<JH0M364HEER</JK6%
MTQSPO)[9\C#K@Z5@O"GHGXE"DD#%F9IW)KP4J'2F,3%G9*]U*!E=GEC$@<J8
M937<N]/S#H6)^5YE1G4=YEQ9S(%KDN5RBW1]K6>27D+ R;*#'&5XT&H%:@='
M,7G#;,'7N&SGN2 .46^<"'K?"#8R@5H%K9%OC:;)>N:-[6=SAUQX75/AX6K<
M;$D? <I69JROV=*,812%2\I )(T>P0NN71.2 4_/P;@$I11!^XH6>28%X5,I
M0Y*:-0NES5%$K%2ZI)@-YC)5U4R-=4M=CQ,U O&S1;!RE207N:*F -C:1LPI
M51'9)0YI,XN(6;GGC;D L;8)."[8SB^$^#+^=?@3O@W^%>-VD\NQJW1L)P?H
M>#&<XE*W(U#\C'!XJV:Y%#9,RI'&,[+ /%4;9I-:,V'8]C;LC$*9(VC81YFD
M="(S=VY[*"G.(!FH4\/R?FK>6XA.:-N'N+=!'+RK7X<F[R<>9KJ8;YX4?).*
M'WZY"^P%@;U?[@)[-ZSXX>&- 3%<ZO/J8_$JZ@QWSJ4*\)7OLH#FKNVO@/U#
MW6?"%9#+X#=@;V@Q.MS[.;JGS5AO,NZVF:$=:AN&<A. U%FL8E6SO4I_A[V>
M:LX")4N*<^OL1*4U*;KIG/V-_%3Z7O%G,=4SSH?,R[/2?8<F/L6&8*HP8%O;
M;T88"HH_>./>RGAW?U.>\3JPZ$./&WEX7'\ZE:EY8S]8P''^A;LDCVRC75X;
M#AV$:7XYYB:5&2-,B"9!.2EP->?UVK4,%RXEQ ?O>T@ENE?H"_15FRB+,A@+
M@8TBSP?M.'DPTYY+9/#!L<^#6IY=Z\$9/WB&29?L,;W.\-=[K?4UA/!UU&*=
M-V$38: 1K2H4K9B6PYH+)\*AO48V[+2\H"3T69LK"BABEP,C\X@4-NM^L0A2
ME%:$00!>#; TIY2(3]''9EIF)1 G!<SXIS%A43<J%6,>::=2B%G JT(I_1.[
M)@A4/+';-INWZ/*HRTES@8Z0X!5I1-2QVFK,IYA1A."N3(Q1FPUES6]Z (Y_
MMAE8W_,@ &II86/J",?F*#>J.*,$<#T;E9D).  V#8&)D2^#ZO8I)(7EHSHS
M[8RSC!$$RVI$:+++8*QUAZC<%U,#^T:N34)HIA(N[=5/BM]2*PC2Z2ZF9<YE
MM>BK!$7=*IQ!OPGTH[.7&D&*Q:O!2C^A:,$C\X[KB)I/V.JNT2+R1](,4ZMV
MCE6M'50Y3A87M@.'E0J2,F\'!1PIGRWKT+CS.2VKXAAPE^':[O6;7C=P\FIQ
M5NL!U)Y^E=KM+$\+Y/UJ44:#IC[+TT/Z9JL3O<%-88IB=&[4>- 3[%V37*3H
M[!B+\>>=[V2 802?S28XGXY[H0-/LM+_S10W<DF^.MM./J+,7_)N%C:;V9M.
M*44\2D+VN>*IG"V'5]/H62URUK\W(P[ZC(S.]4\#=2ET5#LV)#R_PQF[Y_$J
M /^ECL3-U'8[8 [OF#;F82!<YU@DD0@;4IH6M7O54.B8 L:0>$7;T-\;#!"5
M!RR$0'T2<CDC@ZV;LF*B(-P_!"_% :9P%TH:%FU.[E#R]5E;>=U'!!D*68.^
M5G2^NX@DB$Z<&*H?CI-9D8S)VK!BVKY;1F4FK#_5)'L01Q7TJ&+,<)0D.5'B
M1VW'6-+6+"R=0T7DK/L1\6!X< D5L/##]>!<<@>.P=LCNVX]Y0Y[ 34?E(F4
MSVL;CMGDC<#S:WN-H@[$X2Z=65D<M>WU0'_7SYCJ 2O(@VS^2+5DZB1[6= 6
M.JKQ@I_^N>GA('!*H))G+&$S$R4[B^ZW\7FS<\X0T= 6@_CJ%D/91JY?0)#<
M@B^ K82B H"*OD*\V>25,KE4D\02"HY&' G$1L\8LPSBS\NRXE2G(*B,]1[/
M:A3WBB(V*("B]?(JP-LB)%E$_A"=.0]\2(8.VV!RR&!A[C 88-0#@WE<E,HE
ML2;.1,C!G $=D_/X.+!SC4K<U,\A$QY+5YWIDCHWFW%2@R;NPHR#$X7C&<_T
MS)SK;B+; /PCA3C%\NF&(,L\JRVR:!PYMFDID1;!C0?9,[L,<3**T[&&;3,R
M;465?!O/91 ?MH\:Z?#*AS<SRF@;A))<>8NPR[VF3^Z\IH'7],F=U_3&1@)9
M9-S\GK<)54>C=FR+L7W1+2>XOJ!.6S>".7Q?DWA%$*I1.V*Q+L-=N9Y$1U$K
M/=) )$PQP0:]KIQH$DJA=$"L8NIQA ;,:3XBI:Q/$#,T, J(TM84_VQ9(;@\
M;QLCL&R!S<J"E4_N4U<G7GR.R/Y*5(;]3QM*G==9+_G$*:VIQ==48QN6]J6/
M# !-BQ<JRI>7"R.D2"4ZC8-NR/0$\\+"Y);>'-&Q1I7K7\!8JZG GW(XSZ6H
MWN7EV_9UF)Y$WCQ*OW7[%<EY[UZ[M,O=U^65N=Z@81XA[F+! [O8OG@MU]>H
MTRAM=J5S[$@GJT[EF][^9U 39^T)-8+(+;)@4 : H/ZZH'U1^)R5JDA;\G8)
M]EDC'#ZU8 \#+[B8KP*M8'P75J=CJ7.PI\)>+9=D]]X6<\8SN)4GM/^MS:@\
M/7F#6(L2!(@:KW-UL.L<&+"WRX^#1<1!GWAC.QL83$,0=L (#9T41F> P.W>
M_H#Y.0N$NPA9]I'R9YYDT/N.S8H+36G<@B,9WXD$F%+9$5(A76(T@57/TNZE
MOF$AGU@W_UM(LJMU4V/+=;O\QN-@1;3*=N-R*RRB0.3VD@S+)&@JD@,9]V$2
MLJLDDXD%MK&MJGSS5R?7Q/?$H>E 5MD#Q-1-4E95PC0M8Q7G3^.P/F+3G3U@
M?2<47<\BP:$,J%'IDO-Y65Q=&DL 4!=,G1D?^)%KAXQ^>H%A]>06'H#5@E)R
M8[, N>2RCAQ+O!41/@2I2H(!G'GO\B4:J50L2GS2-GWHU8Q060WJFP'X3P^V
M_Q;2STK<F!$#Q8JF6IC68".%@1)>UHUU[+$22$IA89+BGPI#$MJAQ)O2]?,S
MTIBJ=C%G48-Q4IGN=(O0!)<F/$Z^&R"W"T7I&CS'VT)2TN#DYQ^ZG] ;8$4Z
MSU6AR[;^_CZ.%3>)^?G':!+SP0*/'3(N//S;@B6>,ZL(G>29KJ@V<AD :>#<
ME]J?$-2,QJ8DE#$_@+#3N!03 [XL14(+=7N@JJW2<PSVVD8U<5+-\##)!/[(
MV28]+_,6N%4%>T!6K[;@B+;VT'50=<H6*GOF>T?C5DNW/P1D[CNB![?+=9=>
M TJAQ"K"ZFYZ$!=6X%3<D;XH(^&6AJ%W-!3\*: 4.U]BEU#W+LI^F!(Q*@9B
MY >P^VU>N49^"#R!<2>J3N,V2SQS:VUT&YK90="HCEM6LIF!$>@<9FWSO+J!
ML7X97A@VQ_=ON0%*6853#NO>:/)@5;.+"!\+2V@J*[X=L@<877X;8GR1H?ZZ
MM^IHK<3 _FK'>#O&('19\=$YX*IT;W;8LX.& &<!=@E.K(C:#D3^SZ9F.&D>
MU27O +E0RAE#_II_M2:3!!(P96I@V/RA5CGCI? 0H9>=9V4Q2B:=0E<!D*R"
MA- 0$##AQ.T%9Z>/M,]K9-?^RLGS\J#M[LY=U#:(VN[NW(5M;S@+O/D5N EU
MQD:45]0F3]1%-W9K66'$\ZRQR_BPS#\X]=#V2%\" H XJ:YK Z)TE\6%5CGZ
M*"=)U,7!!X+B)IV@2!=C,\^US1TD5<!&;Q"-'Y@Q 1:'P3M0@RGW$\=C[#*;
MV"J0(X.O9VQ+#,&.[4%QLY_69_5<]CH,4!YRXL@E*C@%%N;?NPJ8C<=(,Y'3
MTSHV:3(;M22@\G >D=GU1L8KK";(<@T##;0,[FGA^*ELW(+6;X*9C:V.8I#A
M.@N\>B_8B2G1J,G!W01*#?35SGHXS#T<FB :ZP')9S/D<T1TC$5LU4]2:,M<
MWGB&#<(JM_4L&P>\/GT=U*914SVK?5I9D"%%JQ'W&_G8DD>G0G,2R$$2@0FN
MJ)U,ROPSV9F(BA/?Y]+&Q-=.05LA (>$LWRK5RZMOR<G_2%R)G_#TU8%VB,=
MOZI'J')XV&7@];:RLK_$ ?PRN#6LM<Z07#/LWB#/B0(CRT?GWY<^ T^E'=%R
M0GZ4:_XDS=XS22?L0-PI:EH"9ZXW4M"T7H59('*-)"=&I1#$<S/?N"$<CA%H
M-!U-JMR1,V,'8 2Q,NHEC[=_;V_]:H_.S<\=(Z8,NQJ%0G^;ZH*\#;9E2LH,
MTD>S^XFX7G##SL^QV5CFT '@_0H4!S;/55.0DD)"Y"Z#I;0].<+6!^IB.WE=
M7C"TD)$&H9=,P=0,],\/,06-"W?FK)-0V7 8MK4)*2[H8&MZ\3[N2\&W"G)8
M<#<MEN<($G4=:&4PF!-CUXI@<N!PIU@98=4W4C?X.1FC&Y7MV51"Q5>]DE^>
MJ<(L;V*!6./$_D4?1;E5Q_#G'^(8MM6Y@?U=KO77= 6'7"E]WRHFEX*57H+A
M.FGSB:$:\:GVP#^V!JK@$-GM]*#]\B.0#*CP"$ MJ-L%.9<0;8#$;M!Z*W'X
M>645()0-N4D=;R(P2ZQ.9GV"J (+#EE#!M6%+5=4=% EINZ^6 \X4]3P([J
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M?(9,L3_VV%:>.Z%UU]!7XPPS[R5,4_$]-Z2>L-Z9N/PYHT.*1LD@;!V'1RD
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M?TA U Q,AYT$&;>V" ,(!3Z:$'%0T&+Y1!9]@@_$4,QF9\(MISZ?E[44[=S
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M.30T.60Q7V5X,3 M,BYH=&U02P$"% ,4    " "WAIY1Y8@YOE Y  "[/@$
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I,#,Y-#0Y9#%?97@Q,"TV+FAT;5!+!08     "@ * )T"   VAP$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
